Method for preparing neural tissue
By suspending the culture medium regulated by TGFβ and Sonic hedgehog signal under feeder-free conditions, pluripotent stem cells are formed to form high-quality cell aggregates and induce neural tissue, it solves the difficulty in preparing high-quality neural cells in the prior art. Problem, efficient neural tissue preparation is achieved.
Patent Information
- Application Number
- CN202110841033.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2014-10-24
- Filing Date
- 2015-10-23
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2035-10-23
AI Technical Summary
The prior art is difficult to efficiently prepare and maintain undifferentiated pluripotent stem cells in the absence of feeder cells, thereby preparing high-quality neural tissue and nerve cells, especially retinal tissue.
Pluripotent stem cells were cultured in culture medium containing TGFβ family signal transduction pathway inhibitory substances and/or Sonic hedgehog signal transduction pathway activation substances and formed cell aggregates by suspension culture, followed by conditions in the presence or absence of differentiation inducing factors Further culture was performed to achieve induction of nerve cells or neural tissue.
High-quality cell aggregates were successfully formed and neural tissues and nerve cells such as retinal tissues and nerve cells were efficiently induced, solving the problem of maintaining an undifferentiated state and preparing nerve cells under feeder-free conditions.
Smart Images

Figure CN113564123B_ABST
Abstract
Description
[0001] This application is a divisional application of the patent application with international application number PCT / JP2015 / 080016, international application date October 23, 2015, Chinese application number 201580071124.1, and invention name “Method for preparing neural tissue”. [Technical field]
[0002] The present invention relates to a method for preparing neural tissue such as retinal tissue from pluripotent stem cells. [Background Technology]
[0003] As a method for preparing neural tissues such as retinal tissues from pluripotent stem cells, a method for preparing neural tissues has been reported, the method comprising forming uniform pluripotent stem cell aggregates in a serum-free medium, suspending and culturing the aggregates, suspending and culturing the aggregates in a medium for differentiation induction under the conditions of differentiation induction factors, etc., as appropriate, thereby inducing the differentiation of pluripotent stem cells to target neural cells (patent document 1 and non-patent document 1). For example, a method for obtaining multilayer retinal tissues from pluripotent stem cells is known (non-patent document 2 and patent document 2), and a method for obtaining multilayer retinal tissues, the method comprising forming uniform pluripotent stem cell aggregates in a serum-free medium containing a Wnt signal transduction pathway inhibitory substance, suspending and culturing them under the conditions of a basement membrane preparation, and suspending and culturing them in a serum-containing medium (non-patent document 3 and patent document 3). In addition, a method for inducing pluripotent stem cells to differentiate into hypothalamic tissue (patent document 4 and non-patent document 4) and a method for inducing pluripotent stem cells to differentiate into neural precursor cells (non-patent documents 5 and 6) have also been reported.
[0004] Under the condition of having feeder cells and adding the factor for maintaining undifferentiated state, cultivate the pluripotent stem cells as the starting material of these preparation methods, particularly in the case of primate pluripotent stem cells, so as to maintain the undifferentiated state. In recent years, some improvements have been made in the cultivation of maintaining the undifferentiated state, and the method (non-patent literature 7, 8 and 9) of adding the factor for maintaining the undifferentiated state to cultivate primate pluripotent stem cells under the condition of not having feeder cells (no feeder cells) has been reported. It is necessary to use the pluripotent stem cells without feeder cells cultured by the method as the stable method for preparing neural cells or neural tissue of starting material.
[0005] [Reference list]
[0006] [Patent Document]
[0007] [Patent Document 1] WO 2009 / 148170
[0008] [Patent Document 2] WO 2011 / 055855
[0009] [Patent Document 3] WO 2013 / 077425
[0010] [Patent Document 4] WO 2013 / 065763
[0011] [Non-patent literature]
[0012] [Non-patent document 1] Cell Stem Cell, 3, 519-32 (2008)
[0013] [Non-patent document 2] Nature, 472, 51-56 (2011)
[0014] [Non-patent document 3] Cell Stem Cell, 10(6), 771-775 (2012)
[0015] [Non-patent document 4] Nature, 480, 57-62 (2011)
[0016] [Non-patent document 5] Nature Biotechnology, 27(3), 275-80 (2009)
[0017] [Non-patent document 6] Proc Natl Acad Sci USA, 110(50), 20284-9 (2013)
[0018] [Non-patent document 7] Nature Methods, 8, 424-429 (2011)
[0019] [Non-patent document 8] Scientific Reports, 4, 3594 (2014)
[0020] [Non-patent document 9] In Vitro Cell Dev Biol Anim., 46, 247-58 (2010) [Summary of the Invention]
[0021] [Problems to be solved by the invention]
[0022] The problem to be solved by the present invention is to provide a method for preparing neural tissues such as retinal tissues and neural cells from pluripotent stem cells prepared or cultured in the absence of feeder cells to maintain an undifferentiated state.
[0023] [Solution to the problem]
[0024] The present inventors have conducted intensive studies in an attempt to solve the aforementioned problems, and have found that by culturing pluripotent stem cells in a culture medium containing a TGFβ family signal transduction pathway inhibitory substance and / or a Sonic hedgehog signal transduction pathway activating substance in the absence of feeder cells (under feeder-free conditions), and then subjecting the cells to suspension culture, spherical cell aggregates having a smooth surface and a dense interior and maintaining an undifferentiated state can be efficiently formed. In addition, the present inventors have found that by using such high-quality cell aggregates, neural tissues such as retinal tissues and neural cells can be efficiently induced, which has led to the completion of the present invention.
[0025] That is, the present invention relates to the following:
[0026] [1] A method for preparing neural cells or neural tissues, the method comprising the following steps (1) to (3):
[0027] (1) In the first step, pluripotent stem cells are cultured in a medium containing 1) a TGFβ family signal transduction pathway inhibitory substance and / or a Sonic hedgehog signal transduction pathway activating substance and 2) a factor for maintaining an undifferentiated state in the absence of feeder cells,
[0028] (2) in the second step, suspending and culturing the cells obtained in the first step to form cell aggregates, and
[0029] (3) In the third step, the aggregates obtained in the second step are suspended and cultured in the presence or absence of differentiation inducing factors, thereby obtaining aggregates including neural cells or neural tissues.
[0030] [2] The production method of [1], wherein in the second step, the cells obtained in the first step are dispersed and the dispersed cells are subjected to suspension culture.
[0031] [3] The method of [1] or [2], wherein the factor for maintaining the undifferentiated state is an FGF signal transduction pathway activating substance.
[0032] [4] The method of [3], wherein the FGF signal transduction pathway activating substance is bFGF.
[0033] [5] The method of any one of [1] to [4], wherein in the second step, the cells are suspended and cultured in a serum-free medium containing a Sonic hedgehog signal transduction pathway activating substance.
[0034] [6] The production method according to any one of [1] to [5], wherein in the third step, the aggregates are cultured in suspension in the presence of a differentiation inducing factor.
[0035] [7] The method of any one of [1] to [6], wherein the TGFβ family signal transduction pathway inhibitory substance is a Nodal / Activin signal transduction pathway inhibitory substance, a TGFβ signal transduction pathway inhibitory substance or a BMP signal transduction pathway inhibitory substance.
[0036] [8] The method according to any one of [1] to [7], wherein the TGFβ family signal transduction pathway inhibitory substance is Lefty, SB431542, A-83-01 or LDN193189.
[0037] [9] The method according to any one of [1] to [8], wherein the Sonic hedgehog signal transduction pathway activator is Shh, SAG or Purmorphamine.
[0038]
[10] The method according to any one of [1] to [9], wherein the differentiation inducing factor in the third step is a BMP signal transduction pathway activating substance.
[0039]
[11] The preparation method of
[10] , wherein the BMP signal transduction pathway activating substance is one or more proteins selected from the group consisting of BMP2, BMP4, BMP7 and GDF7.
[0040]
[12] The preparation method of
[10] , wherein the BMP signal transduction pathway activating substance is BMP4.
[0041]
[13] The method of any one of [1] to
[12] , wherein the aggregate obtained in the third step comprises retinal tissue.
[0042]
[14] The method of any one of [1] to
[13] , wherein the aggregates obtained in the third step contain one or more cells selected from the group consisting of: retinal progenitor cells, neural retinal progenitor cells, photoreceptor precursor cells, photoreceptor cells, rod photoreceptor cells, cone photoreceptor cells, horizontal cells, amacrine cells, interneurons, ganglion cells, retinal pigment epithelial cells, and ciliary marginal zone cells.
[0043]
[15] The preparation method of
[13] or
[14] , wherein the differentiation inducing factor in the third step is a BMP signal transduction pathway activating substance, and the culture medium in the second step contains a Sonic hedgehog signal transduction pathway activating substance.
[0044]
[16]
[15] The preparation method of
[15] , wherein the pluripotent stem cells are human pluripotent stem cells, the Sonic hedgehog signaling pathway activating substance in the culture medium in the second step has a concentration corresponding to the Sonic hedgehog signaling activity of SAG of 10nM-700nM, and the retinal tissue is human retinal tissue.
[0045]
[17] The preparation method of
[15] or
[16] , wherein in the third step, the BMP signal transduction pathway activating substance is added to the culture medium between the first day and the ninth day after the start of the second step.
[0046]
[18] The preparation method of
[13] or
[14] , wherein in the third step, the aggregate is cultured in a culture medium containing a Sonic hedgehog signaling pathway activating substance at a concentration not exceeding a concentration corresponding to the Sonic hedgehog signaling activity of 700 nM SAG.
[0047]
[19] The preparation method of [1]-[9], wherein the differentiation inducing factor in the third step is a TGFβ family signal transduction pathway inhibitory substance and / or a Wnt signal transduction pathway inhibitory substance.
[0048]
[20] The preparation method of
[19] , wherein the TGFβ family signal transduction pathway inhibitory substance is Lefty, SB431542, A-83-01 or LDN193189.
[0049]
[21] The method of
[19] or
[20] , wherein the Wnt signaling pathway inhibitory substance is IWR-1-endo.
[0050]
[22] The method of any one of [1]-[9] or
[19] -
[21] , wherein the aggregate obtained in the third step comprises brain tissue.
[0051]
[23] The method of any one of [1] to
[22] , wherein the culturing time period in the first step is 0.5 hours to 144 hours.
[0052]
[24] The preparation method of any one of [1] to
[23] , wherein the first step is carried out by an adherent culture method.
[0053]
[25] The method of any one of [1] to
[24] , wherein in the third step, a differentiation inducing factor is added to the culture medium between the third day and the sixth day after the start of the second step.
[0054]
[26] The method of any one of [1] to
[15] and
[17] to
[25] , wherein the pluripotent stem cells are primate pluripotent stem cells.
[0055]
[27] The method of any one of [1] to
[26] , wherein the pluripotent stem cells are human pluripotent stem cells.
[0056]
[28] The method of any one of [1] to
[27] , wherein the pluripotent stem cells are induced pluripotent stem cells.
[0057]
[29] The production method of any one of [1] to
[28] , wherein uniform aggregates are formed in the second step.
[0058]
[30] The production method according to any one of [1] to
[29] , wherein the suspension culture is performed in the absence of a basement membrane preparation.
[0059]
[31] A reagent for evaluating the toxicity or efficacy of a test substance, comprising a neural cell or neural tissue prepared by the method of any one of [1] to
[30] .
[0060]
[32] A method for evaluating the toxicity or efficacy of a test substance, the method comprising contacting the substance with neural cells or neural tissue prepared by the method of any one of [1] to
[30] , and detecting the effect of the substance on the cells or tissue.
[0061]
[33] A drug for treating a disease caused by a disorder of nerve cells or nerve tissues, comprising the nerve cells or nerve tissues prepared by the method of any one of [1] to
[30] .
[0062]
[34] The drug of
[33] , wherein the neural cell or neural tissue is a retinal progenitor cell, a neuron specific to a retinal layer, a retinal tissue, a brain neural progenitor cell, a neuron specific to a cerebral layer, or a brain tissue.
[0063]
[35] A method for treating a disease caused by a disorder of neural cells or neural tissues, the method comprising transplanting an effective amount of neural cells or neural tissues prepared by the method of any one of [1] to
[30] into a subject in need of transplantation.
[0064]
[36] A neural cell or neural tissue prepared by the method of any one of [1] to
[30] , which is used for treating a disease caused by a disorder of the neural cell or neural tissue.
[0065]
[37] A pharmaceutical composition comprising the nerve cell or nerve tissue prepared by the method of any one of [1] to
[30] as an active ingredient.
[0066] [Effects of the invention]
[0067] According to the present invention, high-quality cell aggregates, as well as neural tissues and neural cells such as retinal cells, can be efficiently produced from pluripotent stem cells cultured in the absence of feeder cells. [Brief Description of the Figures]
[0068] Figure 1 The culture conditions of Example 1 and the morphology of human iPS cells after culture are shown.
[0069] Figure 2 The culture conditions of Example 2, bright field images of cells after culture, and immunohistochemical staining images for Oct3 / 4 are shown.
[0070] Figure 3 Bright field images of aggregates are shown (A and B), and graphs quantifying the morphological level of aggregates (C).
[0071] Figure 4 Bright-field images of aggregates are shown.
[0072] Figure 5 Bright field images of aggregates (A and B) and immunohistochemical staining images of aggregates for neural tissue markers (nestin, TuJ1, PSA-NCAM) (CE) are shown.
[0073] Figure 6 The culture conditions of Example 7 and images of immunohistochemical staining of aggregates against retinal tissue markers (Chx10, Rx) are shown (AD).
[0074] Figure 7 The culture conditions of Example 8, bright field images of aggregates after culture (AH), and a graph quantifying the morphological level of aggregates (I) are shown.
[0075] Figure 8 Images showing immunohistochemical staining of aggregates against neural tissue markers (nestin, TuJ1, PSA-NCAM).
[0076] Fig. 9 The culture conditions of Example 9 are shown, and the immunohistochemical staining images of aggregates for retinal tissue markers (Chx10, Rx) are shown (AH).
[0077] Fig.10 Bright-field images of aggregates formed under different conditions are shown.
[0078] Fig.11The culture conditions of Example 11 and images of immunohistochemical staining of aggregates against neural tissue markers (nestin, TuJ1, PSA-NCAM) are shown (AF).
[0079] Fig.12 The culture conditions of Example 12 and images of immunohistochemical staining of aggregates against retinal tissue markers (Chx10, Rx) are shown (AD).
[0080] Fig.13 The culture conditions of Example 13 and immunohistochemical staining images of aggregates associated with Chx10 (AD) are shown.
[0081] Fig.14 The culture conditions of Example 14, bright field images of aggregates, and immunohistochemical staining images of aggregates for retinal tissue markers (Chx10, Rx) are shown.
[0082] Fig.15 The culture conditions of Example 15 and bright field images (AD) of cells after culture are shown.
[0083] Fig.16 The culture conditions of Example 16, bright field images of cells after culture (A, B), and immunohistochemical staining images of aggregates against Chx10 (C) are shown.
[0084] Fig.17 The culture conditions of Example 17 and bright field images (AF) of cells after culture are shown.
[0085] Fig.18 The culture conditions of Example 18, bright field images of cells after culture (AE), and immunohistochemical staining images of aggregates against Chx10 (FI) are shown.
[0086] Fig.19 The culture conditions of Example 19, bright field images of cells after culture (AD), and immunohistochemical staining images of aggregates against Chx10 (EH) are shown.
[0087] Fig. 20 The culture conditions of Example 20 and bright field images of cells after culture are shown (AJ).
[0088] Fig.21 The culture conditions of Example 21 and the bright field images (AL) of the cells after culture are shown.
[0089] Fig. 22 The culture conditions of Example 22, bright field images of cells after culture (AC), and immunohistochemical staining images of aggregates against Chx10 (DF) are shown.
[0090] Fig.23 The culture conditions of Example 23, bright field images of cells after culture (A, B), and immunohistochemical staining images of aggregates against Chx10 (C, D) are shown.
[0091] Fig.24 The culture conditions of Example 24 and bright field images (AD) of cells after culture are shown.
[0092] Fig.25 The culture conditions of Example 25 are shown, and bright field images (AD) of cells after culture.
[0093] Fig.26 The culture conditions of Example 26, bright field images of cells after culture (AE), and immunohistochemical staining images of aggregates against Chx10 (FI) are shown.
[0094] Fig. 27 The culture conditions of Example 27, the culture image of human ES cells (A), the bright field image of the cells after culture (BD), and the fluorescence images for Rx::GFP (E, F) are shown.
[0095] Fig.28 Immunohistochemical staining images of aggregates against retinal tissue markers (Rx, Chx10, Crx, Blimp1, Brn3b) and Ki67 are shown (AF).
[0096] Fig.29 Immunohistochemical staining images of aggregates against retinal tissue markers (calretinin, S-opsin, Rx, Pax6, recoverin, rhodopsin, NRL, calbindin) are shown (AH).
[0097] Fig.30 Bright field images of cells after culture (A, B) and immunohistochemical staining images of aggregates against retinal tissue markers (SSEA1, Mitf, Aqp1) (CE) are shown.
[0098] Fig.31 The culture conditions of Example 31 and bright field images of cells after culture (AC) are shown.
[0099] Fig.32 Immunohistochemical staining images of aggregates against brain tissue markers (Sox2, FoxG1, Pax6, Tbr1, Ctip2) are shown (AF).
[0100] Fig.33 Bright field images of cells cultured under different conditions are shown (AJ).
[0101] Fig.34 The culture conditions of Example 33, bright field images of cells after culture (A, B), and immunohistochemical staining images of aggregates against Chx10 (C, D) are shown.
[0102] Fig.35 The culture conditions of Example 34, bright field images of cells after culture (AD), and immunohistochemical staining images of aggregates against Chx10 (EH) are shown.
[0103] Fig.36 The culture conditions of Example 35, bright field images of cells after culture (AE), and immunohistochemical staining images of aggregates against Chx10 (FI) are shown.
[0104] [Description of implementation plan]
[0105] 1. Definition
[0106] In the present invention, "stem cell" means an undifferentiated cell with differentiation potential and the ability to proliferate (particularly the ability to self-renew) to maintain the differentiation potential. Stem cells include a variety of subpopulations based on differentiation potential, such as pluripotent stem cells, multipotent stem cells, unipotent stem cells, etc. Pluripotent stem cells refer to stem cells that can be cultured in vitro and have the potential (pluripotency) to differentiate into any cell lineage belonging to the three germ layers (ectoderm, mesoderm, endoderm) and / or extraembryonic tissues. Multipotent stem cells refer to stem cells that have the potential to differentiate into various types of tissues or cells but not all types of tissues or cells. Unipotent stem cells refer to stem cells that have the potential to differentiate into specific tissues or cells.
[0107] Pluripotent stem cells can be induced by stem cells, somatic cells, etc. in fertilized eggs, cloned embryos, germ stem cells, tissues. The example of pluripotent stem cells includes embryonic stem cells (ES cells), EG cells (embryonic germ cells), induced pluripotent stem cells (iPS cells) etc. The Muse cells (multi-lineage differentiation stress enduring cells (Multi-lineage differentiating stress enduring cell)) obtained by mesenchymal stem cells (MSC) and the GS cells produced by germ cells (for example, testis) are also included in pluripotent stem cells. Embryonic stem cells were first established in 1981, and have also been used to produce knockout mice since 1989. In 1998, human embryonic stem cells were established, which are also used for regenerative medicine. ES cells can be produced by culturing inner cell mass on feeder cells or in a culture medium containing LIF. The preparation method of ES cells is described in, for example, WO 96 / 22362, WO 02 / 101057, US 5,843,780, US 6,200,806, US 6,280,718, etc. Embryonic stem cells can be obtained from a given institution, or commercial products can be purchased. For example, human embryonic stem cells, KhES-1, KhES-2 and KhES-3, can be obtained from Kyoto University's Institute for Frontier Medical Sciences. As a human embryonic stem cell, Rx::GFP cell line (derived from KhES-1) can be obtained from RIKEN. As a mouse embryonic stem cell, EB5 can be obtained from Incorporated Administrative Agency RIKEN, and as a mouse embryonic stem cell, D3 cell line can be obtained from ATCC.
[0108] Nuclear transfer ES cells (ntES cells), which are one of ES cells, can be established from cloned embryos produced by transplanting the nucleus of a somatic cell into an enucleated egg.
[0109] EG cells can be generated by culturing primordial germ cells in a medium containing mSCF, LIF and bFGF (Cell, 70: 841-847, 1992).
[0110] The "induced pluripotent stem cells" in the present invention are cells induced to have pluripotency by reprogramming somatic cells by known methods, etc. Specifically, there can be mentioned cells induced to have pluripotency by reprogramming differentiated somatic cells (such as fibroblasts, peripheral blood mononuclear cells, etc.) by expressing a combination of multiple genes, wherein the multiple genes are selected from the group consisting of reprogramming genes including the following: Oct3 / 4, Sox2, Klf4, Myc (c-Myc, N-Myc, L-Myc), Glis1, Nanog, Sall4, lin28, Esrrb, etc. Examples of preferred combinations of reprogramming factors include: (1) Oct3 / 4, Sox2, Klf4, and Myc (c-Myc or L-Myc), and (2) Oct3 / 4, Sox2, Klf4, Lin28 and L-Myc (Stem Cells, 2013; 31: 458-466).
[0111] Induced pluripotent stem cells were established in mouse cells by Yamanaka et al. in 2006 (Cell, 2006, 126 (4), pp. 663-676). In 2007, induced pluripotent stem cells were also established from human fibroblasts, and have similar pluripotency and self-renewal capabilities as embryonic stem cells (Cell, 2007, 131 (5), pp. 861-872; Science, 2007, 318 (5858), pp. 1917-1920; Nat. Biotechnol., 2008, 26 (1), pp. 101-106).
[0112] In addition to the production method based on direct reprogramming by gene expression, induced pluripotent stem cells can also be obtained from somatic cells by adding compounds or the like (Science, 2013, 341, pp. 651-654).
[0113] Established induced pluripotent stem cells can also be obtained, and, for example, human induced pluripotent cell lines established by Kyoto University, such as 201B7 cells, 201B7-Ff cells, 253G1 cells, 253G4 cells, 1201C1 cells, 1205D1 cells, 1210B2 cells, or 1231A3 cells, etc. are available from Kyoto University and iPS Academia Japan, Inc. As established induced pluripotent stem cells, for example, Ff-I01 cells and Ff-I14 cells established by Kyoto University are available from Kyoto University.
[0114] Although the somatic cells used to obtain induced pluripotent stem cells are not particularly limited, tissue-derived fibroblasts, blood lineage cells (e.g., peripheral blood mononuclear cells, T cells), hepatocytes, pancreatic cells, intestinal epithelial cells, smooth muscle cells and the like can be mentioned.
[0115] When induced pluripotent stem cells are generated by reprogramming by expressing some kinds of genes, there is no particular limitation on the method of gene expression. Examples of the aforementioned methods include infection methods using viral vectors (e.g., retroviral vectors, lentiviral vectors, Sendai virus vectors, adenoviral vectors, adeno-associated virus vectors), gene transfer methods using plasmid vectors (e.g., plasmid vectors, episomal vectors) (e.g., calcium phosphate method, lipofection method, RetroNectin method, electroporation method), gene transfer methods using RNA vectors (e.g., calcium phosphate method, lipofection method, electroporation method), methods of direct protein injection, etc.
[0116] When preparing induced pluripotent stem cells, it can be produced under the condition of feeder cells or in the absence of feeder cells (no feeder cells). When producing induced pluripotent stem cells under the condition of feeder cells, the induced pluripotent stem cells can be produced by known methods under the condition of factors for maintaining an undifferentiated state. Although the culture medium for producing induced pluripotent stem cells under the condition of no feeder cells is not particularly limited, it is possible to use the known maintenance culture medium for embryonic stem cells and / or induced pluripotent stem cells and the culture medium for establishing induced pluripotent stem cells under the condition of no feeder cells. The example of the culture medium for establishing induced pluripotent stem cells under the condition of no feeder cells includes feeder-free culture medium, such as Essential 8 culture medium, TeSR culture medium, mTeSR culture medium, mTeSR-E8 culture medium, StemFit culture medium, etc. When preparing induced pluripotent stem cells, for example, it can be produced by gene transfer of Oct3 / 4, Sox2, Klf4 and Myc 4 factors to somatic cells using Sendai virus vectors in the absence of feeder cells.
[0117] The pluripotent stem cells used in the present invention are preferably ES cells or induced pluripotent stem cells, more preferably induced pluripotent stem cells.
[0118] As the multipotent stem cells, tissue stem cells (also called stem cells in tissues, tissue-specific stem cells or somatic stem cells) such as hematopoietic stem cells, neural stem cells, retinal stem cells, mesenchymal stem cells and the like can be mentioned.
[0119] Genetically modified pluripotent stem cells can be produced, for example, by using homologous recombination technology. Examples of genes to be modified on chromosomes include cell marker genes, histocompatibility antigen genes, genes associated with diseases caused by neuronal disorders, etc. The target gene on chromosome can be modified using the methods described in the following: Manipulating the Mouse Embryo, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1994); Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993); Biomanual Series 8, Gene Targeting, Making of Mutant Mouse using ES cell, YODOSHA CO., LTD. (1995); Etc.
[0120] Specifically, for example, a genomic DNA containing a target gene to be modified (e.g., a cell marker gene, a tissue compatibility antigen gene, a disease-related gene, etc.) is isolated, and a targeting vector for homologous recombination of the target gene is produced using the isolated genomic DNA. The produced targeting vector is introduced into stem cells, and cells showing homologous recombination between the target gene and the targeting vector are selected, thereby producing stem cells having the modified gene in the chromosome.
[0121] Examples of methods for isolating genomic DNA containing a target gene include known methods described in the following: Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1989), Current Protocols in Molecular Biology, John Wiley & Sons (1987-1997), etc. The genomic gene containing the target gene can also be separated using a genomic DNA library screening system (manufactured by Genome Systems), a universal genome walker kit (Universal Genome Walker Kits) (manufactured by CLONTECH), etc. A polynucleotide encoding a target protein can also be used to replace genomic DNA. The polynucleotide can be obtained by amplifying the corresponding polynucleotide using a PCR method.
[0122] The production of a targeting vector for homologous recombination of a target gene and the efficient selection of homologous recombinants can be carried out according to the methods described in the following: Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993); Biomanual Series 8, Gene Targeting, Making of Mutant Mouse using ES cell, YODOSHA CO., LTD. (1995); etc. As the targeting vector, any of a replacement type or an insertion type can be used. As the selection method, methods such as positive selection, promoter selection, negative selection, polyadenylic acid (polyA) selection, etc. can be used.
[0123] Examples of methods for selecting desired homologous recombinants from the selected cell line include Southern hybridization method for genomic DNA, PCR method, and the like.
[0124] The "mammals" in the present invention include rodents, ungulates, carnivores, primates, etc. Rodents include mice, rats, hamsters, guinea pigs, etc. Ungulates include pigs, cattle, goats, horses, sheep, etc., and carnivores include dogs, cats, etc. "Primates" in the present invention refer to mammals belonging to the primate class, and primates include prosimians, such as lemurs, loris, tupai, etc., and anthropoidea, such as monkeys, apes, humans, etc.
[0125] The pluripotent stem cells used in the present invention are mammalian pluripotent stem cells, preferably rodent (e.g., mouse, rat) or primate (e.g., human, monkey) pluripotent stem cells, more preferably human pluripotent stem cells, and more preferably human induced pluripotent stem cells (iPS cells).
[0126] "Suspension culture" or "suspension culture method" in the present invention refers to a method of culturing and performing the culture while maintaining a state in which cells or cell aggregates are suspended in a culture medium. That is, suspension culture is performed under conditions in which cells or cell aggregates do not adhere to a culture container, etc., and culture performed under conditions that allow adhesion to a culture container, etc. (adherent culture or adherent culture method) is not included in the scope of suspension culture. In this case, cell adhesion means forming a strong cell-substratum junction between a cell or cell aggregate and a culture container. More specifically, suspension culture refers to culture under conditions in which a strong cell-substratum junction is not formed between a cell or cell aggregate and a culture container, and adherent culture refers to culture under conditions in which a strong cell-substratum junction is formed between a cell or cell aggregate and a culture container, etc.
[0127] In cell aggregates cultured in suspension, planar cell-cell adhesions are formed. In cell aggregates cultured in suspension, cell-substrate bonds with culture containers and the like are hardly formed, and even if cell-substrate bonds with culture containers and the like are formed, their contribution is small. In some embodiments, endogenous cell-substrate bonds exist inside the aggregates, but cell-substrate bonds with culture containers and the like are hardly formed, and even if cell-substrate bonds with culture containers and the like are formed, their contribution is small.
[0128] Planar cell-cell adhesion (planar attachment) means that a cell is connected to another cell via a plane. More specifically, planar cell-cell adhesion means, for example, that a cell is not less than 1%, preferably not less than 3%, and more preferably not less than 5% of the surface area adheres to the surface of another cell. The surface of the cell can be observed by staining with a reagent (e.g., DiI) for membrane staining, immunostaining of cell adhesion molecules (e.g., E-cadherin and N-cadherin).
[0129] The cell culture container used when performing suspension culture is not particularly limited, as long as it can allow "suspension culture", and those of ordinary skill in the art can appropriately determine such cell culture containers. Examples of such cell culture containers include flasks, tissue culture bottles, culture plates (plates), culture dishes, tissue culture dishes, multiple culture dishes, microplates, microporous plates, micropores, multiple plates, multi-well plates, chamber slides, bowls (schale), tubes, trays, culture bags, rotating flasks, Erlenmeyer flasks (Erlenmeyer flasks), shake bottles, etc. In order to allow suspension culture, these culture containers are preferably non-cell adhesive. Available non-cell adhesive culture containers include surfaces that have not been artificially treated to improve cell adhesion (for example, surface treatments such as basement membrane preparations, laminin, entactin, collagen, gelatin, etc., or coatings or positive charge treatments such as polylysine, polyornithine, etc.) and similarly treated culture dishes. As a non-cell-adhesive culture container, a culture container whose surface has been artificially treated to reduce adhesion to cells (e.g., superhydrophilic treatment using MPC polymers, protein low adsorption treatment, etc.) and similar treatments can be used. Roller culture can be performed using a rotating flask, a shaking bottle, etc. The culture surface of the culture container may be flat or may have depressions and projections.
[0130] The culture vessel for adherent culture is not particularly limited, as long as "adherent culture" can be carried out, and those of ordinary skill in the art can appropriately select suitable culture vessels according to culture scale, culture conditions and culture time. Examples of such culture vessels include flasks, tissue culture bottles, culture plates (plates), tissue culture dishes, multiple culture plates, microplates, microporous plates, multiple plates, porous plates, chamber slides, bowls (schale), pipes, trays, culture bags, microcarriers, beads, stacked plates, rotating flasks and shaking bottles. In order to allow adherent culture, these culture vessels are preferably cell-adhesive. The cell-adhesive culture vessel includes a culture vessel that artificially treats the surface to improve cell adhesion, and is specifically a surface-treated culture vessel, or the culture vessel coated with an internal coating agent can be mentioned. Examples of coating agents include extracellular matrices such as laminin [including laminin α5β1γ1 (hereinafter laminin 511), laminin α1β1γ1 (hereinafter laminin 111), etc. and laminin fragments (laminin 511E8, etc.)], haptoprotein, collagen, gelatin, vitronectin, Synthemax (Corning Incorporated), Matrigel, etc., or polymers such as polylysine, polyornithine, etc. Examples of the surface-treated culture vessel include culture vessels surface-treated by positive charge treatment, etc.
[0131] In the present invention, the culture medium for culturing cells can be prepared by using a culture medium commonly used for culturing animal cells as a basal culture medium. Examples of the basal culture medium include a culture medium that can be used to culture animal cells, such as BME culture medium, BGJb culture medium, CMRL1066 culture medium, Glasgow MEM (GMEM) culture medium, modified MEM zinc selection culture medium, IMDM culture medium, Medium199 culture medium, Eagle MEM culture medium, αMEM culture medium, DMEM culture medium, F-12 culture medium, DMEM / F-12 culture medium, IMDM / F12 culture medium, Ham culture medium, RPMI1640 culture medium, Fisher's medium, and mixed culture medium thereof, etc.
[0132] "Serum-free medium" in the present invention means a medium that does not contain unregulated or unpurified serum. In the present invention, a medium containing purified blood-derived components and animal tissue-derived components (e.g., growth factors) is also included in the serum-free medium unless it contains unregulated or unpurified serum.
[0133] The serum-free medium may contain a serum substitute. Examples of serum substitutes include those that appropriately contain the following substances: albumin, transferrin, fatty acids, collagen precursors, trace elements, 2-mercaptoethanol or 3'mercaptoglycerol, or their equivalents, etc. Such serum substitutes can be prepared by the method described in, for example, WO98 / 30679. In addition, the serum substitute may be a commercially available product. Examples of such commercially available serum substitutes include Knockout TM Knockout serum replacement TM Serum Replacement, Life Technologies, now ThermoFisher: sometimes referred to as KSR below), Chemically Defined Lipid Concentrate (produced by Life Technologies), and Glutamax TM (manufactured by Life Technologies), B27 (manufactured by Life Technologies), N2 supplement (manufactured by Life Technologies).
[0134] The serum-free medium for suspension culture may contain fatty acids or lipids, amino acids (e.g., non-essential amino acids), vitamins, growth factors, cytokines, antioxidants, 2-mercaptoethanol, pyruvic acid, buffers, inorganic salts and the like as appropriate.
[0135] To avoid complicated preparation, a serum-free medium supplemented with an appropriate amount (e.g., about 0.5% to about 30%, preferably about 1% to about 20%) of commercially available KSR (produced by Life Technologies) can be used as the serum-free medium (e.g., a medium supplemented with a 1:1 mixture of an F-12 medium and an IMDM medium containing 10% KSR, a chemically defined lipid concentrate, and 450 μM 1-monothioglycerol). As for products equivalent to KSR, the medium disclosed in JP-A-2001-508302 can be mentioned.
[0136] The "serum-containing medium" in the present invention refers to a medium containing unregulated or unpurified serum. The medium may contain fatty acids, lipids, amino acids (e.g., non-essential amino acids), vitamins, growth factors, cytokines, antioxidants, 2-mercaptoethanol, 1-monothioglycerol, pyruvic acid, buffers, inorganic salts, etc. For example, when inducing pluripotent stem cells to differentiate into retinal tissues, etc. by using basement membrane preparations (e.g., matrigel, etc.), serum medium can be used (Cell Stem Cell, 10 (6), 771-775 (2012)). In addition, serum medium can be used in the step of maintaining the neural tissue (e.g., retinal tissue, brain tissue) produced by the present invention (also referred to as maturation culture).
[0137] In the present invention, the culture is preferably performed under xeno-free conditions. "Xeno-free" means a condition that eliminates components derived from species different from the cells to be cultured.
[0138] In the present invention, "a medium containing substance X" and "under the condition in which substance X is present" mean a medium supplemented with an exogenous substance X or a medium containing an exogenous substance X, or under the condition in which an exogenous substance X is present. That is, when cells or tissues present in the medium endogenously express, secrete or produce substance X, endogenous substance X is distinguished from exogenous substance X, and it is understood that a medium without endogenous substance X falls outside the category of "a medium containing substance X" (even when it contains endogenous substance X).
[0139] For example, a "medium containing a TGFβ family signaling pathway inhibitory substance" is a medium supplemented with an exogenous TGFβ family signaling pathway inhibitory substance or a medium containing an exogenous TGFβ family signaling pathway inhibitory substance.
[0140] In the present invention, feeder cells refer to cells other than stem cells that coexist when culturing stem cells. Examples of feeder cells for culturing pluripotent stem cells while maintaining an undifferentiated state include mouse fibroblasts (MEF, etc.), human fibroblasts, SNL cells, etc. About feeder cells, preferably feeder cells that undergo growth inhibition treatment. Examples of growth inhibition treatment include treatments such as growth inhibitors (e.g., mitomycin C), gamma radiation, UV irradiation, etc. Feeder cells for culturing pluripotent stem cells while maintaining an undifferentiated state contribute to maintaining the undifferentiation of pluripotent stem cells by secreting hormone factors (preferably factors for maintaining an undifferentiated state) or producing a framework (extracellular substrate) for cell adhesion.
[0141] In the present invention, the absence of feeder cells (feeder-free) means culturing under conditions in which feeder cells are absent. The absence of feeder cells means, for example, conditions without feeder cell addition, or conditions substantially free of feeder cells (for example, the ratio of the number of feeder cells relative to the total number of cells is no greater than 3%).
[0142] In the present invention, the "aggregate" of cells refers to a mass formed by a cell assembly dispersed in a culture medium, wherein cells adhere to each other. Cell clumps, embryoid bodies, spheres, and spheroids are also included in the cell aggregates. Preferably, planar cell-cell adhesion is formed in the cell aggregates. In some embodiments, in some or all of the aggregates, cells sometimes form cell-cell junctions and / or cell adhesions, for example, adhesion junctions. The "aggregate" in the present invention particularly includes: an aggregate produced in the second step of the present invention [1] mentioned above, which is formed by cells dispersed when suspension culture is started, and an aggregate produced in the third step of the present invention [1] mentioned above, which contains induced neural cells differentiated from pluripotent stem cells, and the "aggregate" also includes an aggregate that has been formed at the beginning of the second step of the present invention [1] mentioned above (i.e., at the beginning of suspension culture). The cell aggregate formed in the second step includes "embryoid bodies (EB)".
[0143] In the present invention, "uniform aggregates" means that when a plurality of aggregates are cultured, the size of each aggregate is consistent, and when the size of the aggregate is evaluated by the length of the maximum diameter, the length of the maximum diameter varies little. More specifically, this means that not less than 75% of the aggregates in the entire aggregate population are within the average value of the maximum diameter in the aggregate population ±100%, preferably the average value ±50%, and more preferably the average value ±20%.
[0144] In the present invention, “forming uniform cell aggregates” means that, when cells are aggregated to form cell aggregates and the cell aggregates are cultured in suspension, “a given number of dispersed cells are rapidly aggregated” to form cell aggregates of uniform size.
[0145] Dispersion means dividing cells or tissues into small cell masses (not less than 2 cells and not more than 100 cells, preferably not more than 50 cells) or single cells by a dispersion treatment such as enzyme treatment, physical treatment, etc. A given number of dispersed cells is a collection of a specific number of cell masses or single cells.
[0146] Examples of methods for dispersing pluripotent stem cells include mechanical dispersion treatment, cell dispersion solution treatment, and cell protective agent addition treatment. These treatments may be performed in combination. Preferably, cell dispersion treatment is performed, followed by mechanical dispersion treatment.
[0147] As the method of mechanical dispersion treatment, there may be mentioned a blowing and suction treatment or an operation by a doctor blade.
[0148] As the cell dispersion used for the cell dispersion treatment, there can be mentioned a solution containing any enzyme such as trypsin, collagenase, hyaluronidase, elastase, pronase, DNase, papain, etc. and a chelating agent such as ethylenediaminetetraacetic acid, etc. Commercially available cell dispersions such as TrypLE Select (produced by Life Technologies) and TrypLE Express (produced by Life Technologies) can also be used.
[0149] When pluripotent stem cells are dispersed, cell death of pluripotent stem cells can be suppressed by treating with a cell protectant. Regarding the cell protectants used for cell protectant treatment, FGF signal transduction pathway activating substances, heparin, IGF signal transduction pathway activating substances, serum and serum substitutes can be mentioned. In order to suppress cell death (especially cell death of human pluripotent stem cells) caused by dispersion, Rho-associated coiled-coil kinase (ROCK) inhibitory substances or myosin inhibitory substances can be added during dispersion. Regarding ROCK inhibitory substances, Y-27632, Fasudil (Fasudil) (HA1077), H-1152, etc. can be mentioned. Regarding myosin inhibitory substances. Blebbistatin can be mentioned. Regarding preferred cell protectants, ROCK inhibitory substances can be mentioned.
[0150] For example, the method for dispersing pluripotent stem cells includes, for example, a method comprising treating a colony of pluripotent stem cells with a cell dispersing solution (TrypLE Select) in the presence of a ROCK inhibitory substance as a cell protectant, and further dispersing it by pipetting.
[0151] In the preparation method of the present invention, it is preferred to form pluripotent stem cell aggregates by rapidly gathering pluripotent stem cells. When pluripotent stem cell aggregates are formed in this way, epithelial-like structures can be formed in cells induced and differentiated by the formed aggregates with good reproducibility. Examples of experimental operations for forming aggregates include those involving the use of a plate with a small hole (e.g., when calculated in a flat-bottomed manner, having a base area of about 0.1-2.0 cm 2 A method of holding cells in a small space by using a plate with holes of 24 wells, micro-wells, etc., involves a method of aggregating cells by short-term centrifugation using a small centrifuge tube. As for a plate with small holes, for example, a 24-well plate (when calculated in a flat-bottom manner, the area is about 1.88 cm) can be mentioned. 2 ), 48-well plate (when calculated as a flat-bottomed plate, the area is approximately 1.0 cm 2), 96-well plate (when calculated as a flat-bottomed plate, the area is approximately 0.35 cm 2 , inner diameter is about 6-8mm) and 384-well plates. Preferably, a 96-well plate. Regarding the shape of the plate with small holes, for example, the shape of the bottom surface when the hole is viewed from above is polygonal, rectangular, elliptical, true circle, preferably true circle. Regarding the shape of the plate with small holes when the hole is viewed from the side hole, the shape of the bottom surface can be a flat bottom structure or a structure with a high outer perimeter and a low internal depression. The shape of the bottom surface includes, for example, a U-shaped bottom, a V-shaped bottom, an M-shaped bottom, preferably a U-shaped bottom or a V-shaped bottom, more preferably a V-shaped bottom. Regarding the plate with small holes, cell culture dishes (for example, 60mm-150mm dishes, culture bottles) with concave-convex or serrated shapes on the bottom surface can also be used. The bottom surface of the plate with small holes is preferably a non-cell adhesive bottom surface, preferably the aforementioned non-cell adhesive coated bottom surface.
[0152] The formation of aggregates containing pluripotent stem cells or cell groups containing pluripotent stem cells and their uniformity can be determined based on the size of the aggregate mass and the number of cells therein, the macroscopic morphology, the microscopic morphology analyzed by tissue staining and their homogeneity, etc. In addition, the formation of epithelial-like structures in aggregates and their uniformity can be determined based on the macroscopic morphology of the aggregates, the microscopic morphology analyzed by tissue staining and their uniformity, the expression of differentiation and undifferentiation markers and their uniformity, the control of differentiation marker expression and its synchronization, the reproducibility of differentiation efficiency between aggregates, etc.
[0153] In the present invention, "tissue" refers to a cell group structure having a configuration in which one type of cells having a uniform morphology or property, or a plurality of types of cells having different morphologies and properties are spatially arranged in a given pattern.
[0154] In the present invention, "nervous tissue" refers to a tissue composed of nerve cells, including the cerebrum, midbrain, cerebellum, spinal cord, retina, peripheral nerves, forebrain, hindbrain, telencephalon, diencephalon, etc. in the developmental stage or adult stage. The nervous tissue sometimes forms an epithelial structure (neuroepithelium) having a layer structure, and the amount of neuroepithelium in the cell aggregate can be evaluated by bright field observation using an optical microscope.
[0155] In the present invention, "neuronal cell" refers to cells derived from ectodermal tissue except epidermal lineage cells. That is, it includes cells such as neural precursor cells, neurons (neuronal cells), glial cells, neural stem cells, neuronal precursor cells, glial precursor cells, etc. Neuronal cells also include cells constituting retinal tissue (retinal cells), retinal progenitor cells, neurons, neural retinal cells and retinal pigment epithelial cells mentioned below. Neuronal cells can be identified by using nestin, TuJ1, PSA-NCAM, N-cadherin, etc. as markers.
[0156] Neurons (or neuronal cells) are functional cells that form neural circuits and contribute to signal transduction, and can be identified by using the expression of immature neuronal markers (such as TuJ1, Dcx, HuC / D, etc.) and / or mature neuronal cell markers (such as Map2, NeuN, etc.) as indicators.
[0157] As for glial cells, there can be mentioned astrocytes, oligodendrocytes, Müller glial cells, etc. As for astrocyte markers, there can be mentioned GFAP, as for oligodendrocyte markers, there can be mentioned O4, and as for Müller glial markers, there can be mentioned CRALBP, etc.
[0158] Neural stem cells are cells with differentiation potential (pluripotency) to neurons and glial cells and the ability to proliferate (sometimes referred to as self-renewal ability) to maintain pluripotency. About neural stem cell markers, nestin, Sox2, Musashi, Hes family, CD133, etc. can be mentioned; However, these markers are usually markers for progenitor cells / precursor cells and are not considered to be neural stem cell-specific markers. The number of neural stem cells can be assessed by neurosphere assay, clonal assay, etc.
[0159] Neuronal precursor cells are cells with proliferation ability, which produce neurons and do not produce glial cells. About neuronal precursor cell markers, Tbr2, Tα1 etc. can be mentioned. Alternatively, immature neuronal markers (TuJ1, Dcx, HuC / D)-positive and growth markers (Ki67, pH3, MCM)-positive cells can also be identified as neuronal precursor cells.
[0160] Glial precursor cells are cells with the ability to proliferate that give rise to glial cells and do not give rise to neurons.
[0161] Neural precursor cells are a collection of precursor cells, including neural stem cells, neuronal precursor cells and glial precursor cells, and have proliferation ability and neuron- and glial-producing ability. Neural precursor cells can be identified as markers using nestin, GLAST, Sox2, Sox1, Musashi, Pax6, etc. Alternatively, neural cell marker-positive and growth marker (Ki67, pH3, MCM)-positive cells can also be identified as neural precursor cells.
[0162] In the present invention, "retinal tissue" means a tissue in which one type or at least two or more types of cells constituting each retinal layer in vivo are spatially arranged in layers, such as photoreceptor cells, photoreceptor precursor cells, rod photoreceptor cells, cone photoreceptor cells, interneurons, horizontal cells, bipolar cells, amacrine cells, retinal ganglion cells (ganglion cells), retinal pigment epithelial cells (RPE), ciliary marginal zone cells, their progenitors / precursor cells, and retinal progenitor cells, etc. The retinal layer composed of each cell can be verified by a known method, for example, by the presence or absence of cell marker expression or its level, etc.
[0163] The "retinal layer" in the present invention means each layer constituting the retina. Specific examples thereof include retinal pigment epithelium, photoreceptor layer, external limiting membrane, outer nuclear layer, outer plexiform layer, inner nuclear layer, inner plexiform layer, ganglion cell layer, nerve fiber layer and inner limiting membrane.
[0164] The "retinal progenitor cells" in the present invention refer to progenitor cells that can differentiate into any mature retinal cells (including photoreceptor cells, horizontal cells, bipolar cells, amacrine cells, retinal ganglion cells and retinal pigment epithelial cells, etc.).
[0165] In the present invention, "neural retinal progenitor cells" refer to progenitor cells that can differentiate into any of a variety of mature retinal cells (including photoreceptor cells, horizontal cells, bipolar cells, amacrine cells, retinal ganglion cells, etc.) Usually, neural retinal progenitor cells do not differentiate into retinal pigment epithelial cells.
[0166] Photoreceptor precursor cells, horizontal cell precursor cells, bipolar cell precursor cells, amacrine cell precursor cells, retinal ganglion cell precursor cells and retinal pigment epithelial precursor cells refer to precursor cells that are determined to differentiate into photoreceptor cells, horizontal cells, bipolar cells, amacrine cells, retinal ganglion cells and retinal pigment epithelial cells, respectively.
[0167] In the present invention, "neurons specific to the retinal layer" are cells constituting the retinal layer and are neurons specific to the retinal layer. Examples of neurons specific to the retinal layer include bipolar cells, retinal ganglion cells, amacrine cells, horizontal cells, photoreceptor cells, retinal pigment epithelial cells, rod cells, and cone cells.
[0168] Examples of retinal cell markers include Rx (also known as Rax), PAX6, and Chx10 expressed in retinal progenitor cells, Nkx2.1 expressed in the progenitor cells of hypothalamic neurons but not expressed in retinal progenitor cells, Sox1 expressed in the hypothalamic neuroepithelium but not expressed in the retina, Crx, Blimp1, etc. expressed in the progenitor cells of photoreceptor cells, and similar markers. Examples of markers of neurons specific to the retinal layers include Chx10, PKCα, and L7 expressed in bipolar cells, TUJI and Brn3 expressed in retinal ganglion cells, calretinin expressed in amacrine cells, calcium binding proteins expressed in horizontal cells, rhodopsin and recoverin expressed in mature photoreceptor cells, Nrl and rhodopsin expressed in rod cells, Rxr-γ and S-opsin expressed in cone cells, RPE65 and Miff expressed in retinal pigment epithelial cells, Rdh10 and SSEA1 expressed in the ciliary marginal zone, etc.
[0169] In the present invention, "brain tissue" is a tissue in which one type or at least multiple types of cells (e.g., cortical neural precursor cells, dorsal cerebral neural precursor cells, ventral cerebral neural precursor cells, neurons specific to cerebral layer structures, layer 1 neurons, layer 2 neurons, layer 3 neurons, layer 4 neurons, layer 5 neurons, layer 6 neurons, glial cells (astrocytes and oligodendrocytes), these precursor cells, etc.) that make up the brain in the fetal stage or in an adult are spatially arranged in layers. The brain in the fetal stage is also called the forebrain or telencephalon. The presence of each cell can be verified by a known method, for example, by the presence or absence of expression of a cell marker or its level, etc.
[0170] In the present invention, "cerebral layer" means each layer constituting the adult brain or the fetal stage brain, and particularly includes the molecular layer, external granular layer, external pyramidal layer, internal granular layer, ganglionic layer (internal pyramidal layer), polymorphic layer, layer 1, layer 2, layer 3, layer 4, layer 5, layer 6, cortical zone, intermediate zone, subventricular zone and ventricular zone.
[0171] Examples of "cerebral neural precursor cells" in the present invention include neuronal precursor cells, layer 1 neuronal precursor cells, layer 2 neuronal precursor cells, layer 3 neuronal precursor cells, layer 4 neuronal precursor cells, layer 5 neuronal precursor cells, layer 6 neuronal precursor cells, astrocyte precursor cells, oligodendrocyte precursor cells, etc. They are precursor cells that are determined to differentiate into layer 1 neurons, layer 2 neurons, layer 3 neurons, layer 4 ganglia, layer 5 neurons, layer 6 neurons, astrocytes, and oligodendrocytes, respectively.
[0172] In the present invention, "brain neural precursor cells" include pluripotent stem cells (multipotent neural stem cells) having differentiation potential (multipotency) toward at least multiple differentiation lineages from layer 1 neurons, layer 2 neurons, layer 3 neurons, layer 4 neurons, layer 5 neurons, layer 6 neurons, astrocytes and oligodendrocytes.
[0173] In the present invention, "cerebral layer-specific neurons" are cells that constitute the cerebral layer and are neurons that are specific to the cerebral layer. As for the neurons that are specific to the cerebral layer, there can be mentioned layer 1 neurons, layer 2 neurons, layer 3 neurons, layer 4 ganglia, layer 5 neurons, layer 6 neurons, brain excitatory neurons, brain inhibitory neurons, etc.
[0174] Examples of brain cell markers include FoxG1 (also known as Bf1) expressed in brain cells, Sox2 and Nestin expressed in brain neural progenitor cells, Pax6 and Emx2 expressed in dorsal brain neural progenitor cells, Dlx1, Dlx2 and Nkx2.1 expressed in ventral brain neural progenitor cells, Tbr2, Nex, Svet1 expressed in neuronal progenitor cells, Tbr1 expressed in layer 6 neurons, Ctip2 expressed in layer 5 neurons, RORβ expressed in layer 4 neurons, Cux1 or Brn2 expressed in layer 3 neurons or layer 2 neurons, Reelen expressed in layer 1 neurons, etc.
[0175] 2. Methods for preparing neural cells or neural tissues
[0176] The preparation method 1 of the present invention is a method for preparing neural cells or neural tissues, and the method comprises the following steps (1)-(3):
[0177] (1) In the first step, pluripotent stem cells are cultured in a medium containing 1) a TGFβ family signal transduction pathway inhibitory substance and / or a Sonic hedgehog signal transduction pathway activating substance and 2) a factor for maintaining an undifferentiated state in the absence of feeder cells,
[0178] (2) in the second step, suspending and culturing the cells obtained in the first step to form cell aggregates, and
[0179] (3) In the third step, the aggregates obtained in the second step are suspended and cultured in the presence or absence of differentiation inducing factors, thereby obtaining aggregates containing neural cells or neural tissues.
[0180] In step (1), pluripotent stem cells are cultured in a medium containing 1) a TGFβ family signal transduction pathway inhibitory substance and / or a Sonic hedgehog signal transduction pathway activating substance and 2) a factor for maintaining an undifferentiated state in the absence of feeder cells.
[0181] As preferred pluripotent stem cells in step (1), induced pluripotent stem cells or embryonic stem cells (ES cells) can be mentioned, more preferably human induced pluripotent stem cells.
[0182] The preparation method of induced pluripotent stem cells is not particularly limited, and they can be produced by methods known to those of ordinary skill in the art, as mentioned above. It is also desirable to carry out the step of preparing induced pluripotent stem cells (i.e., the step of reprogramming somatic cells to establish pluripotent stem cells) under feeder-free conditions.
[0183] Although the preparation method of embryonic stem cells (ES cells) is not particularly limited and can be prepared by methods known to ordinary technicians in the field, as mentioned above, it is also desirable to perform the step of preparing embryonic stem cells (ES cells) under feeder cell-free conditions.
[0184] The maintenance culture or expansion culture of the pluripotent stem cells used in step (1) can be carried out by methods well known to those of ordinary skill in the art, as mentioned above. Although the maintenance culture and expansion culture of pluripotent stem cells can be carried out by adherent culture or suspension culture, it is preferably carried out by adherent culture. Although the maintenance culture and expansion culture of pluripotent stem cells can be carried out under the condition of the presence of feeder cells or under the condition of no feeder cells, it is preferably carried out under the condition of no feeder cells. The absence of feeder cells (no feeder cells) in the maintenance culture and expansion culture of pluripotent stem cells means a condition that is substantially free of feeder cells (for example, the ratio of the number of feeder cells to the total number of cells is not more than 3%). Preferably, the maintenance culture and expansion culture of pluripotent stem cells are carried out under the condition of no feeder cells.
[0185] The absence of feeder cells (feeder-free) in step (1) means a condition in which there are substantially no feeder cells (for example, the ratio of the number of feeder cells to the total number of cells is not greater than 3%). Preferably, step (1) is performed under feeder-free conditions. The culture medium used in step (1) is not particularly limited as long as it is a culture medium that allows the maintenance of pluripotent stem cell culture in an undifferentiated state under feeder-free conditions (feeder-free culture medium). Preferably, in order to allow the maintenance of culture in an undifferentiated state, it contains factors for maintaining an undifferentiated state.
[0186] The factor for maintaining the undifferentiated state is not particularly limited, as long as it is a substance with the effect of inhibiting the differentiation of pluripotent stem cells. In the case of sensitized (primed) pluripotent stem cells (e.g., human ES cells, human iPS cells), examples of factors for maintaining the undifferentiated state widely used by those of ordinary skill in the art include FGF signal transduction pathway activating substances, TGFβ family signal transduction pathway activating substances, insulin, etc. About FGF signal transduction pathway activating substances, fibroblast growth factors (e.g., bFGF, FGF4, FGF8) can be particularly mentioned. About TGFβ family signal transduction pathway activating substances, TGFβ signal transduction pathway activating substances can be mentioned, Nodal / activator protein signal transduction pathway activating substances. About TGFβ signal transduction pathway activating substances, TGFβ1 and TGFβ2 can be mentioned. About Nodal / activator protein signal transduction pathway activating substances, Nodal, activator protein A, activator protein B can be mentioned. When culturing human pluripotent stem cells (human ES cells, human iPS cells), the medium of step (1) preferably contains bFGF as a factor for maintaining an undifferentiated state.
[0187] The factors for maintaining the undifferentiated state used in the present invention are generally factors for maintaining the undifferentiated state of mammals. The mammals are, for example, those mentioned above. Since the factors for maintaining the undifferentiated state can have cross-reactivity between mammalian species, factors for maintaining the undifferentiated state of any mammal can also be used, as long as the undifferentiated state of the pluripotent stem cells to be cultured can be maintained. Preferably, factors for maintaining the undifferentiated state of mammals of the same species as the cells to be cultured are used. For example, for the culture of human pluripotent stem cells, human factors (e.g., bFGF, FGF4, FGF8, EGF, Nodal, activator A, activator B, TGFβ1, TGFβ2, etc.) are used to maintain the undifferentiated state. Here, "human protein X" means that protein X has the amino acid sequence of protein X naturally expressed in the human body.
[0188] The factors for maintaining the undifferentiated state used in the present invention are preferably isolated. "Isolated" means that an operation has been performed to remove factors other than the desired components or cells, and the components or cells no longer exist in a naturally occurring state. Therefore, "isolated protein X" does not include endogenous protein X produced by cultured cells or tissues and contained in cells or tissues or in culture medium. The purity of "isolated protein X" (the percentage of protein X weight to total protein weight) is usually not less than 70%, preferably not less than 80%, more preferably not less than 90%, also preferably not less than 99%, and further preferably 100%. Therefore, in one embodiment, the present invention includes the step of providing an isolated factor for maintaining the undifferentiated state. In one embodiment, it includes the step of exogenously adding an isolated factor for maintaining the undifferentiated state to the culture medium used in step (1). Alternatively, the factors for maintaining the undifferentiated state can be added in advance to the culture medium used in step (1).
[0189] The concentration of the factor for maintaining the undifferentiated state in the culture medium used in step (1) is a concentration capable of maintaining the undifferentiated state of the pluripotent stem cells to be cultured, and can be appropriately determined by a person of ordinary skill in the art. For example, specifically, when bFGF is used as a factor for maintaining the undifferentiated state in the absence of feeder cells, its concentration is generally about 4 ng-500 ng / mL, preferably about 10 ng-200 ng / mL, and more preferably about 30 ng-150 ng / mL.
[0190] Regarding feeder-free culture media, various synthetic culture media have been developed and are commercially available, and for example, Essential 8 medium can be mentioned. Essential 8 medium is a DMEM / F12 medium containing the following as additives: L-ascorbic acid-2-phosphate magnesium (64 mg / l), sodium selenium (sodium selenium) (14 μg / l), insulin (19.4 mg / l), NaHCO3 (543 mg / l), transferrin (10.7 mg / l), bFGF (100 ng / mL), and TGFβ family signal transduction pathway activator (TGFβ 1 (2 ng / mL) or Nodal (100 ng / mL)) (Nature Methods, 8, 424-429 (2011)). Examples of commercially available feeder-free culture media include Essential 8 (manufactured by Life Technologies), S-medium (manufactured by DS Pharma Biomedical), StemPro (manufactured by Life Technologies), hESF9 (Proc Natl Acad Sci US A. 2008 Sep 9; 105(36): 13409-14), mTeSR1 (manufactured by STEMCELL Technologies), mTeSR2 (manufactured by STEMCELL Technologies), and TeSR-E8 (manufactured by STEMCELL Technologies). In addition to these, StemFit (manufactured by Ajinomoto Co., Inc.) can be mentioned as a feeder-free culture medium. The present invention can be conveniently performed by using these in step (1) mentioned above.
[0191] In step (1), the pluripotent stem cells may be cultured under any conditions of suspension culture and adherent culture, preferably adherent culture.
[0192] Although there is no particular limitation on the culture container used for adherent culture, as long as "adherent culture" can be performed, a cell-adhesive culture container is preferred. Cell-adhesive culture containers include culture containers whose surfaces have been artificially treated to improve cell adhesion, and specifically, the surface-treated culture containers mentioned above, culture containers coated with coating agents inside can be mentioned. Examples of coating agents include extracellular matrix, such as laminin [including laminin α5β1γ1 (hereinafter laminin 511), laminin α1β1γ1 (hereinafter laminin 111), etc. and laminin fragments (laminin 511E8, etc.)], tactile protein, collagen, gelatin, vitronectin, Synthemax (Corning Incorporated), Matrigel, etc., or polymers, such as polylysine, polyornithine, etc., and similar substances. Culture containers whose surfaces have been treated with positive charge treatment, etc. can also be used. Laminin is preferred, and laminin 511E-8 is more preferred. Laminin 511E-8 may be a commercially available product (eg, iMatrix-511, Nippi).
[0193] The culture medium used in step (1) contains a TGFβ family signal transduction pathway inhibitory substance and / or a Sonic hedgehog signal transduction pathway activating substance. In the first step, pluripotent stem cells are treated with a TGFβ family signal transduction pathway inhibitory substance and / or a Sonic hedgehog signal transduction pathway activating substance, and in the second step, suspension culture is performed, as a result of which the state of the pluripotent stem cells is changed, the quality of the aggregates is improved, and spherical cell aggregates having a smooth surface and a dense interior and maintaining an undifferentiated state can be produced with high efficiency.
[0194] The TGFβ family signal transduction pathway (ie, the TGFβ superfamily signal transduction pathway) is a signal transduction pathway transmitted within cells by the Smad family using TGFβ, Nodal / activin or BMP as ligands.
[0195] The TGFβ family signal transduction pathway inhibitory substance refers to a substance that inhibits the TGFβ family signal transduction pathway (i.e., the signal transduction pathway transmitted by the Smad family), and specific examples include TGFβ signal transduction pathway inhibitory substances, Nodal / activin signal transduction pathway inhibitory substances and BMP signal transduction pathway inhibitory substances.
[0196] The TGFβ signal transduction pathway inhibitory substance is not particularly limited as long as it inhibits the signal transduction pathway caused by TGFβ, and can be any one of a nucleic acid, a protein, and a low molecular weight organic compound. Examples of the substance include substances that directly act on TGFβ (e.g., proteins, antibodies, aptamers, etc.), substances that inhibit the expression of genes encoding TGFβ (e.g., antisense oligonucleotides, siRNA, etc.), substances that inhibit the binding of TGFβ receptors to TGFβ, and substances that inhibit the physiological activity caused by the signal transduction of TGFβ receptors (e.g., TGFβ receptor inhibitors, Smad inhibitors, etc.). Proteins known as TGFβ signal transduction pathway inhibitory substances can be mentioned, such as Lefty. Regarding TGFβ signal transduction pathway inhibitory substances, compounds known to those of ordinary skill in the art can be used, and specifically, SB431542, LY-364947, SB-505124, A-83-01, etc. can be mentioned. Here, SB431542 (4-(5-benzo[1,3]dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)-benzamide) and A-83-01 (3-(6-methyl-2-pyridinyl)-N-phenyl-4-(4-quinolyl)-1H-pyrazole-1-carbonylthioamide (carbothioamide)) are compounds known as inhibitors of TGFβ receptor (ALK5) and activin receptor (ALK4 / 7) (i.e., TGFβR inhibitors). The TGFβ signal transduction pathway inhibitory substance is preferably SB431542 or A-83-01.
[0197] The Nodal / activator protein signal transduction pathway inhibitory substance is not particularly limited, as long as it inhibits the signal transduction pathway caused by Nodal or activator protein, and can be any one of nucleic acids, proteins and low molecular weight organic compounds. Examples of the substance include substances that directly act on Nodal or activator protein (e.g., antibodies, aptamers, etc.), substances that inhibit the expression of genes encoding Nodal or activator protein (e.g., antisense oligonucleotides, siRNA, etc.), substances that inhibit the binding of Nodal / activator protein receptors to Nodal / activator protein, and substances that inhibit the physiological activity caused by the signal transduction of Nodal / activator protein receptors. Regarding Nodal / activator protein signal transduction pathway inhibitory substances, compounds known to those of ordinary skill in the art can be used, and specifically, SB431542, A-83-01, etc. can be mentioned. In addition, proteins known as Nodal / activator protein signal transduction pathway inhibitory substances (Lefty, Cerberus, etc.) can be used. The Nodal / Activin signal transduction pathway inhibitory substance is preferably SB431542, A-83-01 or Lefty.
[0198] The BMP signal transduction pathway inhibitory substance is not particularly limited as long as it inhibits the signal transduction pathway caused by BMP, and may be any one of a nucleic acid, a protein, and a low molecular weight organic compound. Here, with respect to BMP, BMP2, BMP4, BMP7 and GDF7 may be mentioned. Examples of the substance include substances that directly act on BMP (e.g., antibodies, aptamers, etc.), substances that inhibit the expression of genes encoding BMP (e.g., antisense oligonucleotides, siRNA, etc.), substances that inhibit the binding of BMP receptors (BMPR) to BMP, and substances that inhibit the physiological activity caused by signal transduction of BMP receptors. With respect to BMPR, ALK2 and ALK3 may be mentioned. With respect to BMP signal transduction pathway inhibitory substances, compounds known to those of ordinary skill in the art may be used, and specifically, LDN193189, Dorsomorphin, etc. may be mentioned. Here, LDN193189 (4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline) is a known BMPR (ALK2 / 3) inhibitor (hereinafter referred to as BMPR inhibitor), and is generally commercially available in the form of a hydrochloride. In addition, proteins known as BMP signal transduction pathway inhibitors (Chordin, Noggin, etc.) can be used. The BMP signal transduction pathway inhibitor is preferably LDN193189.
[0199] The TGFβ family signal transduction pathway inhibitory substance is preferably Lefty, SB431542, A-83-01 or LDN193189.
[0200] A variety of TGFβ family signal transduction pathway inhibitors with different action sites can be used in combination. By combining them, it is expected to improve the quality improvement effect of aggregates. For example, the combination of TGFβ signal transduction pathway inhibitors and BMP signal transduction pathway inhibitors, the combination of TGFβ signal transduction pathway inhibitors and Nodal / activator protein signal transduction pathway inhibitors, and the combination of BMP signal transduction pathway inhibitors and Nodal / activator protein signal transduction pathway inhibitors can be mentioned. Preferably, TGFβ signal transduction pathway inhibitors are used in combination with BMP signal transduction pathway inhibitors. For example, a particularly preferred combination is a combination of SB431542 and LDN193189.
[0201] Sonic hedgehog (hereinafter sometimes referred to as Shh) signal transduction pathway activating substance is a substance capable of enhancing signal transduction mediated by Shh. Examples of Shh signal transduction pathway activating substance include proteins belonging to the Hedgehog family (e.g., Shh and Ihh), Shh receptors, Shh receptor agonists, PMA (Purmorphamine; 9-cyclohexyl-N-[4-(4-morpholinyl)phenyl]-2-(1-naphthyloxy)-9H-purin-6-amine), SAG (Smoothened agonist; N-methyl-N'-(3-pyridylbenzyl)-N'-(3-chlorobenzo[b]thiophene-2-carbonyl)-1,4-diaminocyclohexane), etc. The Shh signal transduction pathway activating substance is preferably Shh protein (Genbank accession number: NM_000193, NP_000184), SAG or PMA.
[0202] TGFβ family signal transduction pathway inhibitory substances and Shh signal transduction pathway activating substances can be used in combination. By combining them, it is expected to improve the quality improvement effect of aggregates. Regarding specific combinations, it can be mentioned that any TGFβ family signal transduction pathway inhibitory substances selected from the group consisting of Lefty, SB431542, A-83-01 and LDN193189 and the combination of Shh signal transduction pathway activating substances selected from the group consisting of Shh protein, SAG and PMA can be used. When TGFβ family signal transduction pathway inhibitory substances and Shh signal transduction pathway activating substances are used in combination, cells can be cultured in a culture medium comprising both TGFβ family signal transduction pathway inhibitory substances and Shh signal transduction pathway activating substances, or cells can be treated with any one of TGFβ family signal transduction pathway inhibitory substances and Shh signal transduction pathway activating substances, and continue to be treated with any one or both of them.
[0203] The concentrations of the TGFβ family signal transduction pathway inhibitor and the Sonic hedgehog signal transduction pathway activator can be appropriately determined to fall within the range capable of providing the aforementioned effects. For example, SB431542 is usually used at a concentration of 0.1-200 μM, preferably 2-50 μμM. A-83-01 is usually used at a concentration of 0.05-50 μM, preferably 0.5-5 μM. LDN193189 is usually used at a concentration of 1-2000 nM, preferably 10-300 nM. Lefty is usually used at a concentration of 5-200 ng / ml, preferably 10-50 ng / ml. Shh protein is usually used at a concentration of 20-1000 ng / ml, preferably 50-300 ng / ml. SAG is usually used at a concentration of 1-2000 nM, preferably 10-700 nM, more preferably 30-600 nM. PMA is usually used at a concentration of 0.002-20 μM, preferably 0.02-2 μM. In one embodiment, the TGFβ family signal transduction pathway inhibitory substance can be appropriately used in an amount that imparts a TGFβ family signal transduction pathway inhibitory activity equivalent to the aforementioned concentration of SB43154. In one embodiment, the Sonichedgehog signal transduction pathway activating substance can be appropriately used in an amount that imparts a Shh signal transduction promoting activity equivalent to the aforementioned concentration of SAG.
[0204] The TGFβ family signal transduction pathway inhibitory activity of SB431542, LDN193189, etc. can be determined by methods known to those skilled in the art, for example, by detecting the phosphorylation of Smad by Western blotting (Mol Cancer Ther. (2004) 3, 737-45). The Sonic hedgehog signal transduction promoting activity of SAG, etc. can be determined by methods known to those skilled in the art, for example, by reporter gene assay focusing on Gli1 gene expression (Oncogene (2007) 26, 5163-5168).
[0205] Although the culture medium used in step (1) may be a serum-containing medium or a serum-free medium, a serum-free medium is preferred to avoid contamination with chemically undefined components.
[0206] In order to avoid contamination by chemically undefined components, the culture medium used in step (1) may be a culture medium with chemically defined components.
[0207] In step (1), the pluripotent stem cells may be cultured under any conditions of suspension culture or adherent culture, but adherent culture is preferred.
[0208] For culturing pluripotent stem cells under feeder-free conditions in step (1), the feeder-free medium mentioned above can be used as a medium. As for the feeder-free medium, Essential 8, S-medium, StemPro, hESF9, mTeSR1, mTeSR2, TeSR-E8, or StemFit can be mentioned, and Essential 8 or StemFit is preferably used.
[0209] For culturing pluripotent stem cells without feeder cells in step (1), an appropriate matrix can be used as a framework to provide the pluripotent stem cells with a framework that replaces feeder cells. The pluripotent stem cells are cultured in a cell container whose surface is coated with the matrix as a framework.
[0210] As matrices that can be used as frameworks, laminin (Nat Biotechnol 28, 611-615 (2010)), laminin fragments (Nat Commun 3, 1236 (2012)), basement membrane preparations (Nat Biotechnol 19, 971-974 (2001)), gelatin, collagen, heparan sulfate proteoglycan, haptoprotein, vitronectin and the like can be mentioned.
[0211] "Laminin" is a heterotrimeric molecule composed of α, β, and γ chains, and is an extracellular matrix protein containing isomers with different subunit chain compositions. Specifically, based on a heterotrimeric combination with 5 α chains, 4 β chains, and 3 γ chains, laminin has about 15 isomers. The name of laminin is determined by combining the respective numbers of α chains (α1-α5), β chains (β1-β4), and γ chains (γ1-γ3). For example, the laminin with a combination of α5 chains, β1 chains, and γ1 chains is called laminin 511. In the present invention, laminin 511 is preferably used (Nat Biotechnol 28, 611-615 (2010)).
[0212] The laminin used in the present invention is usually mammalian laminin. Regarding mammals, those mentioned above can be mentioned. In order to obtain xeno-free conditions, it is preferred to use laminin of a mammal of the same species as the cells to be cultured. For example, human laminin (preferably, human laminin 511) is used to culture human pluripotent stem cells.
[0213] The laminin fragment used in the present invention is not particularly limited as long as it has adhesion to pluripotent stem cells and allows the maintenance and culture of pluripotent stem cells under feeder cell-free conditions, and it is preferably an E8 fragment. Among the multiple fragments obtained by digesting laminin 511 with elastase, the laminin E8 fragment was identified as a fragment having strong cell adhesion activity (EMBO J., 3: 1463-1468, 1984, J. Cell Biol., 105: 589-598, 1987). In the present invention, the E8 fragment of laminin 511 is preferably used (Nat Commun 3, 1236 (2012), Scientific Reports 4, 3549 (2014)). The laminin E8 fragment used in the present invention does not need to be an elastase digestion product of laminin, and may be recombinant. In order to avoid contamination by uncertain components, a recombinant laminin fragment is preferably used in the present invention. The E8 fragment of laminin 511 is commercially available and can be purchased from, for example, Nippi, Inc. or the like.
[0214] The laminin or laminin fragment used in the present invention is preferably isolated.
[0215] "Basement membrane preparation" in the present invention refers to a preparation that, when target cells capable of forming a basement membrane are coated thereon and cultured, contains a preparation of basement membrane components having functions similar to those of epithelial cells for controlling cell morphology, differentiation, growth, mobility, functional expression, etc. For example, when further adherent culture is performed, the nerve cells and nerve tissue prepared by the present invention can be dispersed and cultured under the condition of the presence of a basement membrane preparation. Here, "basement membrane components" refer to the extracellular matrix molecules in the form of a thin film existing between the epithelial cell layer and the interstitial cell layer in animal tissues, etc. For example, a basement membrane preparation can be produced by removing cells capable of forming a basement membrane from a support with a solution of lipids capable of dissolving cells, an alkaline solution, etc., and the cells adhere to the support through the basement membrane. Examples of basement membrane preparations include products commercially available as basement membrane preparations (e.g., Matrigel TM (manufactured by Corning Incorporated: hereinafter sometimes referred to as Matrigel), Geltrex TM (manufactured by Life Technologies), and extracellular matrix known as a component of the basement membrane (e.g., laminin, type IV collagen, heparan sulfate proteoglycan, haptophore, etc.).
[0216] Matrigel TMIt is a basement membrane preparation extracted from Engelbreth Holm Swarn (EHS) mouse sarcoma. TM The main components of Matrigel are type IV collagen, laminin, heparan sulfate proteoglycans, and haptophores. In addition to these, it contains TGF-β, FGF, tissue plasminogen activator, and growth factors naturally produced by EHS tumors. TM The "reduced growth factor product" has a higher TM The growth factor concentration is low, and its standard concentration is: <0.5 ng / ml EGF, <0.2 ng / ml NGF, <5 pg / ml PDGF, 5 ng / ml IGF1, and 1.7 ng / ml TGFβ.
[0217] In order to avoid contamination by unidentified components, isolated laminin or laminin fragments are preferably used in the present invention.
[0218] Preferably, when culturing pluripotent stem cells under feeder cell-free conditions in step (1), the pluripotent stem cells are cultured in an adherent state in a cell container whose surface is coated with isolated laminin 511 or E8 fragment of laminin 511 (more preferably, E8 fragment of laminin 511).
[0219] Although the time period for culturing pluripotent stem cells in step (1) is not particularly limited, as long as the effect of improving the quality of the aggregates formed in step (2) can be achieved, it is generally 0.5-144 hours. The time period for culturing pluripotent stem cells in step (1) is preferably not less than 1 hour, not less than 2 hours, not less than 6 hours, not less than 12 hours, not less than 18 hours, or not less than 24 hours. The time period for culturing pluripotent stem cells in step (1) is within 96 hours or 72 hours. In one embodiment, the time period for culturing pluripotent stem cells in step (1) is preferably 2-96 hours, more preferably 6-48 hours, further preferably 12-48 hours, and further more preferably 18-28 hours (for example, 24 hours). That is, the first step starts 0.5-144 hours (preferably 18-28 hours) before step (2) starts, and step (2) continues at the end of step (1). In another embodiment, the time period for culturing pluripotent stem cells in step (1) is preferably 18-144 hours, 24-144 hours, 24-96 hours, or 24-72 hours. When cells are treated with any one of a TGFβ family signal transduction pathway inhibitor and a Shh signal transduction pathway activator, and then treated with the other, the treatment time of each can be set to fall within the aforementioned culture time period range.
[0220] The culture conditions in step (1), such as the culture temperature and CO2 concentration, can be appropriately determined. For example, although the culture temperature is about 30° C. to about 40° C., it is preferably about 37° C. For example, the CO2 concentration is about 1% to about 10%, preferably about 5%.
[0221] In a preferred embodiment, human pluripotent stem cells (e.g., human iPS cells) are cultured in an adherent state in the absence of feeder cells and in a serum-free medium containing bFGF. Preferably, adherent culture is performed in a cell container coated with laminin 511, the E8 fragment of laminin 511, or vitronectin on the surface. Adherent culture is preferably performed using Essential 8, TeSR medium, mTeSR medium, mTeSR-E8 medium, or StemFit medium, more preferably Essential 8 or StemFit medium as a medium without feeder cells.
[0222] In a preferred embodiment, human pluripotent stem cells (eg, human iPS cells) are cultured in suspension in the absence of feeder cells and in a serum-free medium containing bFGF. In suspension culture, human pluripotent stem cells can form human pluripotent stem cell aggregates.
[0223] In a preferred embodiment, the cells obtained in step (1) maintain a pluripotent state, and the pluripotent state is maintained throughout the process of step (1). The pluripotent state means a state in which at least a portion of the characteristics (including pluripotency) that are unique to pluripotent stem cells and shared by pluripotent stem cells are maintained. The pluripotent state is not necessarily strictly pluripotent. Specifically, the "pluripotent state" includes a state in which all or part of the markers that are indicators of the pluripotent state are expressed. Regarding markers of the pluripotent state, Oct3 / 4 positive, alkaline phosphatase positive, etc. can be mentioned. In one embodiment, cells that maintain a pluripotent state are Oct3 / 4 positive. Even when the expression level of Nanog is low compared to ES cells or iPS cells, it is included in the "cells showing a pluripotent state".
[0224] In one embodiment, the cells obtained in step (1) are stem cells with the potential to differentiate into at least neural cells or neural tissue (preferably, retinal tissue, retinal cells, retinal progenitor cells, or neurons exclusively in the retinal layer). In one embodiment, the cells obtained in step (1) are Oct3 / 4-positive stem cells with the potential to differentiate into at least neural cells or neural tissue (preferably, retinal tissue, retinal cells, retinal progenitor cells, or neurons exclusively in the retinal layer).
[0225] In a preferred embodiment, human pluripotent stem cells (eg, iPS cells) are cultured in an adherent state in a serum-free medium containing a TGFβ family signaling pathway inhibitory substance and / or a Sonic hedgehog signaling pathway activating substance and bFGF in the absence of feeder cells.
[0226] The aforementioned adherent culture is preferably carried out in a cell container whose surface is coated with laminin 511 or the E8 fragment of laminin 511. The TGFβ family signal transduction pathway inhibitory substance is preferably a TGFβ signal transduction pathway inhibitory substance (e.g., SB431542, A-83-01, Lefty), a Nodal / activin signal transduction pathway inhibitory substance (e.g., Lefty, SB431542, A-83-01), a BMP signal transduction pathway inhibitory substance (e.g., LDN193189, Chordin, Noggin) or a combination thereof (e.g., SB431542 and LDN193189). The TGFβ family signal transduction pathway inhibitory substance is more preferably Lefty, SB431542, A-83-01, or LDN193189, or a combination thereof (e.g., SB431542 and LDN193189). The Sonic hedgehog signal transduction pathway activating substance is preferably Shh protein, SAG or Purmorphamine (PMA), more preferably SAG. TGFβ family signal transduction pathway inhibitory substances (e.g., Lefty, SB431542, A-83-01, LDN193189) and Sonic hedgehog signal transduction pathway activating substances (e.g., Shh protein, SAG, PMA) can be used in combination. The time period for culturing is 0.5-144 hours (preferably, 18-144 hours, 24-144 hours, 24-96 hours, or 24-72 hours (e.g., 18-28 hours)).
[0227] For example, step (1) is performed as follows: pluripotent stem cells are cultured in advance in a culture medium containing factors for maintaining an undifferentiated state in the absence of feeder cells to maintain an undifferentiated state, a TGFβ family signal transduction pathway inhibitory substance and / or a Sonic hedgehog signal transduction pathway activating substance is added to the culture, and the culture is continued.
[0228] For example, human pluripotent stem cells (e.g., human iPS cells) are cultured in the absence of feeder cells and in a serum-free medium containing bFGF to maintain an undifferentiated state. The maintenance culture is preferably performed by adherent culture. The adherent culture is preferably performed in a cell container whose surface is coated with vitronectin, laminin 511, or the E8 fragment of laminin 511. Then, a TGFβ family signal transduction pathway inhibitory substance and / or a Sonic hedgehog signal transduction pathway activating substance are added to the culture, and the culture is continued. The TGFβ family signal transduction pathway inhibitory substance is preferably a TGFβ signal transduction pathway inhibitory substance (e.g., SB431542, A-83-01, Lefty), a Nodal / activin signal transduction pathway inhibitory substance (e.g., SB431542, A-83-01, Lefty), a BMP signal transduction pathway inhibitory substance (e.g., LDN193189), or a combination thereof (e.g., SB431542 and LDN193189). The TGFβ family signal transduction pathway inhibitory substance is more preferably Lefty, SB431542, A-83-01, or LDN193189, or a combination thereof (e.g., SB431542 and LDN193189). The Sonic hedgehog signal transduction pathway activating substance is preferably Shh protein, SAG or PMA. TGFβ family signal transduction pathway inhibitory substances (e.g., Lefty, SB431542, A-83-01, LDN193189) and Sonic hedgehog signal transduction pathway activating substances (e.g., Shh protein, SAG, PMA) can be used in combination. After the addition, the culture is continued for 0.5-144 hours (preferably, 18-144 hours, 24-144 hours, 24-96 hours, or 24-72 hours (e.g., 18-28 hours)).
[0229] Explain step (2), wherein the cells obtained in step (1) are cultured in suspension in a culture medium to form cell aggregates.
[0230] The culture medium used in step (2) is not particularly limited as long as it is described in the definition section mentioned above. The culture medium used in step (2) can be a serum-containing culture medium or a serum-free culture medium. In order to avoid contamination by chemically uncertain components, a serum-free culture medium is preferably used in the present invention. For example, a serum-free culture medium without both a BMP signal transduction pathway activating substance and a Wnt signal transduction pathway inhibitory substance can be used. For example, in order to avoid complicated preparation, a serum-free culture medium supplemented with an appropriate amount of commercially available serum substitutes (such as KSR, etc.) is preferably used (for example, a culture medium supplemented with a 1:1 mixture of IMDM and F-12 of 10% KSR, 450 μM 1-monothioglycerol and 1x chemically defined lipid concentrate, or a GMEM culture medium supplemented with 5%-20% KSR, NEAA, pyruvic acid, 2-mercaptoethanol). In the case of human pluripotent stem cells, the amount of KSR to be added to the serum-free culture medium is generally about 1% to about 30%, preferably about 2% to about 20%.
[0231] Regarding the formation of aggregates, first, dispersed cells are prepared by a dispersion operation on the cells obtained in step (1). The "dispersed cells" obtained by the dispersion operation refer to a state in which, for example, not less than 70% of the cells are single cells and not more than 30% of the cells are clumps of 2-50 cells. Preferably, with respect to dispersed cells, it can be mentioned that not less than 80% of the cells are single cells and not more than 20% of the cells are clumps of 2-50 cells. Dispersed cells refer to a state in which there is almost no mutual adhesion (e.g., planar attachment) of cells. In a part of this embodiment, dispersed cells refer to a state in which there is almost no cell-cell junction (e.g., adhesion connection).
[0232] The cell dispersion operation obtained in step (1) may include the mechanical dispersion treatment, cell dispersion solution treatment and cell protective agent treatment mentioned above. These treatments may be performed in combination. Preferably, the cell dispersion solution treatment and the cell protective agent treatment are performed simultaneously, and then the mechanical dispersion treatment is performed.
[0233] Regarding the cell protectants used for cell protectant treatment, FGF signal transduction pathway activating substances, heparin, IGF signal transduction pathway activating substances, serum, and serum substitutes can be mentioned. Regarding the cell protectants used to inhibit the cell death of pluripotent stem cells caused by dispersion (especially, the cell death of human pluripotent stem cells), Rho-associated coiled-coil kinase (ROCK) inhibitors or myosin inhibitors can be added. In order to inhibit the cell death of pluripotent stem cells (especially human pluripotent stem cells) caused by dispersion and protect the cells, Rho-associated coiled-coil kinase (ROCK) inhibitors or myosin inhibitors can be added at the beginning of the second step of culture. Regarding ROCK inhibitors, Y-27632, Fasudil (HA1077), H-1152, etc. can be mentioned. Regarding myosin inhibitors, Blebbistatin can be mentioned.
[0234] As the cell dispersion solution used for the cell dispersion treatment, there can be mentioned a solution containing any enzyme such as trypsin, collagenase, hyaluronidase, elastase, pronase, DNase, papain, etc. and a chelating agent such as ethylenediaminetetraacetic acid, etc. Commercially available cell dispersion solutions such as TrypLE Select (produced by Life Technologies) and TrypLE Express (produced by Life Technologies) can also be used.
[0235] As the mechanical dispersion treatment method, there may be mentioned a blowing and suction treatment or scraping with a doctor blade.
[0236] The dispersed cells are suspended in the above-mentioned medium.
[0237] Then, the suspension of dispersed cells is inoculated in the above-mentioned culture container, and the dispersed cells are cultured under the condition that they do not adhere to the culture container, whereby a plurality of cells aggregate together to form aggregates.
[0238] In this case, multiple cell aggregates can be formed simultaneously in one culture vessel by inoculating the dispersed cells in a relatively large culture vessel, such as a 10 cm dish. However, in this case, the sizes of the aggregates are different. Therefore, for example, a given amount of dispersed stem cells is placed in each well of a multi-well plate (U-shaped bottom, V-shaped bottom) (such as a 96-well microplate) and statically cultured, whereby cells rapidly condense to form an aggregate in each well. Aggregates are recovered from multiple wells, whereby a uniform aggregate population can be obtained.
[0239] The concentration of cells in step (2) can be appropriately set so that cell aggregates are formed more uniformly and effectively. For example, when a 96-well microplate is used to culture human cells (e.g., cells obtained from human iPS cells in step (1)) in suspension, about 1×10 3 About 1x10 5 cells, preferably about 3x10 3 About 5x10 4 cells, more preferably about 4 x 10 3 About 2x10 4 cells, more preferably about 4×10 3 About 1.6x10 4 cells, and more preferably about 8×10 3 About 1.2x10 4 The plate was left to stand to form aggregates.
[0240] The culture conditions of step (2) such as culture temperature, CO2 concentration, etc. can be appropriately determined. For example, the culture temperature is about 30° C. to about 40° C., preferably about 37° C. For example, the CO2 concentration is about 1% to about 10%, preferably about 5%.
[0241] In step (2), when the medium replacement operation is performed, for example, there can be mentioned an operation of adding a fresh medium without discarding the existing medium (medium addition operation), an operation of discarding about half the amount of the existing medium (about 30-90% of the volume of the existing medium, for example, 40-60%) and adding about half the amount of fresh medium (about 30-90% of the volume of the existing medium, for example, 40-60%) (half medium replacement operation), and an operation of discarding about the entire amount of the existing medium (not less than 90% of the amount of the existing medium) and adding about the entire amount of fresh medium (not less than 90% of the amount of the existing medium) (complete medium replacement operation).
[0242] When a specific component (e.g., a differentiation inducing factor) is added at a specific time point, for example, the following operation can be performed: the final concentration is calculated, about half of the existing culture medium is discarded, and about half of the fresh culture medium is added (half-culture medium replacement operation, half-culture medium replacement), wherein the fresh culture medium contains the specific component at a concentration higher than the final concentration (specifically, 1.5 to 3 times the final concentration, for example, about 2 times the final concentration).
[0243] When the concentration of a specific component contained in the existing culture medium is maintained at a specific time point, for example, an operation can be performed in which about half the amount of the existing culture medium is discarded and about half the amount of fresh culture medium containing the same concentration of the specific component as in the existing culture medium is added.
[0244] When the concentration of the components contained in the existing culture medium is reduced by dilution at a specific time point, for example, the culture medium replacement operation can be performed multiple times a day, preferably multiple times (e.g., 2-3 times) within 1 hour. In addition, when the concentration of the components contained in the existing culture medium is reduced by dilution at a specific time point, the cells or aggregates can be transferred to another culture container.
[0245] Although the tool used for the medium replacement operation is not particularly limited, for example, there can be mentioned a pipette, a micropipette, a multichannel micropipette, a continuous dispenser, etc. For example, when a 96-well plate is used as a culture container, a multichannel micropipette can be used.
[0246] The time period of suspension culture required to form cell aggregates can be appropriately determined according to the cells to be used so that the cells can be uniformly aggregated. In order to form uniform cell aggregates, it is ideally as short as possible. The step of forming cell aggregates with dispersed cells can be divided into a step of aggregating cells and a step of forming cell aggregates by the aggregated cells. For example, in the case of human cells (for example, stem cells obtained from human iPS cells in step (1)), in the step of inoculating dispersed cells (that is, at the beginning of suspension culture) to aggregate cells, preferably within about 24 hours, more preferably within about 12 hours, aggregated cells are formed. In the case of human pluripotent stem cells (for example, human iPS cells), from the time point of inoculating dispersed cells (that is, at the beginning of suspension culture) to the time period of forming aggregates, for example, preferably within about 72 hours, more preferably within about 48 hours. The time period for the formation of cell aggregates can be appropriately adjusted by controlling the tools, centrifugal conditions, etc. that aggregate cells.
[0247] The formation of cell aggregates and their uniformity can be determined based on the size and cell number of the aggregates, their macroscopic morphology, their microscopic morphology and their uniformity as analyzed by tissue staining, the expression of differentiation and undifferentiation markers and their uniformity, the control of differentiation marker expression and its synchronization, the reproducibility of differentiation efficiency between aggregates, etc.
[0248] After the aggregates are formed, the aggregates can continue to be cultured as they are. The time period of the suspension culture in step (2) is usually about 12 hours to 6 days, preferably about 12 hours to 48 hours.
[0249] In one embodiment, the culture medium used in step (2) contains a Sonic hedgehog signal transduction pathway activating substance. In step (1), the pluripotent stem cells are treated with a TGFβ family signal transduction pathway inhibitory substance and / or a Sonic hedgehog signal transduction pathway activating substance; and in the second step, the cells obtained in the first step are suspended and cultured in a culture medium (preferably a serum-free culture medium) containing a Sonic hedgehog signal transduction pathway activating substance, thereby further improving the quality of the aggregates and being able to form spherical, smooth-surfaced, non-collapsed, internally dense cell aggregates that maintain undifferentiated properties with high efficiency.
[0250] As for the Sonic hedgehog signal transduction pathway activating substance, those mentioned above can be used. Preferably, the Sonic hedgehog signal transduction pathway activating substance is SAG, Purmorphamine (PMA) or Shh protein. The concentration of the Sonic hedgehog signal transduction pathway activating substance in the culture medium can be appropriately determined so as to fall within the range capable of achieving the aforementioned effects. SAG is generally used at a concentration of 1-2000nM, preferably 10nM-1000nM, more preferably 10nM-700nM, further preferably 50nM-700nM, further preferably 100nM-600nM, further preferably 100nM-500nM. PMA is generally used at a concentration of 0.002-20μM, preferably 0.02-2μμM. Shh protein is generally used at a concentration of 20-1000ng / ml, preferably 50-300ng / ml. When a Sonic hedgehog signaling pathway activating substance other than SAG, PMA and Shh protein is used, it is desirably used at a concentration that imparts Sonic hedgehog signaling promoting activity equivalent to the activity of SAG at the above-mentioned concentration.
[0251] The timing of adding the Sonic hedgehog signal transduction pathway activating substance to the culture medium is not particularly limited as long as the above-mentioned effects can be provided, but the earlier the addition, the higher the effect can be obtained. The Sonic hedgehog signal transduction pathway activating substance is usually added to the culture medium within 6 days, preferably within 3 days, more preferably within 1 day, and further preferably at the start of step (2) from the start of step (2).
[0252] In a preferred embodiment, in step (2), the human cells obtained in step (1) (e.g., cells obtained from human iPS cells in step (1)) are suspended and cultured in a serum-free medium containing a Sonic hedgehog signal transduction pathway activating substance (e.g., SAG, PMA, Shh protein) to form aggregates. The Sonic hedgehog signal transduction pathway activating substance is preferably contained in the medium at the beginning of the suspension culture. A ROCK inhibitor (e.g., Y-27632) may also be added to the medium. The culture period is 12 hours to 6 days, preferably 12 hours to 48 hours. The aggregates formed are preferably uniform aggregates.
[0253] For example, the human cells obtained in step (1) (e.g., cells obtained from human iPS cells in step (1)) are recovered, dispersed into a single cell or a state close to a single cell in a serum-free medium containing a Sonic hedgehog signal transduction pathway activating substance (e.g., SAG, PMA, Shh protein), and subjected to suspension culture. The serum-free medium may contain a ROCK inhibitor (e.g., Y-27632). A suspension of human pluripotent stem cells (e.g., human iPS cells) is inoculated in the culture container mentioned above, and the dispersed pluripotent stem cells are cultured under conditions where the pluripotent stem cells do not adhere to the culture container, thereby assembling a plurality of pluripotent stem cells to form aggregates. The culture period is 12 hours to 6 days, preferably 12 hours to 48 hours. The aggregates formed are preferably uniform aggregates.
[0254] In a preferred embodiment, in step (1), pluripotent stem cells are treated with a TGFβ signal transduction pathway inhibitory substance, and in step (2), the cells obtained in step (1) are suspended and cultured in a culture medium containing a Sonic hedgehog signal transduction pathway activating substance (e.g., SAG, PMA, Shh protein). Preferably, SB431542 or A-83-01 can be used as a TGFβ signal transduction pathway inhibitory substance.
[0255] In a preferred embodiment, in step (1), the pluripotent stem cells are treated with a BMP signal transduction pathway inhibitory substance, and in step (2), the cells obtained in step (1) are suspended and cultured in a culture medium that does not contain a Sonic hedgehog signal transduction pathway activating substance (e.g., SAG, PMA, Shh protein). Preferably, LDN193189 can be used as a BMP signal transduction pathway inhibitory substance.
[0256] In a preferred embodiment, in step (1), pluripotent stem cells (e.g., human pluripotent stem cells) are treated with the following: TGFβ family signal transduction pathway inhibitory substances (e.g., TGFβ signal transduction pathway inhibitory substances (e.g., Lefty, SB431542, A-83-01), Nodal / activator protein signal transduction pathway inhibitory substances (e.g., Lefty, SB431542, A-83-01), BMP signal transduction pathway inhibitory substances (e.g., LDN193189), or combinations thereof (e.g., SB431542 and LDN193189), etc.); Sonic hedgehog signal transduction pathway activating substances (e.g., Shh protein, SAG, PMA); or TGFβ family signal transduction pathway inhibitory substances (e.g., Lefty, SB431542, A-83-01, LDN193189) and Sonic A combination of Sonic hedgehog signal transduction pathway activating substances (e.g., Shh protein, SAG, PMA), and in step (2), suspension culture of the cells obtained in step (1) is performed in a culture medium containing Sonic hedgehog signal transduction pathway activating substances (e.g., SAG, PMA, Shh protein).
[0257] In another embodiment, in step (1), pluripotent stem cells (e.g., human pluripotent stem cells) are treated with the following: a TGFβ family signal transduction pathway inhibitory substance (e.g., a TGFβ signal transduction pathway inhibitory substance (e.g., Lefty, SB431542, A-83-01), a Nodal / activator protein signal transduction pathway inhibitory substance (e.g., Lefty, SB431542, A-83-01), a BMP signal transduction pathway inhibitory substance (e.g., LDN193189), or a combination thereof (e.g., SB431542 and LDN193189), etc.); a Sonic hedgehog signal transduction pathway activating substance (e.g., Shh protein, SAG, PMA); or a TGFβ family signal transduction pathway inhibitory substance (e.g., Lefty, SB431542, A-83-01, LDN193189) and a Sonic A combination of Sonic hedgehog signal transduction pathway activating substances (e.g., Shh protein, SAG, PMA), and in step (2), suspension culture of the cells obtained in step (1) is performed in a culture medium that does not contain Sonic hedgehog signal transduction pathway activating substances (e.g., SAG, PMA, Shh protein).
[0258] In any embodiment, the culture medium in step (2) preferably contains a ROCK inhibitor (eg, Y-27632).
[0259] By carrying out step (2) in this manner, aggregates of the cells obtained in step (1) or cells derived therefrom are formed. The present invention also provides a method for preparing the aggregates. Compared with the aggregates formed by not treating with TGFβ family signal transduction pathway inhibitors and / or Sonic hedgehog signal transduction pathway activators in step (1), the aggregates obtained in step (2) have higher quality. Specifically, a population of aggregates having a high proportion of spherical cell aggregates having a smooth surface, a dense interior, and a non-collapsed shape can be obtained. In one embodiment, when aggregates (e.g., not less than 100 aggregates) are randomly selected on the 6th day from the start of the second step, for example, the total proportion of non-collapsed aggregates and / or non-cystic aggregates is not less than 70%, preferably not less than 80%.
[0260] The aggregates obtained in step (2) have the potential to differentiate into a variety of differentiated cells and differentiated tissues. In one embodiment, the aggregates obtained in step (2) have the potential to differentiate into neural cells or neural tissues (preferably, retinal tissue, retinal cells, retinal progenitor cells, or neurons specific to the retinal layer).
[0261] In one embodiment, by using the stem cells (preferably, Oct3 / 4-positive stem cells) obtained in step (1) and having the potential to differentiate into at least neural cells or neural tissues (preferably, retinal tissues, retinal cells, retinal progenitor cells, or neurons exclusively in the retinal layer) in step (2), it is possible to obtain an aggregate containing stem cells (preferably, Oct3 / 4-positive stem cells) having the potential to differentiate into at least neural cells or neural tissues (preferably, retinal tissues, retinal cells, retinal progenitor cells, or neurons exclusively in the retinal layer). By culturing the aggregates obtained in step (2) under appropriate differentiation conditions, a variety of differentiated cells and differentiated tissues can be efficiently induced.
[0262] In one embodiment, the aggregate obtained in step (2) comprises cells corresponding to cells in the intermediate stage between cells maintaining a pluripotent state (specifically, expressing Oct3 / 4) obtained at the end of step (1) and neural cells or neural tissue. These cells express any of the pluripotency state marker Oct3 / 4, ectoderm markers (Sox1, Sox2, N-cadherin, TP63), neuroectoderm markers (Sox1, Sox2, nestin, N-cadherin, Otx2) and the neural cell markers mentioned above. That is, in one embodiment, the aggregate obtained in step (2) comprises a mixture of cells expressing any of the pluripotency state marker Oct3 / 4, ectoderm markers (Sox1, Sox2, N-cadherin, TP63), neuroectoderm markers (Sox1, Sox2, nestin, N-cadherin, Otx2) and the neural cell markers mentioned above. That is, the aggregate obtained in step (2) contains stem cells with the potential to differentiate into at least neural cells or neural tissue, and / or ancestors / precursor cells of neural cells or neural tissue. The ancestors / precursor cells are characterized in that when they are cultured under known appropriate culture conditions, they show the ability (activity) of expressing the neural cell markers mentioned above. Therefore, in one embodiment, the aggregate obtained in step (2) contains Oct3 / 4 positive stem cells with the potential to differentiate into at least neural cells or neural tissue, and / or ancestors / precursor cells of neural cells or neural tissue. A portion of the cells contained in the aggregate obtained in step (2) can express the neural tissue markers mentioned above. In one embodiment, the aggregate obtained in step (2) can contain Oct3 / 4 positive cells with a ratio of not less than 50% (e.g., not less than 70%) of the total cells.
[0263] In step (2), when the medium replacement operation is performed, for example, there can be mentioned an operation of adding a fresh medium without discarding the existing medium (medium addition operation), an operation of discarding about a half amount of the existing medium (about 30-90% of the volume of the existing medium, for example, about 40-60%) and adding about a half amount of fresh medium (about 30-90% of the volume of the existing medium, for example, about 40-60%) (half medium replacement operation), and an operation of discarding about the entire amount of the existing medium (not less than 90% of the amount of the existing medium) and adding about the entire amount of fresh medium (not less than 90% of the amount of the existing medium) (complete medium replacement operation).
[0264] When a specific component (e.g., a differentiation inducing factor) is added at a specific time point, for example, the following operation can be performed: the final concentration is calculated, about half of the existing culture medium is discarded, and about half of the fresh culture medium is added (half-culture medium replacement operation, half-culture medium replacement), wherein the fresh culture medium contains the specific component at a concentration higher than the final concentration (specifically, 1.5 times to 3.0 times the final concentration, for example, about 2 times the final concentration).
[0265] When the concentration of a specific component contained in the existing culture medium is maintained at a specific time point, for example, an operation can be performed in which about half the amount of the existing culture medium is discarded and about half the amount of fresh culture medium containing the same concentration of the specific component as in the existing culture medium is added.
[0266] When the concentration of the components contained in the existing culture medium is reduced by dilution at a specific time point, for example, the culture medium replacement operation can be performed multiple times a day, preferably multiple times (e.g., 2-3 times) within 1 hour. In addition, when the concentration of the components contained in the existing culture medium is reduced by dilution at a specific time point, the cells or aggregates can be transferred to another culture container.
[0267] Although the tool used for the medium replacement operation is not particularly limited, for example, there can be mentioned a pipette, a micropipette, a multichannel micropipette, a continuous dispenser, etc. For example, when a 96-well plate is used as a culture container, a multichannel micropipette can be used.
[0268] Explain step (3), wherein aggregates containing neural cells or neural tissues are induced from the aggregates obtained in step (2).
[0269] A variety of methods have been reported for inducing the aggregation of pluripotent stem cells into neural cells or neural tissues by suspension culture. For example, the methods described in the following are known: WO 2005 / 123902, WO 2009 / 148170, WO 2008 / 035110, WO 2011 / 055855, Cell Stem Cell, 3, 519-32 (2008), Nature, 472, 51-56 (2011), Cell Stem Cell, 10 (6), 771-775 (2012), Nature Biotechnology, 27 (3), 275-80 (2009), Proc Natl Acad Sci USA, 110 (50), 20284-9 (2013), etc., but the method is not limited to these. Aggregates containing neural cells or neural tissues can be produced by applying such various neural cell or neural tissue induction methods to the aggregates obtained in step (2) and culturing the aggregates obtained in step (2) under appropriate neuronal differentiation inducing conditions.
[0270] For example, the aggregates obtained in step (2) are cultured in suspension in the presence or absence (preferably in the presence) of a differentiation-inducing factor to produce aggregates containing neural cells or neural tissues.
[0271] The differentiation inducing factor is a factor with the activity of inducing differentiation to cells or tissues, for example, it is a factor with the activity of causing stem cells or ancestors / precursor cells to differentiate into specific differentiation lineages (or determining the fate of stem cells or ancestors / precursor cells). Examples of differentiation inducing factors include, but are not particularly limited to, the following: in vivo gene products, such as growth factors, etc., low molecular weight compounds that regulate the effects of gene products in vivo, hormones, physiologically active substances, such as vitamins, etc., and the like. Examples of differentiation inducing factors widely used by those of ordinary skill in the art include BMP signal transduction activating substances, BMP signal transduction pathway inhibitory substances, Shh signal transduction pathway activating substances, Shh signal transduction pathway inhibitory substances, FGF signal transduction pathway activating substances, FGF signal transduction pathway inhibitory substances, Wnt signal transduction pathway activating substances, and Wnt signal transduction pathway inhibitory substances. The response to the differentiation inducing factor varies with the type and differentiation state (differentiation ability, potential) of the cell, and the effect of the differentiation inducing factor may be different even during the differentiation induction process, depending on the concentration of the differentiation inducing factor and the timing of addition. In addition, the optimal concentration of known differentiation-inducing factors showing similar effects varies with animal species, and, for example, it is known that between mouse cells and human cells, the optimal concentration of human cells is generally higher (particularly in ectoderm, endoderm). There are multiple reports on the method for differentiation induction of pluripotent stem cells to specific cells or tissues, and differentiation-inducing factors or differentiation induction methods suitable for target cells or tissues can be selected.
[0272] The differentiation inducing factors used in the present invention are generally mammalian differentiation inducing factors. Examples of mammals include those mentioned above. Since the differentiation inducing factors may have cross-reactivity between mammalian species, any mammalian differentiation inducing factor may also be used, as long as differentiation induction of cultured pluripotent stem cells can be achieved. Preferably, a mammalian differentiation inducing factor of the same species as the cultured cells is used.
[0273] The differentiation inducing factor used in the present invention is preferably isolated. Therefore, in one embodiment, the present invention includes the step of providing an isolated differentiation inducing factor. And, in one embodiment, the present invention includes the step of exogenously adding the isolated differentiation inducing factor to the culture medium used in step (3).
[0274] In one embodiment, a neuronal differentiation-inducing factor is used as a differentiation-inducing factor in the method of the present invention, thereby producing an aggregate containing neural cells or neural tissues.
[0275] In one embodiment, for example, the culture medium used in step (3) is a serum-free culture medium or a serum-containing culture medium (preferably a serum-free culture medium) supplemented with differentiation inducing factors. The culture medium may or may not contain a basement membrane preparation. Regarding basement membrane preparations, those mentioned above can be used. When a basement membrane preparation is added, its concentration is, for example, 0.1-10% of the volume concentration when using matrigel, more preferably 0.5%-2%. To avoid contamination of chemically uncertain substances, basement membrane preparations are not added.
[0276] The serum-free medium or serum-containing medium used for the culture medium is not particularly limited as long as it is mentioned above. In order to avoid complicated preparation, for example, a serum-free medium supplemented with an appropriate amount of a commercially available serum substitute (such as KSR, etc.) or the like (for example, a medium supplemented with a 1:1 mixture of IMDM and F-12 supplemented with 10% KSR, 450 μM 1-monothioglycerol and 1× chemically defined lipid concentrate or a GMEM medium supplemented with 5%-20% KSR, NEAA, pyruvic acid, 2-mercaptoethanol) is preferably used. In the case of human ES cells, the amount of KSR to be added to the serum-free medium is generally about 1% to about 20%, preferably about 2% to about 20%.
[0277] Regarding the medium (preferably a serum-free medium) to be used in step (3), the medium (preferably a serum-free medium) used in step (2) may be used directly or may be replaced with a fresh medium (preferably a serum-free medium). When the serum-free medium containing no differentiation-inducing factor used in step (2) is directly used in step (3), the differentiation-inducing factor may be added to the medium.
[0278] In step (3), when the medium replacement operation is performed, for example, there can be mentioned an operation of adding a fresh medium without discarding the existing medium (medium addition operation), an operation of discarding about half the amount of the existing medium (about 40-80% of the volume of the existing medium) and adding about half the amount of fresh medium (about 40-80% of the volume of the existing medium) (half medium replacement operation), and an operation of discarding about the entire amount of the existing medium (not less than 90% of the amount of the existing medium) and adding about the entire amount of fresh medium (not less than 90% of the amount of the existing medium) (complete medium replacement operation).
[0279] When a specific component (e.g., a differentiation inducing factor) is added at a specific time point, for example, the following operation can be performed: the final concentration is calculated, about half of the existing culture medium is discarded, and about half of the fresh culture medium is added (half-culture medium replacement operation, half-culture medium replacement), wherein the fresh culture medium contains the specific component at a concentration higher than the final concentration (specifically, 1.5 times to 3.0 times the final concentration, for example, about 2 times the final concentration).
[0280] When the concentration of a specific component contained in the existing culture medium is maintained at a specific time point, for example, an operation can be performed in which about half the amount of the existing culture medium is discarded and about half the amount of fresh culture medium containing the same concentration of the specific component as in the existing culture medium is added.
[0281] When the concentration of the components contained in the existing culture medium is reduced by dilution at a specific time point, for example, the culture medium replacement operation can be performed multiple times a day, preferably multiple times (e.g., 2-3 times) within 1 hour. In addition, when the concentration of the components contained in the existing culture medium is reduced by dilution at a specific time point, the cells or aggregates can be transferred to another culture container.
[0282] Although the tool used for the medium replacement operation is not particularly limited, for example, there can be mentioned a pipette, a micropipette, a multichannel micropipette, a continuous dispenser, etc. For example, when a 96-well plate is used as a culture container, a multichannel micropipette can be used.
[0283] The differentiation inducing factor may be added about 24 hours or later from the start of the suspension culture in step (2), and may also be added to the culture medium within a few days (e.g., 15 days or 18 days) from the start of the suspension culture. Preferably, the differentiation inducing factor is added to the culture medium within 1 to 18 days, or 1 to 15 days, more preferably 1 to 9 days, further preferably 3 to 8 days or 2 to 9 days, still more preferably 3 to 6 days from the start of the suspension culture.
[0284] In another embodiment, differentiation inducing factors (e.g., Wnt signaling pathway inhibitory substances, TGFβ family signaling pathway inhibitory substances, etc.) can be added simultaneously with the initiation of suspension culture in step (2) or within about 24 hours after the initiation of suspension culture in step (2).
[0285] After adding the differentiation inducing factor to the culture medium and starting the induced differentiation of the aggregates into neural cells, it is not necessary to add the differentiation inducing factor to the culture medium, and the culture medium can be replaced with a serum-free culture medium or a serum-containing culture medium that does not contain the differentiation inducing factor, respectively. In one embodiment, after the aggregates start the differentiation induction into neural cells, the concentration of the differentiation inducing factor in the culture medium is gradually or stepwise reduced at a ratio of 40-60% every 2-4 days by replacing the culture medium with a serum-free culture medium or a serum-containing culture medium that does not contain the differentiation inducing factor, respectively.
[0286] In a specific embodiment, after the start of suspension culture (i.e., after the start of the aforementioned step (2)), the culture medium may be partially or completely replaced with a culture medium containing differentiation inducing factors on day 0-18, preferably day 1-9, more preferably day 2-8, and further preferably day 3 or day 4, and the cells may be cultured for about 1-100 days in the presence of the differentiation inducing factors. In order to maintain the concentration of the differentiation inducing factors at the same level, the culture medium may be partially or completely replaced with a culture medium containing the differentiation inducing factors. Alternatively, as mentioned above, the concentration of the differentiation inducing factors may also be gradually reduced.
[0287] Cells that have started differentiation induction into neural cells can be verified by, for example, detecting the expression of neural marker genes in the cells. As one embodiment of step (3), the following step can be mentioned: the aggregates formed in step (2) are suspended and cultured in a serum-free medium or serum medium containing differentiation induction factors at a concentration required for neuronal differentiation induction until cells expressing neural marker genes appear, thereby obtaining aggregates containing neural cells.
[0288] In one embodiment, a BMP signal transduction pathway activating substance is used as a differentiation inducing factor. That is, the aggregates obtained in the second step are suspended and cultured in the presence of a BMP signal transduction pathway activating substance to produce aggregates containing neural cells or neural tissues.
[0289] The BMP signal transduction pathway activating substance is a substance that can enhance the signal transduction mediated by BMP. Examples of BMP signal transduction pathway activating substances include BMP proteins such as BMP2, BMP4 or BMP7, GDF proteins such as GDF7, anti-BMP receptor antibodies, BMP partial peptides, etc. BMP2 protein, BMP4 protein and BMP7 protein can be obtained from, for example, R&D Systems, and GDF7 protein can be obtained from, for example, Wako Pure Chemical Industries, Ltd.
[0290] The concentration of the BMP signal transduction pathway activating substance can be a concentration that can induce the differentiation of pluripotent stem cell aggregates or stem cells derived therefrom into neural cells. For example, in the case of BMP4, it is added to the culture medium at a concentration of about 0.01 nM to about 1 μM, preferably about 0.1 nM to about 100 nM, more preferably about 1 nM to about 10 nM, and further preferably about 1.5 nM (55 ng / mL).
[0291] In one embodiment, differentiation into neural cells or neural tissues (spontaneous differentiation) can also be induced by performing step (3) in a serum-free medium or a serum-containing medium (preferably a serum-free medium) that does not contain the aforementioned differentiation-inducing factors, respectively, and in a serum-free medium or a serum-containing medium (preferably a serum-free medium) that does not contain the aforementioned factors for maintaining an undifferentiated state, respectively. For example, aggregates containing neural cells or neural tissues can also be obtained by suspending and culturing the aggregates obtained in step (2) in a serum-free medium or a serum-containing medium (preferably a serum-free medium) that does not substantially contain (i.e., does not contain at all or contains a concentration not greater than that for expressing physiological activity) a BMP signal transduction pathway activating substance (e.g., BMP4) and a Sonic hedgehog signal transduction pathway activating substance (e.g., SAG, PMA).
[0292] The culture medium is not particularly limited as long as it is mentioned above. In order to avoid complicated preparation, for example, it is preferred to use a serum-free medium supplemented with an appropriate amount of a commercially available serum substitute (such as KSR, etc.) (e.g., a medium supplemented with a 1:1 mixture of IMDM and F-12 of 10% KSR, 450 μM 1-monothioglycerol and 1× chemically defined lipid concentrate). For example, in the case of human ES cells, the amount of KSR to be added to the serum-free medium is generally about 1% to about 20%, preferably about 2% to about 20%.
[0293] Regarding the medium (preferably a serum-free medium) to be used in step (3), the medium (preferably a serum-free medium) used in step (2) may be used as it is, or the medium may be replaced with a fresh medium (preferably a serum-free medium).
[0294] Other culture conditions of step (3) may be appropriately set, such as culture temperature, CO2 concentration, etc. For example, the culture temperature is about 30-40° C., preferably about 37° C. For example, the CO2 concentration is about 1-10%, preferably about 5%.
[0295] For example, the fact that an aggregate containing neural cells is obtained can be verified by detecting the presence of cells expressing neural cell markers in the aggregate. Examples of neural cell markers include, but are not limited to, nestin, TuJ1, PSA-NCAM, etc. In one embodiment, the culturing of step (3) is performed until not less than 20% (preferably, not less than 30%, not less than 40%, not less than 50%, not less than 60%) of the cells contained in the aggregate express any neural cell marker selected from the group consisting of nestin, TuJ1 and PSA-NCAM.
[0296] The obtained aggregates containing neural cells can be used as reagents for evaluating toxicity or drug efficacy as they are. Aggregates containing neural cells can be subjected to dispersion treatment (e.g., trypsin / EDTA treatment or papain treatment), and the obtained cells can be selected using FACS or MACS, thereby obtaining highly purified neural cells.
[0297] In one embodiment, the aggregate containing neural cells obtained in step (3) contains a neuroepithelial structure, and neural tissue and / or neural cells are contained in the epithelial structure. Although the neuroepithelial structure exists covering the surface of the aggregate, part of it is also formed inside the aggregate. Using the aggregate obtained in step (2), an aggregate containing a neuroepithelial structure can be induced with high efficiency. The neuroepithelial structure can be identified as an epithelial structure positive for neural marker genes (e.g., nestin, TuJ1, PSA-NCAM). The neuroepithelial structure can be obtained as neural tissue. In one embodiment, the culturing of step (3) is performed until a neuroepithelial structure is formed in the aggregate. Regarding one embodiment of step (3), the following step can be mentioned: the aggregate formed in step (2) is suspended and cultured under neuronal differentiation induction conditions (e.g., in a serum-free medium or a serum-containing medium containing a differentiation induction factor at a concentration required for neuronal differentiation induction) until a neuroepithelial structure appears, thereby obtaining an aggregate containing a neuroepithelial structure.
[0298] In one embodiment, the aggregates obtained in step (2) or step (3) can be dispersed and inoculated in a cell culture dish, and cultured in an adherent state to produce nerve cells or neural tissue. Alternatively, in one embodiment, the aggregates obtained in step (2) or step (3) can be dispersed, the dispersed cells obtained are inoculated in a cell culture dish, and cultured in an adherent state to produce nerve cells or neural tissue. Regarding culture medium, the culture medium mentioned above can be used, and differentiation inducing factors can be added to the culture medium. Regarding cell culture dishes, the flat dishes mentioned above for adherent culture can be used. Cell culture dishes can be coated with cell adhesion molecules, etc. (e.g., laminin coating). The generation of nerve cells or neural tissue can be confirmed by immunostaining of nerve cell or neural tissue markers.
[0299] In one embodiment, the aggregates without neural cells obtained in the suspension culture process of step (2) or step (3) can be inoculated in a plate for adherent culture and cultured in an adherent state until they differentiate into neural cells. Although the culture medium for adherent culture is not particularly limited, the culture medium used in step (3) mentioned above can also be used.
[0300] In one embodiment, the cells without neural cells obtained during the adherent culture process of step (2) or step (3) can be peeled off from the plate for adherent culture, inoculated in a plate for suspension culture, and subjected to suspension culture until they differentiate into neural cells. Although the culture medium for suspension culture is not particularly limited, the culture medium used in step (3) can also be used.
[0301] The neuroepithelial structure present on the surface of the aggregate can be physically cut from the aggregate using forceps or the like under a microscope.
[0302] The preparation method of the present invention can efficiently obtain neural tissues such as neuroepithelial structures from pluripotent stem cells. Since the neuroepithelial structures obtained by the preparation method of the present invention contain a variety of neural cells, a variety of neurons and their progenitors / precursors can be obtained by using antibodies targeting markers of a variety of neural cells through FACS or the like.
[0303] The obtained aggregates containing neural tissues such as neuroepithelial structures can be used as reagents for evaluating toxicity or drug efficacy as they are. Highly pure neural cells can also be obtained by subjecting the aggregates containing neural tissues such as neuroepithelial structures to dispersion treatment (e.g., trypsin / EDTA treatment or papain treatment), and the obtained cells to selection via FACS or MACS.
[0304] 3. Methods for preparing retinal tissue
[0305] Preparation method 2 of the present invention is a method for preparing retinal tissue, which comprises the following steps (1)-(3):
[0306] (1) In the first step, pluripotent stem cells are cultured in a medium containing 1) a TGFβ family signal transduction pathway inhibitory substance and / or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining an undifferentiated state in the absence of feeder cells,
[0307] (2) in the second step, suspending and culturing the cells obtained in the first step to form cell aggregates, and
[0308] (3) In the third step, the aggregates obtained in the second step are suspended and cultured in the presence of a substance that activates the BMP signal transduction pathway, thereby obtaining aggregates containing retinal tissue.
[0309] Step (1) of the production method 2 of the present invention can be carried out in the same manner as step (1) of the production method 1 of the present invention.
[0310] Preferably, the cells obtained in step (1) include stem cells with the potential to differentiate into at least retinal tissue, retinal cells, retinal progenitor cells or neurons exclusive to the retinal layer. In one embodiment, the cells obtained in step (1) include Oct3 / 4 positive stem cells with the potential to differentiate into at least retinal tissue, retinal cells, retinal progenitor cells or neurons exclusive to the retinal layer. In one embodiment, the cells obtained in step (1) include Oct3 / 4 positive stem cells in a ratio of not less than 60%, for example, not less than 90%.
[0311] Step (2) of the preparation method 2 of the present invention can also be carried out in the same manner as step (2) of the preparation method 1 of the present invention.
[0312] The culture medium used in step (2) of preparation method 2 preferably contains a Sonic hedgehog signal transduction pathway activating substance. In step (1), pluripotent stem cells are treated with a TGFβ family signal transduction pathway inhibitory substance and / or a Sonic hedgehog signal transduction pathway activating substance; and in step (2), the cells obtained in step (1) are suspended and cultured in a culture medium (preferably a serum-free culture medium) containing a Sonic hedgehog signal transduction pathway activating substance to form aggregates, whereby the quality of the aggregates is further improved and the differentiation potential into retinal tissue is improved. Using high-quality aggregates, aggregates containing retinal tissue can be induced with high efficiency.
[0313] As for the Sonic hedgehog signal transduction pathway activating substance, those mentioned above can be used. Preferably, the Sonic hedgehog signal transduction pathway activating substance is Shh protein, SAG or PMA. The concentration of the Sonic hedgehog signal transduction pathway activating substance in the culture medium can be appropriately determined to fall within the range capable of achieving the aforementioned effects. SAG is generally used at a concentration of 1-2000nM, preferably 10-700nM, more preferably 30-600nM. PMA is generally used at a concentration of 0.002-20μM, preferably 0.02-2μM. Shh protein is generally used at a concentration of 20-1000ng / ml, preferably 50-300ng / ml. When a Sonic hedgehog signal transduction pathway activating substance other than Shh protein, SAG or PMA is used, it is ideally used in an amount that imparts Sonic hedgehog signal transduction promoting activity equivalent to the aforementioned concentration of SAG.
[0314] During step (2), the concentration of the Sonic hedgehog signal transduction pathway activating substance in the culture medium may be varied. For example, the Sonic hedgehog signal transduction pathway activating substance is provided so as to fall within the range mentioned above at the beginning of step (2), and the concentration may be gradually or stepwise reduced at a rate of 40-60% every 2-4 days.
[0315] The timing of adding the Sonic hedgehog signal transduction pathway activating substance to the culture medium is not particularly limited as long as the above-mentioned effects can be provided, but the earlier the addition, the higher the effect can be obtained. The Sonic hedgehog signal transduction pathway activating substance is usually added to the culture medium within 6 days, preferably within 3 days, more preferably within 1 day, and further preferably at the start of step (2) from the start of step (2).
[0316] In a preferred embodiment, the human cells obtained in step (1) (e.g., cells obtained from human iPS cells in step (1)) are suspended and cultured in a serum-free medium containing a Sonic hedgehog signal transduction pathway activating substance (e.g., SAG, PMA, Shh protein) to form aggregates. The Sonic hedgehog signal transduction pathway activating substance is preferably contained in the medium at the beginning of the suspension culture. A ROCK inhibitory substance (e.g., Y-27632) may also be added to the medium. The culture period is 12 hours to 6 days, preferably 12 hours to 48 hours. The aggregates formed are preferably uniform aggregates.
[0317] For example, the human cells obtained in step (1) (e.g., cells obtained from human iPS cells in step (1)) are recovered, dispersed into a single cell or a state close to a single cell, and suspended in a serum-free medium containing a Sonic hedgehog signal transduction pathway activating substance (e.g., SAG, PMA). The serum-free medium may contain a ROCK inhibitor (e.g., Y-27632). A suspension of human stem cells (e.g., stem cells derived from human iPS cells) is inoculated in the culture container mentioned above, and the dispersed cells are cultured without adhering to the culture container, thereby assembling a plurality of pluripotent stem cells to form aggregates. The culture period is 12 hours to 6 days (preferably 12 hours to 48 hours). The aggregates formed are preferably uniform aggregates.
[0318] By carrying out step (2) in this manner, aggregates of the cells obtained in step (1) or cells derived therefrom can be formed. The present invention also provides a method for preparing the aggregates. Compared with the aggregates formed in step (1) without treatment with TGFβ family signal transduction pathway inhibitors and / or Sonic hedgehog signal transduction pathway activators, the aggregates obtained in step (2) have higher quality. Specifically, a group of spherical cell aggregates having a smooth surface and a dense interior and a high proportion of uncollapsed aggregates can be obtained. In one embodiment, when aggregates (e.g., not less than 100 aggregates) are randomly selected on the 6th day from the start of the second step, for example, the proportion of non-cystic aggregates is not less than 70%, preferably not less than 80%.
[0319] The aggregates obtained in step (2) have the potential to differentiate into retinal tissue. Aggregates containing retinal tissue can be produced with high efficiency by culturing the aggregates obtained in step (2) under the conditions of step (3) described below.
[0320] In one embodiment, by using the stem cells having the potential to differentiate into at least retinal tissue, retinal cells, retinal progenitor cells or neurons specific to the retinal layers obtained in step (1) (preferably, Oct3 / 4-positive stem cells having the potential to differentiate into at least retinal tissue, retinal cells, retinal progenitor cells or neurons specific to the retinal layers) in step (2), an aggregate containing stem cells having the potential to differentiate into at least retinal tissue, retinal cells, retinal progenitor cells or neurons specific to the retinal layers (e.g., Oct3 / 4-positive stem cells) can be obtained.
[0321] Explain step (3), in which the aggregates obtained in step (2) are cultured in suspension in the presence of a BMP signal transduction pathway activating substance, thereby obtaining aggregates containing retinal tissue.
[0322] For example, the culture medium used in step (3) is a serum-free medium or a serum-containing medium (preferably a serum-free medium) supplemented with a BMP signal transduction pathway activating substance.
[0323] The serum-free medium or serum-containing medium used for the culture medium is not particularly limited, as long as it is mentioned above. In order to avoid complicated preparation, for example, a serum-free medium supplemented with an appropriate amount of commercially available serum substitutes (such as KSR, etc.) (e.g., a medium supplemented with a 1:1 mixture of IMDM and F-12 of 10% KSR, 450 μM 1-monothioglycerol and 1x chemically defined lipid concentrate) can be preferably used. In the case of human pluripotent stem cells (e.g., iPS cells), the amount of KSR to be added to the serum-free medium is generally about 1% to about 20%, preferably about 2% to about 20%.
[0324] The culture medium (preferably, serum-free culture medium) used in step (3) may also be the culture medium (preferably, serum-free culture medium) used in step (2), or may be replaced with a fresh culture medium (preferably serum-free culture medium). When the serum-free culture medium containing no BMP signal transduction pathway substances used in step (2) is directly used in step (3), a BMP signal transduction pathway activating substance may be added to the culture medium.
[0325] Examples of the BMP signal transduction pathway activating substance used in step (3) include BMP proteins such as BMP2, BMP4, BMP7, etc., GDF proteins such as GDF7, etc., anti-BMP receptor antibodies, BMP partial peptides, etc. BMP2 protein, BMP4 protein and BMP7 protein can be obtained from, for example, R&D Systems, and GDF7 protein can be obtained from, for example, Wako Pure Chemical Industries, Ltd. As for preferred BMP signal transduction pathway activating substances, BMP4 can be mentioned.
[0326] The concentration of BMP signal transduction pathway activating substances can be a concentration that can induce the cells forming pluripotent stem cell aggregates to differentiate into retinal cells. For example, in the case of human BMP4, it is added to the culture medium at a concentration of about 0.01nM to about 1μM, preferably about 0.1nM to about 100nM, more preferably about 1nM to about 10nM, and further preferably about 1.5nM (55ng / mL). When using a BMP signal transduction pathway activating substance different from BMP4, it is ideally used to show a concentration of BMP signal transduction promoting activity comparable to the BMP4 of the concentration mentioned above.
[0327] The concentration of the BMP signal transduction pathway activating substance in the culture medium can be changed during step (3). For example, the BMP signal transduction pathway activating substance is provided within the range mentioned above at the beginning of step (3), and the concentration can be gradually or stepwise reduced at a ratio of 40-60% every 2-4 days.
[0328] The BMP signal transduction pathway activating substance can be added about 24 hours or later from the start of the suspension culture in step (2), and can also be added to the culture medium within a few days (e.g., within 15 days) from the start of the suspension culture. Preferably, the BMP signal transduction pathway activating substance is added to the culture medium within the first to fifteenth day, more preferably within the first to ninth day, further preferably within the third to eighth day or within the second to ninth day, still more preferably within the third to sixth day from the start of the suspension culture.
[0329] In a specific embodiment, on the 1st to 9th day, preferably the 2nd to 8th day, and more preferably the 3rd or 4th day after the suspension culture is started (i.e., after the aforementioned step (2) is started), the culture medium can be partially or completely replaced with a culture medium containing BMP4 to adjust the final concentration of BMP4 to about 1-10 nM, and the cells can be cultured in the presence of BMP4 for about 1-12 days, preferably 2-9 days, and more preferably 2-5 days. In order to maintain the concentration of BMP4 at the same level, the culture medium can be partially or completely replaced once or twice with a culture medium containing BMP4. Alternatively, as mentioned above, the concentration of BMP4 can also be gradually reduced.
[0330] After the BMP signal transduction pathway activating substance is added to the culture medium and the cells that form aggregates begin to be induced to differentiate into retinal cells, it is not necessary to add the BMP signal transduction pathway activating substance to the culture medium, and the culture medium can be replaced with a serum-free culture medium or a serum-containing culture medium that does not contain the BMP signal transduction pathway activating substance, respectively. In one embodiment, after the induction of differentiation into retinal cells begins, the concentration of the BMP signal transduction pathway activating substance in the culture medium is gradually or stepwise reduced at a ratio of 40-60% every 2-4 days by replacing the culture medium with a serum-free culture medium or a serum-containing culture medium that does not contain the BMP signal transduction pathway activating substance, respectively. For example, cells that begin to be induced to differentiate into retinal cells can be confirmed by detecting the expression of retinal progenitor cell marker genes (e.g., Rx gene (alias Rax), Pax6 gene, Chx10 gene) in the cells. The aggregates formed in step (2) by using pluripotent stem cells knocked into a fluorescent reporter protein gene (such as GFP, etc.) at the Rax locus are suspended and cultured in the presence of a BMP signal transduction pathway activating substance at a concentration required for inducing differentiation into retinal cells, and the fluorescence emitted by the expressed fluorescent reporter protein is detected, thereby confirming the time period when the induction of differentiation into retinal cells begins. One embodiment of step (3) is a step of suspending and culturing the aggregates formed in step (2) in a serum-free medium or a serum-containing medium containing a BMP signal transduction pathway activating substance at a concentration required for inducing differentiation into retinal cells until cells expressing retinal progenitor cell marker genes (e.g., Rx gene, Pax6 gene, Chx10 gene) begin to appear, thereby obtaining cell aggregates containing retinal progenitor cells.
[0331] In step (3), when the medium replacement operation is performed, for example, there can be mentioned an operation of adding a fresh medium without discarding the existing medium (medium addition operation), an operation of discarding about half the amount of the existing medium (about 40-80% of the volume of the existing medium) and adding about half the amount of fresh medium (about 40-80% of the volume of the existing medium) (half medium replacement operation), and an operation of discarding about the entire amount of the existing medium (not less than 90% of the amount of the existing medium) and adding about the entire amount of fresh medium (not less than 90% of the amount of the existing medium) (complete medium replacement operation).
[0332] When a specific component (e.g., BMP4) is added at a specific time point, for example, the following operation can be performed: the final concentration is calculated, about half of the existing culture medium is discarded, and about half of the fresh culture medium is added (half-culture medium replacement operation, half-culture medium replacement), wherein the fresh culture medium contains the specific component at a concentration higher than the final concentration (specifically, 1.5-3.0 times the final concentration, for example, about 2 times the final concentration).
[0333] When the concentration of a specific component contained in the existing culture medium is maintained at a specific time point, for example, an operation can be performed in which about half the amount of the existing culture medium is discarded and about half the amount of fresh culture medium containing the same concentration of the specific component as in the existing culture medium is added.
[0334] When the concentration of the components contained in the existing culture medium is reduced by dilution at a specific time point, for example, the culture medium replacement operation can be performed multiple times a day, preferably multiple times (e.g., 2-3 times) within 1 hour. In addition, when the concentration of the components contained in the existing culture medium is reduced by dilution at a specific time point, the cells or aggregates can be transferred to another culture container.
[0335] Although the tool used for the medium replacement operation is not particularly limited, for example, there can be mentioned a pipette, a micropipette, a multichannel micropipette, a continuous dispenser, etc. For example, when a 96-well plate is used as a culture container, a multichannel micropipette can be used.
[0336] In one embodiment, when the concentration of the Shh signaling pathway activating substance added to the culture medium in step (2) is relatively low (e.g., not more than 700 nM for SAG, and to a concentration that imparts Shh signaling promoting activity equivalent to or lower than the concentration of SAG mentioned above for other Shh signaling pathway activating substances), medium replacement is not necessary, and a differentiation inducing factor (e.g., BMP4) may be added to the culture medium used in step (2). On the other hand, when the concentration of the Shh signaling pathway activating substance is relatively high (e.g., more than 700 nM or not less than 1000 nM for SAG, and to a concentration that imparts Shh signaling promoting activity equivalent to the concentration of SAG mentioned above for other Shh signaling pathway activating substances), it is necessary to replace the culture medium with a fresh culture medium containing a differentiation inducing factor (e.g., BMP4) to suppress the influence of the residual Shh signaling pathway activating substance when the differentiation inducing factor is added.
[0337] In a preferred embodiment, when calculated in terms of the Shh signaling promoting activity of SAG, the concentration of the Shh signaling pathway activating substance in the medium used in step (3) is not more than 700 nM, preferably not more than 300 nM, more preferably not more than 10 nM, further preferably not more than 0.1 nM, and further preferably does not contain the Shh signaling pathway activating substance. A medium "free of Shh signaling pathway activating substances" also includes a medium that substantially does not contain Shh signaling pathway activating substances, for example, a medium that does not contain Shh signaling pathway activating substances at a concentration that exerts an adverse effect on the selective differentiation of retinal progenitor cells or retinal tissues. A medium "free of Shh signaling pathway activating substances" also includes a medium that is substantially not supplemented with Shh signaling pathway activating substances, for example, a medium that is not supplemented with Shh signaling pathway activating substances at a concentration that exerts an adverse effect on the selective differentiation of retinal progenitor cells or retinal tissues.
[0338] The culture conditions in step (3), such as the culture temperature and CO2 concentration, etc., can be appropriately determined. For example, the culture temperature is about 30° C. to about 40° C., preferably about 37° C. For example, the CO2 concentration is about 1% to about 10%, preferably about 5%.
[0339] By such culture, the cells forming the aggregates obtained in step (2) are induced to differentiate into retinal progenitor cells, thereby obtaining aggregates containing retinal progenitor cells. The present invention also provides a method for preparing such aggregates containing retinal progenitor cells. Obtaining aggregates containing retinal progenitor cells can be confirmed by, for example, detecting the presence of cells expressing Rax, PAX6 or Chx10 (which are retinal progenitor cell markers) in the aggregates. One embodiment of step (3) is a step of suspending and culturing the aggregates formed in step (2) in a serum-free medium or a serum-containing medium containing a BMP signal transduction pathway activating substance at a concentration required for inducing differentiation into retinal cells until cells expressing the Rx gene begin to appear, thereby obtaining aggregates containing retinal progenitor cells. In one embodiment, the culture of step (3) is performed until not less than 20% (preferably, not less than 30%, not less than 40%, not less than 50%, not less than 60%) of the cells contained in the aggregates express Rx.
[0340] In a preferred embodiment for preparing retinal cells and / or retinal tissue, in step (1), human pluripotent stem cells (e.g., human iPS cells) are cultured in an adherent state in a serum-free medium containing a TGFβ signaling pathway inhibitory substance (e.g., SB431542, A-83-01) and bFGF in the absence of feeder cells; in step (2), the cells are suspended and cultured in a serum-free medium containing a Sonic hedgehog signaling pathway activating substance (e.g., SAG, PMA, Shh protein); and in step (3), the aggregates are suspended and cultured in a serum-free medium containing a BMP signaling pathway activating substance (e.g., BMP4).
[0341] In addition, in a preferred embodiment for preparing retinal cells and / or retinal tissue, in step (1), human pluripotent stem cells (e.g., human iPS cells) are cultured in an adherent state in a serum-free medium containing a BMP signaling pathway inhibitory substance (e.g., LDN193189) and bFGF in the absence of feeder cells; in step (2), the cells are suspended and cultured in a serum-free medium containing no or a Sonic hedgehog signaling pathway activating substance (e.g., SAG, PMA); and in step (3), the aggregates are suspended and cultured in a serum-free medium containing a BMP signaling pathway activating substance (e.g., BMP4).
[0342] In a preferred embodiment for preparing retinal cells and / or retinal tissue, in step (1), human pluripotent stem cells (e.g., human iPS cells) are cultured in an adherent state in a serum-free medium containing a Sonic hedgehog signaling pathway activating substance (e.g., SAG, PMA) and bFGF in the absence of feeder cells for preferably not less than 1 day and not more than 6 days, further preferably for 2-4 days, in step (2), the cells are cultured in suspension in a serum-free medium containing a Sonic hedgehog signaling pathway activating substance (e.g., SAG, PMA), and in step (3), the aggregates are cultured in suspension in a serum-free medium containing a BMP signaling pathway activating substance (e.g., BMP4).
[0343] In a preferred embodiment for preparing retinal cells and / or retinal tissues, in step (1), human pluripotent stem cells (e.g., human iPS cells) are cultured in an adherent state in the absence of feeder cells in a serum-free medium comprising the following: a TGFβ family signal transduction pathway inhibitory substance (e.g., a TGFβ signal transduction pathway inhibitory substance (e.g., Lefty, SB431542, A-83-01), a Nodal / activin signal transduction pathway inhibitory substance (e.g., Lefty, SB431542, A-83-01), a BMP signal transduction pathway inhibitory substance (e.g., LDN193189), or a combination thereof (e.g., SB431542 and LDN193189), etc.); A hedgehog signal transduction pathway activating substance (e.g., Shh protein, SAG, PMA); or a combination of a TGFβ family signal transduction pathway inhibitory substance (e.g., Lefty, SB431542, A-83-01, LDN193189) and a Sonic hedgehog signal transduction pathway activating substance (e.g., Shh protein, SAG, PMA); bFGF; in step (2), the cells obtained in step (1) are suspended and cultured in a serum-free medium containing a Sonic hedgehog signal transduction pathway activating substance (e.g., SAG, PMA, Shh protein) to form cell aggregates, and in step (3), the aggregates are suspended and cultured in a serum-free medium containing a BMP signal transduction pathway activating substance (e.g., BMP4) to produce aggregates containing retinal progenitor cells, retinal cells or retinal tissues.
[0344] The culture medium in step (2) preferably contains a ROCK inhibitory substance (eg, Y-27632).
[0345] The obtained aggregates containing retinal progenitor cells can be used as a reagent for evaluating toxicity or drug efficacy as they are. Highly pure retinal progenitor cells can also be obtained by subjecting the aggregates containing retinal progenitor cells to a dispersion treatment (e.g., trypsin / EDTA treatment or papain treatment) and selecting the obtained cells using FACS or MACS.
[0346] Furthermore, the aggregates containing retinal tissues can be further cultured in a serum-free medium or a serum-containing medium to allow the retinal progenitor cells to further differentiate, thereby generating neuroepithelial structure-like retinal tissues.
[0347] The serum-free medium or serum-containing medium used for the culture medium is not particularly limited as long as it is mentioned above. For example, a serum-containing medium as a DMEM-F12 medium supplemented with 10% fetal bovine serum, N2 supplement, 100 μM taurine and 500 nM retinoic acid or a serum-free medium supplemented with an appropriate amount of a commercially available serum substitute (such as KSR, etc.) (e.g., a medium supplemented with a 1:1 mixture of IMDM and F-12 supplemented with 10% KSR, 450 μM 1-monothioglycerol and 1× chemically defined lipid concentrate) and the like can be mentioned.
[0348] Although the culture time period for inducing retinal tissue from retinal progenitor cells varies depending on neurons specific to the target retinal layer, for example, the time period is about 7 days to about 200 days.
[0349] The retinal tissue is covered with the surface of the aggregate. After the suspension culture is completed, the aggregate can be fixed with a fixative (such as a paraformaldehyde solution, etc.), and frozen sections can be prepared, and then the formation of the retinal tissue with a layer structure can be confirmed by immunostaining, etc. Since the various layers of the retinal tissue are composed of different retinal progenitor cells (photoreceptor cells, horizontal cells, bipolar cells, amacrine cells, retinal ganglion cells), the formation of the layer structure can be confirmed by immunostaining using antibodies against the aforementioned markers expressed in these cells. In one embodiment, the retinal tissue is an Rx- or Chx10-positive neuroepithelial structure.
[0350] The retinal tissue present on the surface of the aggregate can be physically cut from the aggregate using forceps, etc. In this case, since neural tissue other than the retinal tissue can be formed on the surface of each aggregate, a portion of the neural tissue cut from the aggregate can be verified by immunostaining, etc. mentioned below, thereby confirming that the tissue is retinal tissue.
[0351] In one embodiment, the aggregate obtained in step (3) comprises retinal tissue and is substantially free of non-neural head ectoderm. In the aggregate comprising retinal tissue and substantially free of non-neural head ectoderm, for example, in the immunostaining image of the frozen section of the aforementioned aggregate, Rx-positive tissue is observed, and Rx-negative tissue is not observed outside it.
[0352] One embodiment of step (3) is a step of suspending and culturing the aggregates formed in step (2) in a serum-free medium or a serum-containing medium containing a BMP signal transduction pathway activating substance at a concentration required for inducing differentiation into retinal cells until cells expressing the Rx gene and / or the Chx10 gene begin to appear, thereby producing aggregates containing retinal progenitor cells, and then suspending and culturing the aggregates containing the retinal progenitor cells in a serum-free medium or a serum-containing medium until retinal tissue is formed, thereby obtaining aggregates containing retinal tissue. When the aggregates containing the retinal progenitor cells are subsequently suspended and cultured in a serum-free medium or a serum-containing medium until retinal tissue is formed, the concentration of the BMP signal transduction pathway activating substance in the medium for inducing retinal progenitor cells can be gradually or stepwise reduced at a ratio of 40-60% every 2-4 days by replacing the medium with a serum-free medium or a serum-containing medium that does not contain the BMP signal transduction pathway activating substance, respectively. In one embodiment, suspension culture of aggregates containing retinal progenitor cells is performed until not less than 20% (preferably, not less than 30%, not less than 40%, not less than 50%, not less than 60%) of cells contained in the aggregates express Chx10.
[0353] In one embodiment of step (3), the aggregates obtained in step (2) or the aggregates obtained by suspension culture of the aggregates obtained in step (2) by the method mentioned above can be cultured in an adherent manner to form adherent aggregates. The adherent aggregates are cultured in an adherent state in a serum-free medium or a serum-containing medium containing a BMP signal transduction pathway activating substance at a concentration required for inducing differentiation into retinal cells until cells expressing Rx genes and / or Chx10 genes begin to appear, thereby producing aggregates containing retinal progenitor cells. The aggregates containing the retinal progenitor cells are cultured in an adherent state in a serum-free medium or a serum-containing medium until retinal tissue is formed, thereby obtaining aggregates containing retinal tissue. In one embodiment, the adherent culture of the aggregates containing retinal progenitor cells is performed until not less than 10% (preferably, not less than 20%, not less than 30%, not less than 40%, not less than 50%) of the cells express Chx10.
[0354] By the preparation method 2 of the present invention, retinal tissue can be efficiently obtained from pluripotent stem cells. The retinal tissue obtained by the preparation method 2 of the present invention contains neurons that are exclusive to each retinal layer, and it is also possible to obtain cells that constitute the retinal tissue, such as photoreceptor cells, horizontal cells, bipolar cells, amacrine cells, retinal ganglion cells or their ancestors / precursor cells, etc. What cells can be obtained from the obtained retinal tissue can be confirmed by methods known per se (e.g., expression of cell markers).
[0355] Aggregates containing the obtained retinal tissue can also be directly used as reagents for evaluating toxicity or drug efficacy. Aggregates containing retinal tissue are dispersed (e.g., trypsin / EDTA treatment) and the obtained cells are selected using FACS or MACS, thereby obtaining highly pure cells constituting retinal tissue, for example, highly pure photoreceptor cells.
[0356] A ciliary marginal zone-like structure can be produced from a cell aggregate comprising a retinal tissue obtained by the production method 2 of the present invention or the like through the following steps (A) and (B).
[0357] The ciliary marginal zone sample structure in the present invention refers to a structure similar to the ciliary marginal zone. The example of " ciliary marginal zone (CMZ) " is included in the tissue present in the marginal zone of the retinal tissue (particularly, neural retina) and retinal pigment epithelium in vivo, and it is the region comprising retinal tissue stem cells (retinal stem cells). The ciliary marginal zone is also referred to as ciliary margin or retinal margin, and ciliary marginal zone, ciliary margin and retinal margin are equal tissues. Known ciliary marginal zone plays an important role in supplying retinal progenitor cells or differentiated cells to retinal tissue, maintaining retinal tissue structure, etc. The example of the marker gene in the ciliary marginal zone includes Rdh10 gene (positive), Otx1 gene (positive), Zicl gene (positive), etc.
[0358] Step (A) comprises culturing the cell aggregates comprising retinal tissue obtained by the preparation method 2 of the present invention in a serum-free medium or a serum-containing medium respectively comprising a Wnt signaling pathway activating substance and / or an FGF signaling pathway inhibitory substance for a period of time just before the appearance of cells expressing the RPE65 gene, wherein Chx10-positive cells are present in the cell aggregates at a ratio of more than 20% and less than 100% of the retinal tissue.
[0359] As for the preferred culture in step (A) herein, suspension culture may be mentioned.
[0360] As for the serum-free medium used in step (A), a serum-free medium as a basal medium supplemented with N2 or KSR can be mentioned. More specifically, a serum-free medium as a DMEM / F-12 medium supplemented with N2 supplement (Life Technologies) can be mentioned. As for the serum-containing medium, a serum-containing medium as a basal medium supplemented with fetal bovine serum can be mentioned.
[0361] The culture conditions of step (A), such as culture temperature, CO2 concentration, can be appropriately set. For example, the culture temperature is in the range of about 30° C. to about 40° C., preferably, for example, about 37° C. For example, the CO2 concentration is in the range of about 1% to about 10%, preferably, for example, about 5%.
[0362] In step (A), when the above-mentioned "cell aggregates containing retinal tissue" are cultured in a culture medium, the Wnt signal transduction pathway activating substance to be contained in the serum-free medium or the serum-containing medium is not particularly limited as long as it can enhance the signal transduction mediated by Wnt. Specific examples of Wnt signal transduction pathway activating substances include proteins belonging to the Wnt family (e.g., Wnt1, Wnt3a, Wnt7a), Wnt receptors, Wnt receptor agonists, GSK3β inhibitors (e.g., 6-Bromoindirubin-3'-oxime (6-Bromoindirubin-3'-oxime, BIO), CHIR99021, Kenpaullone) and the like.
[0363] In the case of a common Wnt signaling pathway activating substance such as CHIR99021, for example, the concentration of the Wnt signaling pathway activating substance contained in the serum-free medium or the serum-containing medium in step (A) is in the range of about 0.1 μM to about 100 μM, preferably, for example, in the range of about 1 μM to about 30 μM, more preferably, for example, is about 3 μM.
[0364] When the above-mentioned "cell aggregates containing retinal tissue" are cultured in a culture medium, the FGF signal transduction pathway inhibitory substance contained in the serum-free medium or the serum-containing medium in step (A) is not particularly limited as long as it can inhibit signal transduction mediated by FGF. Examples of FGF signal transduction pathway inhibitory substances include FGF receptors, FGF receptor inhibitors (e.g., SU-5402, AZD4547, BGJ398), MAP kinase cascade inhibitors (e.g., MEK inhibitors, MAPK inhibitors, ERK inhibitors), PI3 kinase inhibitors, Akt inhibitors, etc.
[0365] The concentration of the FGF signal transduction pathway inhibitory substance contained in the serum-free medium or serum-containing medium in step (A) only needs to be a concentration that can induce the differentiation of aggregates into ciliary marginal zone-like structures. For example, in the case of SU-5402, it is added to the culture medium to a concentration of about 0.1 μM to about 100 μM, preferably about 1 μM to about 30 μM, and more preferably about 5 μM.
[0366] In step (A), "culture continues only for a time period before the cells expressing the RPE65 gene appear" means culture in the whole time period or part of the time period before the cells expressing the RPE65 gene appear. That is, culture in the whole or part of the time period (any time period) is sufficient, and during the time period, the aforementioned "cell aggregates containing retinal tissue" in the culture system are composed of cells that do not substantially express the RPE65 gene. By using such culture, cell aggregates in which cells expressing the RPE65 gene do not appear can be obtained.
[0367] In order to determine the specific time period, the aforementioned "cell aggregates containing retinal tissue" is used as a sample, and the presence or absence of RPE65 gene expression or its level contained in the sample can be measured by a general genetic modification method or a biochemical method. Specifically, for example, the presence or absence of RPE65 gene expression or its level can be examined by immunostaining a frozen section of the aforementioned "cell aggregates containing retinal tissue" using an antibody against the RPE65 protein.
[0368] Regarding the “time period before the appearance of cells expressing the RPE65 gene” in step (A), for example, a time period during which the ratio of Chx10-positive cells present in the above-mentioned retinal tissue decreases and falls within the range of 30% to 0% compared to the time when the aforementioned cell aggregates are cultured in a serum-free medium or a serum-containing medium respectively containing a Wnt signal transduction pathway activating substance and / or an FGF signal transduction pathway inhibitory substance. Regarding “cell aggregates in which cells expressing the RPE65 gene do not appear”, a cell aggregate in which Chx10-positive cells accounting for 30% to 0% of the tissue are present in the aforementioned retinal tissue can be mentioned.
[0369] Although the number of days of "the time period before the appearance of cells expressing the RPE65 gene" in step (A) varies with the type of Wnt signal transduction pathway activating substance and / or FGF signal transduction pathway inhibitory substance, the type of serum-free medium or serum-containing medium, other culture conditions, etc., it is, for example, within 14 days. More specifically, when a serum-free medium (for example, a serum-free medium as a basal medium supplemented with N2) is used, for example, the above-mentioned time period is preferably within 10 days, more preferably, for example, 3 days to 6 days. When a serum-containing medium (for example, a serum-containing medium as a basal medium supplemented with fetal bovine serum) is used, for example, the aforementioned time period is preferably within 12 days, more preferably, for example, 6 days to 9 days.
[0370] Then, regarding step (B), the "cell aggregates in which cells expressing the RPE65 gene are absent" obtained by the above-mentioned culture are cultured in a serum-free medium or a serum-containing medium each not containing a Wnt signaling pathway activating substance.
[0371] As for the preferred culture in step (B), suspension culture can be mentioned.
[0372] The serum-free medium of step (B) preferably does not contain FGF signal transduction pathway inhibitory substances.
[0373] As for the serum-free medium in step (B), a medium as a basal medium supplemented with N2 or KSR can be mentioned. As for the serum-containing medium, a medium as a basal medium supplemented with fetal bovine serum can be mentioned. More specifically, a serum-containing medium as a DMEM / F-12 medium supplemented with fetal bovine serum can be mentioned.
[0374] The serum-free medium or serum-containing medium in step (B) may contain known growth factors, additives, and growth-promoting chemicals. Examples of known growth factors include EGF, FGF, IGF, insulin, etc. Examples of growth-promoting additives include N2 supplement (Life Technologies), B27 supplement (Life Technologies), KSR (Life Technologies), etc. Examples of growth-promoting chemicals include retinoids (e.g., retinoic acid) and taurine.
[0375] For example, the preferred time period for culturing in step (B) is a culturing time period during which the proportion of Chx10-positive cells present in the above-mentioned retinal tissue increases and reaches 30% or more compared to the time when the above-mentioned cell aggregates are cultured in a serum-free medium or a serum-containing medium that does not contain a Wnt signaling pathway activating substance, respectively.
[0376] The culture conditions in step (B) such as culture temperature, CO2 concentration, etc. can be appropriately set. For example, the culture temperature is in the range of about 30° C. to about 40° C., preferably, for example, about 37° C. For example, the CO2 concentration is in the range of about 1% to about 10%, preferably, for example, about 5%.
[0377] Although the above-mentioned number of days of culture until the "cell aggregates containing ciliary marginal zone-like structures" are obtained in step (B) varies depending on the type of serum-free medium or serum-containing medium, other culture conditions, etc., it is, for example, within 100 days. For example, the aforementioned number of days of culture is preferably 20 to 70 days, and more preferably, for example, 30 to 60 days.
[0378] In the "cell aggregate comprising ciliary marginal zone sample structure" prepared by the aforementioned steps (A), (B), in the same cell aggregate, there are retinal pigment epithelium and retinal tissue (particularly, neural retina) adjacent to the ciliary marginal zone sample structure. The structure can be confirmed by microscopic observation etc. Particularly, for example, the existence of the ciliary marginal zone sample structure can be confirmed by microscopic observation, which exists as an epithelial structure with a thick retinal side and a thin retinal pigment epithelium side, and it is formed between the retinal tissue with high transparency and the retinal pigment epithelium showing pigmentation. In addition, the existence of the ciliary marginal zone sample structure can be confirmed by utilizing the immunostaining of aggregate frozen sections to identify Rdh10 positive, Otx1 positive or Zic1 positive cells.
[0379] In another embodiment, through the aforementioned steps (A) and (B), the differentiation of the retinal tissue (neuroepithelium) contained in the aggregate continues, and mature retinal tissue and all cells containing at least one, preferably multiple, and more preferably selected from the group consisting of the following items can be produced: photoreceptor precursor cells, photoreceptor cells, cone photoreceptor cells, rod photoreceptor cells, horizontal cells, and interneurons (amarine cells, ganglion cells, etc.).
[0380] Retinal pigment epithelial cells can be produced from the cell aggregates containing retinal tissue obtained by the preparation method 2 of the present invention and similar methods by the following step (C). Retinal pigment epithelial sheets can be produced from the retinal pigment epithelial cells obtained by the following step (C) by the following step (D).
[0381] "Retinal pigment epithelial cells" in the present invention means epithelial cells present outside the neural retinal tissue in the retina in vivo. Whether it is a retinal pigment epithelial cell can be verified by a person of ordinary skill in the art based on, for example, the expression of cell markers (RPE65 (mature retinal pigment epithelial cells), Miff (juvenile or mature retinal pigment epithelial cells), etc.), the presence of melanin granules, polygonal characteristic cell morphology, etc.
[0382] First, in step (C), the cell aggregates containing retinal tissue obtained by preparation method 2 of the present invention are suspended and cultured in a serum-free culture medium or a serum-containing culture medium that does not contain BMP signaling pathway activating substances but contains Wnt signaling pathway activating substances, thereby producing aggregates containing retinal pigment epithelial cells.
[0383] As for the serum-free medium used in step (C), a serum-free medium as a basal medium supplemented with N2 or KSR can be mentioned. More specifically, a serum-free medium as a DMEM / F-12 medium supplemented with N2 supplement (Life Technologies) can be mentioned. As for the serum-containing medium, a serum-containing medium as a basal medium supplemented with fetal bovine serum can be mentioned.
[0384] The serum-free medium used in step (C) may further contain the aforementioned Nodal / activin signal transduction pathway activating substance and / or the aforementioned FGF signal transduction pathway inhibitory substance in addition to the aforementioned Wnt signal transduction pathway activating substance.
[0385] For example, the culture in step (C) is preferably a suspension culture.
[0386] The step (D) is explained in which the aggregates obtained in the step (C) of the present invention are dispersed and the obtained cells are cultured in an adherent state.
[0387] Step (D) is performed within 60 days, preferably within 30 days, more preferably within 3 days after the start of step (C).
[0388] Regarding the serum-free medium or serum-containing medium for adherent culture in step (D), the aforementioned medium can be mentioned. In order to avoid complicated preparation, it is preferred to use a serum-free medium supplemented with an appropriate amount of commercially available serum substitutes (such as KSR, etc.) (e.g., a medium of a 1:1 mixture of DMEM / F-12 and Neurobasal supplemented with 1 / 2x N2 supplement, 1 / 2x B27 supplement and 100 μM 2-mercaptoethanol). In the case of cells derived from human iPS cells, for example, the amount of KSR to be added to the serum-free medium is generally about 1% to about 20%, preferably about 2% to about 20%.
[0389] In step (D), the cells are preferably cultured in the aforementioned serum-free medium or serum-containing medium containing a ROCK inhibitory substance.
[0390] In step (D), the cells are more preferably cultured in a serum-free medium or a serum-containing medium further comprising one or more substances selected from the group consisting of: a Wnt signaling pathway activating substance, an FGF signaling pathway inhibitory substance, an activator protein signaling pathway activating substance and a BMP signaling pathway activating substance.
[0391] Activator signal transduction pathway activating substances are substances that can enhance the signal mediated by activator proteins. Examples of activator signal transduction pathway activating substances include proteins belonging to the activator family (e.g., activator A, activator B, activator C, activator AB, etc.), activator receptors, and activator receptor agonists.
[0392] The concentration of the activator signal transduction pathway activator used in step (D) can be any concentration as long as a uniform retinal pigment epithelial cell sheet can be effectively formed. For example, recombinant human / mouse / rat activator protein A (R&D systems, #338-AC) is added to a concentration of about 1 ng / ml to about 10 μg / ml, preferably about 10 ng / ml to about 1 μg / ml, and more preferably about 100 ng / ml.
[0393] For example, the activin signal transduction pathway activating substance is added within 18 days, preferably on the 6th day, from the start of step (D).
[0394] In step (D), adherent culture is preferably performed on a culture vessel whose surface is treated with a culture substrate. As for the culture substrate used to treat the culture vessel in step (D), a cell culture substrate that allows adherent culture of aggregate-derived cells and retinal pigment epithelial sheet formation can be mentioned.
[0395] 4. Methods for preparing brain tissue
[0396] Preparation method 3 of the present invention is a method for preparing brain tissue, which comprises the following steps (1)-(3):
[0397] (1) In the first step, pluripotent stem cells are cultured in a medium containing 1) a TGFβ family signal transduction pathway inhibitory substance and / or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining an undifferentiated state in the absence of feeder cells,
[0398] (2) in the second step, suspending and culturing the cells obtained in the first step to form cell aggregates, and
[0399] (3) In the third step, the aggregates obtained in the second step are suspended and cultured in the presence of a TGFβ family signal transduction pathway inhibitory substance and / or a Wnt signal transduction pathway inhibitory substance, thereby obtaining aggregates containing brain tissue.
[0400] Step (1) of the production method 3 of the present invention can be performed in the same manner as step (1) of the production method 1 of the present invention.
[0401] Step (2) of the production method 3 of the present invention can also be carried out in the same manner as step (2) of the production method 1 of the present invention.
[0402] The culture medium used in step (2) of preparation method 3 may or may not contain a Sonic hedgehog signal transduction pathway activating substance.
[0403] The culture medium used in step (2) may contain a TGFβ family signal transduction pathway inhibitory substance and / or a Wnt signal transduction pathway inhibitory substance. In step (2), a TGFβ family signal transduction pathway inhibitory substance or a Wnt signal transduction pathway inhibitory substance may be added to the culture medium alone, and preferably both are added in combination.
[0404] In step (3), regarding the differentiation inducing factor, a TGFβ family signal transduction pathway inhibitory substance or a Wnt signal transduction pathway inhibitory substance may be added to the culture medium alone, and preferably both are added in combination.
[0405] For example, the culture medium used in step (3) is a serum-free medium or a serum-containing medium (preferably a serum-free medium) supplemented with a TGFβ family signal transduction pathway inhibitory substance and / or a Wnt signal transduction pathway inhibitory substance.
[0406] The serum-free medium or serum-containing medium used for the culture medium is not particularly limited as long as it is mentioned above. In order to avoid complicated preparation, for example, a serum-free medium (e.g., a GMEM medium supplemented with 20% KSR, 0.1 mM 2-mercaptoethanol, non-essential amino acids, 1 mM pyruvic acid) supplemented with an appropriate amount of commercially available serum substitutes (e.g., KSR, etc.) is preferably used. In the case of human pluripotent stem cells (e.g., iPS cells), the amount of KSR to be added to the serum-free medium is generally about 1% to about 30%, preferably about 2% to about 20%.
[0407] The culture medium (preferably, serum-free culture medium) used in step (3) may also be the culture medium (preferably, serum-free culture medium) used in step (2), or may be replaced with a fresh culture medium (preferably serum-free culture medium). When the culture medium containing no TGFβ family signal transduction pathway inhibitory substance and / or Wnt signal transduction pathway inhibitory substance used in step (2) is directly used in step (3), the TGFβ family signal transduction pathway inhibitory substance and / or Wnt signal transduction pathway inhibitory substance may be added to the culture medium. When the culture medium containing TGFβ family signal transduction pathway inhibitory substance and / or Wnt signal transduction pathway inhibitory substance used in step (2) is directly used in step (3), half of the culture medium may be replaced with the same culture medium.
[0408] Examples of the TGFβ family signal transduction pathway inhibitory substance to be used in steps (2) and (3) include a TGFβ signal transduction pathway inhibitory substance, a Nodal / activin signal transduction pathway inhibitory substance, and a BMP signal transduction pathway inhibitory substance.
[0409] The TGFβ signal transduction pathway inhibitory substance is not particularly limited as long as it inhibits the signal transduction pathway caused by TGFβ, and can be any one of a nucleic acid, a protein, and a low molecular weight organic compound. Examples of the substance include substances that directly act on TGFβ (e.g., proteins, antibodies, aptamers, etc.), substances that inhibit the expression of genes encoding TGFβ (e.g., antisense oligonucleotides, siRNA, etc.), substances that inhibit the binding of TGFβ receptors to TGFβ, and substances that inhibit the physiological activity caused by the signal transduction of TGFβ receptors (e.g., TGFβ receptor inhibitors, Smad inhibitors, etc.). Proteins known as TGFβ signal transduction pathway inhibitory substances can be mentioned, such as Lefty. Regarding TGFβ signal transduction pathway inhibitory substances, compounds known to those of ordinary skill in the art can be used, and specifically, SB431542, LY-364947, SB-505, A-83-01, etc. can be mentioned. Here, SB431542 (4-(5-benzo[1,3]dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)-benzamide) and A-83-01 (3-(6-methyl-2-pyridinyl)-N-phenyl-4-(4-quinolyl)-1H-pyrazole-1-carbonylthioamide (carbothioamide)) are compounds known as inhibitors of TGFβ receptor (ALK5) and activin receptor (ALK4 / 7) (i.e., TGFβR inhibitors). The TGFβ signal transduction pathway inhibitory substance is preferably SB431542 or A-83-01.
[0410] The Nodal / activator protein signal transduction pathway inhibitory substance is not particularly limited, as long as it inhibits the signal transduction pathway caused by Nodal or activator protein, and can be any one of nucleic acids, proteins and low molecular weight organic compounds. Examples of the substance include substances that directly act on Nodal or activator protein (e.g., antibodies, aptamers, etc.), substances that inhibit the expression of genes encoding Nodal or activator protein (e.g., antisense oligonucleotides, siRNA, etc.), substances that inhibit the binding of Nodal / activator protein receptors to Nodal / activator protein, and substances that inhibit the physiological activity caused by the signal transduction of Nodal / activator protein receptors. Regarding Nodal / activator protein signal transduction pathway inhibitory substances, compounds known to those of ordinary skill in the art can be used, and specifically, SB431542, A-83-01, etc. can be mentioned. In addition, proteins known as Nodal / activator protein signal transduction pathway inhibitory substances (Lefty, Cerberus, etc.) can be used.
[0411] The BMP signal transduction pathway inhibitory substance is not particularly limited as long as it inhibits the signal transduction pathway caused by BMP, and may be any of a nucleic acid, a protein, and a low molecular weight organic compound. Here, with respect to BMP, BMP2, BMP4, BMP7 and GDF7 may be mentioned. Examples of the substance include substances that directly act on BMP (e.g., antibodies, aptamers, etc.), substances that inhibit the expression of genes encoding BMP (e.g., antisense oligonucleotides, siRNA, etc.), substances that inhibit the binding of BMP receptors (BMPR) to BMP, and substances that inhibit the physiological activity caused by signal transduction of BMP receptors. With respect to BMPR, ALK2 and ALK3 may be mentioned. With respect to BMP signal transduction pathway inhibitory substances, compounds known to those of ordinary skill in the art may be used, and specifically, LDN193189, Dorsomorphin, etc. may be mentioned. Here, LDN193189 (4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline) is a known BMPR (ALK2 / 3) inhibitor and is generally commercially available in the form of a hydrochloride. In addition, proteins known as BMP signal transduction pathway inhibitors (Chordin, Noggin, etc.) can be used. The BMP signal transduction pathway inhibitor is preferably LDN193189.
[0412] The TGFβ family signal transduction pathway inhibitory substance is preferably SB431542, A-83-01 or LDN193189.
[0413] The Wnt signal transduction pathway inhibitory substance used in steps (2) and (3) is not particularly limited as long as it can inhibit signal transduction mediated by Wnt, and can be any of a protein, a nucleic acid, and a low molecular weight compound, etc. The signal mediated by Wnt is transmitted via the Wnt receptor that exists as a heterodimer of Frizzled (Fz) and LRP5 / 6 (low-density lipoprotein receptor-related protein 5 / 6). Examples of the Wnt signal transduction pathway inhibitory substance include, but are not limited to, substances that directly act on Wnt or Wnt receptors (anti-Wnt antibodies, anti-Wnt receptor antibodies, etc.), substances that inhibit the expression of genes encoding Wnt or Wnt receptors (e.g., antisense oligonucleotides, siRNA, etc.), substances that inhibit the binding of Wnt receptors to Wnt (soluble Wnt receptors, dominant negative Wnt receptors, etc., Wnt activating substances, Dkk1, Cerberus proteins, etc.), substances that inhibit the physiological activity caused by signal transduction of Wnt receptors [low molecular weight compounds, such as CKI-7 (N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide), D4476 (4-[4-(2,3-dihydro-1,4-benzodihydro-1,4- [(3aR,4S,7R,7aS)-1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl]-N-8-quinolyl-benzamide), IWP-2 (N-(6-methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]acetamide) and the like, etc.], etc. CKI-7, D4476, IWR-1-endo (IWR1e), IWP-2, etc. are known Wnt signal transduction pathway inhibitory substances, and commercially available products, etc. are appropriately available. For example, a preferred Wnt signal transduction pathway inhibitory substance is IWR1e.
[0414] The concentration of the Wnt signal transduction pathway inhibitory substance only needs to be a concentration that can induce the cells that form pluripotent stem cell aggregates to differentiate into brain cells. For example, in the case of IWR-1-endo, it is added to the culture medium at a concentration of about 0.1 μM to about 100 μM, preferably about 0.3 μM to about 30 μM, more preferably about 1 μM to about 10 μM, and further preferably about 3 μM. When a Wnt signal transduction pathway activating substance other than IWR-1-endo is used, it is ideally used at a concentration that imparts a signal transduction pathway inhibitory activity equivalent to the concentration of IWRle mentioned above.
[0415] The TGFβ family signaling pathway inhibitory substance and / or the Wnt signaling pathway inhibitory substance can be added to the culture medium simultaneously with the start of suspension culture in step (2) or after a specific time has passed (e.g., about 24 hours or later) after the start of suspension culture in step (2).
[0416] In step (3), when the medium replacement operation is performed, for example, it can be performed by: an operation of adding a fresh medium without discarding the existing medium (medium addition operation), an operation of discarding about half the amount of the existing medium (about 40-80% of the volume of the existing medium) and adding about half the amount of fresh medium (about 40-80% of the volume of the existing medium) (half medium replacement operation), and an operation of discarding about the entire amount of the existing medium (not less than 90% of the amount of the existing medium) and adding about the entire amount of fresh medium (not less than 90% of the amount of the existing medium) (complete medium replacement operation), etc.
[0417] When a specific component (e.g., IWR-1-endo) is added at a specific time point, for example, the following operation can be performed: the final concentration is calculated, about half of the existing culture medium is discarded, and about half of the fresh culture medium is added (half culture medium replacement operation, half culture medium replacement), wherein the fresh culture medium contains the specific component at a concentration higher than the final concentration (specifically, 1.5 times to 3.0 times the final concentration, for example, about 2 times the final concentration).
[0418] When the concentration of a specific component contained in the existing culture medium is maintained at a specific time point, for example, an operation can be performed in which about half the amount of the existing culture medium is discarded and about half the amount of fresh culture medium containing the same concentration of the specific component as in the existing culture medium is added.
[0419] When the concentration of the components contained in the existing culture medium is reduced by dilution at a specific time point, for example, the culture medium replacement operation can be performed multiple times a day, preferably multiple times (e.g., 2-3 times) within 1 hour. In addition, when the concentration of the components contained in the existing culture medium is reduced by dilution at a specific time point, the cells or aggregates can be transferred to another culture container.
[0420] Although the tool used for the medium replacement operation is not particularly limited, for example, there can be mentioned a pipette, a micropipette, a multichannel micropipette, a continuous dispenser, etc. For example, when a 96-well plate is used as a culture container, a multichannel micropipette can be used.
[0421] The culture conditions of step (3) such as culture temperature, CO2 concentration, etc. can be appropriately determined. For example, the culture temperature is about 30° C. to about 40° C., preferably about 37° C. For example, the CO2 concentration is about 1% to about 10%, preferably about 5%.
[0422] By such culture, the cells forming aggregates obtained in step (2) are induced to differentiate into brain neural precursor cells, thereby obtaining aggregates containing brain neural precursor cells. The present invention also provides a method for preparing such aggregates containing brain neural precursor cells. The acquisition of aggregates containing brain neural precursor cells can be confirmed by, for example, detecting the presence of cells expressing FoxG1, Lhx2, PAX6, Emx2, etc. (which are brain neural precursor cell markers) in the aggregates. One embodiment of step (3) includes the following steps: suspending and culturing the aggregates formed in step (2) in a serum-free medium or a serum-containing medium until cells expressing FoxG1 begin to appear. In one embodiment, the culture of step (3) is performed until not less than 20% (preferably, not less than 30%, not less than 40%, not less than 50%, not less than 60%) of the cells contained in the aggregates express FoxG1.
[0423] In a preferred embodiment of preparing brain cells and / or brain tissues, in step (1), human pluripotent stem cells (e.g., human iPS cells) are cultured in an adherent state in a serum-free medium containing a TGFβ signaling pathway inhibitory substance (e.g., SB431542) and bFGF in the absence of feeder cells; in step (2), the cells obtained in step (1) are cultured in suspension in a serum-free medium; and in step (3), the aggregates obtained in step (2) are cultured in suspension in a serum-free medium containing a Wnt signaling pathway inhibitory substance (IWR-1-endo) and a TGFβ signaling pathway inhibitory substance (e.g., SB431542).
[0424] In addition, in a preferred embodiment of preparing brain cells and / or brain tissues, in step (1), human pluripotent stem cells (e.g., human iPS cells) are cultured in an adherent state in a serum-free medium containing a BMP signaling pathway inhibitory substance (e.g., LDN193189) and bFGF in the absence of feeder cells; in step (2), the cells obtained in step (1) are suspended and cultured in a serum-free medium; and in step (3), the aggregates obtained in step (2) are suspended and cultured in a serum-free medium containing a Wnt signaling pathway inhibitory substance (IWR--1-endo) and a TGFβ signaling pathway inhibitory substance (e.g., SB431542).
[0425] In a preferred embodiment of preparing brain cells and / or brain tissues, in step (1), human pluripotent stem cells (e.g., human iPS cells) are cultured in an adherent state in the absence of feeder cells in a serum-free medium comprising: a TGFβ family signal transduction pathway inhibitory substance (e.g., a TGFβ signal transduction pathway inhibitory substance (e.g., SB431542, A-83-01), a Nodal / activin signal transduction pathway inhibitory substance (e.g., Lefty), a BMP signal transduction pathway inhibitory substance (e.g., LDN193189), or a combination thereof (e.g., SB431542 and LDN193189), etc.); a Sonic hedgehog signal transduction pathway activating substance (e.g., Shh protein, SAG, PMA); or a TGFβ family signal transduction pathway inhibitory substance (e.g., Lefty, SB431542, A-83-01, LDN193189) and a Sonic hedgehog signal transduction pathway activating substances (e.g., Shh protein, SAG, PMA); and bFGF. In step (2), the cells obtained in step (1) are suspended and cultured in a serum-free medium containing the following items: TGFβ family signal transduction pathway inhibitory substances (e.g., TGFβ signal transduction pathway inhibitory substances (e.g., SB431542, A-83-01), Nodal / activator protein signal transduction pathway inhibitory substances (e.g., Lefty), BMP signal transduction pathway inhibitory substances (e.g., LDN193189, or combinations thereof (e.g., SB431542 and LDN193189) etc.); and Wnt signal transduction pathway inhibitory substances (IWR--1-endo ) to form cell aggregates, and in step (3), the aggregates obtained in step (2) are suspended and cultured in a serum-free culture medium containing the following: TGFβ family signal transduction pathway inhibitors (e.g., TGFβ signal transduction pathway inhibitors (e.g., SB431542, A-83-01), Nodal / activin signal transduction pathway inhibitors (e.g., Lefiy), BMP signal transduction pathway inhibitors (e.g., LDN193189), or combinations thereof (e.g., SB431542 and LDN193189), etc.); and Wnt signal transduction pathway inhibitors (IWR-1-endo), thereby producing aggregates containing brain neural progenitor cells, brain cells or brain tissues.
[0426] The culture medium in step (2) preferably contains a ROCK inhibitory substance (eg, Y-27632).
[0427] More preferably, in step (2), the cells obtained in step (1) are suspended and cultured in a serum-free medium containing the following: a TGFβ family signal transduction pathway inhibitory substance (e.g., a TGFβ signal transduction pathway inhibitory substance (e.g., SB431542, A-83-01), a Nodal / activin signal transduction pathway inhibitory substance (e.g., Lefty); a Wnt signal transduction pathway inhibitory substance (IWR--1-endo); and a ROCK inhibitory substance (e.g., Y-27632 ), thereby forming cell aggregates, and in step (3), the aggregates obtained in step (2) are suspended and cultured in a serum-free culture medium containing the following: a TGFβ signaling pathway inhibitory substance (e.g., SB431542, A-83-01), or a Nodal / activin signaling pathway inhibitory substance (e.g., Lefty); and a Wnt signaling pathway inhibitory substance (IWR--1-endo), thereby producing aggregates containing brain neural precursor cells, brain cells or brain tissues.
[0428] The obtained aggregates containing brain neural precursor cells can be used as reagents for evaluating toxicity or drug efficacy as they are. The aggregates containing brain neural precursor cells can be dispersed (e.g., trypsin / EDTA treatment or papain treatment), and the obtained cells can be selected using FACS or MACS, thereby obtaining high-purity brain neural precursor cells.
[0429] Furthermore, the aggregates containing the brain neural progenitor cells are further cultured in a serum-free medium or a serum-containing medium to further differentiate the brain neural progenitor cells or brain cells, thereby producing brain tissue having a layered structure.
[0430] The serum-free medium or serum-containing medium used for the medium is not particularly limited as long as it is mentioned above. For example, a serum-containing medium that is a DMEM-F12 medium supplemented with 10% fetal bovine serum, an N2 supplement, and retinoic acid, or a serum-free medium supplemented with an appropriate amount of a commercially available serum substitute (such as an N2 supplement, etc.) (e.g., a medium such as a DMEM-F12 medium supplemented with an N2 supplement) and the like can be mentioned.
[0431] Although the culture period for inducing brain tissue from brain neural precursor cells varies depending on neurons specific to the target brain layer, for example, the period is about 7 days to about 200 days.
[0432] Brain tissue exists and forms neuroepithelial structure in aggregate. After suspension culture is completed, the aggregate can be fixed with a fixative (such as paraformaldehyde solution, etc.), and frozen sections can be prepared, and then the formation of brain tissue with layer structure can be confirmed by immunostaining, etc. Since the various layers of brain tissue are composed of different brain neural precursor cells, ventricular zone precursor cells, and neurons exclusive to brain layer structure, the formation of layer structure can be confirmed by immunostaining using antibodies for the aforementioned markers expressed in these cells. In one embodiment, the brain tissue is a FoxG1-positive neuroepithelial structure.
[0433] The brain tissue present on the surface of the aggregate can be physically cut from the aggregate using forceps, etc. In this case, since nerve tissue other than brain tissue can be formed on the surface of each aggregate, a part of the nerve tissue cut from the aggregate can be verified by immunostaining, etc. mentioned below, thereby confirming that the tissue is brain tissue.
[0434] One embodiment of step (3) is a step of culturing the aggregates formed in step (2) in suspension in a serum-free medium or a serum-containing medium containing a TGFβ signal transduction pathway inhibitory substance and / or a Wnt signal transduction pathway inhibitory substance at a concentration required for inducing differentiation into brain cells until cells expressing the FoxG1 gene begin to appear, thereby generating aggregates containing brain neural precursor cells, and continuing to culture the aggregates containing the brain neural precursor cells in suspension in a serum-free medium or a serum-containing medium until brain tissue is formed, thereby obtaining aggregates containing brain tissue. In one embodiment, suspension culture of the aggregates containing brain neural precursor cells is performed until not less than 20% (preferably, not less than 30%, not less than 40%, not less than 50%, not less than 60%) of the cells contained in the aggregates express FoxG1.
[0435] In one embodiment of step (3), the aggregates obtained in step (2) or the aggregates obtained by suspension culture of the aggregates obtained in step (2) by the method mentioned above can be subjected to adherent culture to form adherent aggregates. The adherent aggregates are cultured in an adherent state in a serum-free medium or a serum-containing medium containing a TGFβ signal transduction pathway inhibitory substance and / or a Wnt signal transduction pathway inhibitory substance at a concentration required for inducing differentiation into brain cells until cells expressing the FoxG1 gene begin to appear, thereby producing aggregates containing brain neural precursor cells. The aggregates containing the brain neural precursor cells are continuously suspended in a serum-free medium or a serum-containing medium until brain tissue is formed, thereby obtaining aggregates containing brain tissue. In one embodiment, the adherent culture of the aggregates containing brain neural precursor cells is performed until not less than 10% (preferably, not less than 20%, not less than 30%, not less than 40%, not less than 50%) of the cells express FoxG1.
[0436] By the preparation method 3 of the present invention, brain tissue can be efficiently obtained from pluripotent stem cells. Because the retinal tissue obtained by the preparation method 3 of the present invention contains neurons specific to each brain layer, it is also possible to obtain cells constituting brain tissue, such as neurons specific to layer structures or their precursor cells, etc. What cells can be obtained from the obtained brain tissue can be verified by methods known per se (e.g., expression of cell markers).
[0437] The obtained aggregates containing brain tissue can also be directly used as reagents for evaluating toxicity or drug efficacy. Aggregates containing brain tissue are dispersed (e.g., trypsin / EDTA treatment), and the obtained cells are selected using FACS or MACS, thereby obtaining highly pure cells constituting brain tissue, for example, highly pure neurons specific to the brain layer structure.
[0438] 4. Methods for evaluating toxicity or efficacy
[0439] Since the neural tissue or neural cells (e.g., retinal tissue, retinal progenitor cells, neurons exclusive to the retinal layer, brain tissue, brain neural progenitor cells, neurons exclusive to the brain layer) produced by the preparation method 1, 2 or 3 of the present invention can be used as materials for disease research or drug discovery for screening drugs for treating diseases caused by disorders of neural tissue or neural cells, or for toxicity evaluation, it can be used as a reagent for evaluating the toxicity or efficacy of a test substance. For example, iPS cells are produced from human patients suffering from diseases, especially genetic diseases, caused by disorders of neural tissue (e.g., retinal tissue, brain tissue), and using the iPS cells, neural tissue or neural cells (e.g., retinal tissue, retinal progenitor cells, neurons exclusive to the retinal layer, brain tissue, brain neural progenitor cells, neurons exclusive to the brain layer) are produced by the method of the present invention. The neural tissue or neural cells can reproduce the neural tissue disorder that causes the patient's disease in vitro. Therefore, the present invention provides a method for evaluating the toxicity or efficacy of a test substance, the method comprising contacting the test substance with a neural tissue or neural cell (e.g., retinal tissue, retinal progenitor cells, neurons specific to retinal layers, brain tissue, brain neural progenitor cells, neurons specific to brain layers) produced by preparation method 1, 2 or 3 of the present invention, and detecting the effect of the substance on the cell or tissue.
[0440] For example, in the presence or absence of (negative control) test substances, the neural tissue or neural cells (e.g., retinal tissue, retinal progenitor cells, neurons exclusive to the retinal layer, brain tissue, brain neural precursor cells, neurons exclusive to the brain layer) produced by the preparation method 1, 2 or 3 of the present invention with a specific disorder (e.g., a genetic disorder) are cultured. Then, the severity of the disorder of the neural tissue or neural cells treated with the test substance is compared with the severity of the negative control. As a result, the test substance that reduces the severity of the disorder can be selected as a candidate substance for a drug for treating a disease caused by the disorder. For example, a test substance that improves the physiological activity (e.g., survival promotion or maturation) of the neural cells produced by the preparation method of the present invention can be sought as a candidate substance for a pharmaceutical product. Alternatively, according to the preparation method of the present invention, neural cells are prepared by inducing differentiation of induced pluripotent stem cells prepared from somatic cells, and the somatic cells have gene mutations that cause specific disorders such as neurological diseases.
[0441] Based on whether the nerve cells to which the test substance is added show the aforementioned disorder as an indicator, a candidate test substance that is effective as a therapeutic or preventive drug for the disorder can be searched.
[0442] For toxicity evaluation, the neural tissue or neural cells (e.g., retinal tissue, retinal progenitor cells, neurons exclusively in the retinal layer, brain tissue, brain neural progenitor cells, neurons exclusively in the brain layer) produced by the preparation method 1, 2 or 3 of the present invention are cultured in the presence or absence (negative control) of the test substance. Then, the severity of toxicity to the neural tissue or neural cells treated with the test substance is compared with the negative control. As a result, compared with the negative control, it can be judged that the test substance showing toxicity is a substance that is toxic to the neural tissue or neural cells (e.g., retinal tissue, retinal progenitor cells, neurons exclusively in the retinal layer).
[0443] That is, the present invention includes a method for evaluating toxicity, the method comprising the steps of:
[0444] (Step 1) a step of culturing the neural tissue or neural cells produced by the preparation method 1, 2 or 3 of the present invention for a given period of time under survival culture conditions in the presence of a test substance, and measuring the severity of cell damage,
[0445] (Step 2) a step of culturing the neural tissue or neural cells produced by the preparation method 1, 2 or 3 of the present invention for a given period of time under survival culture conditions in the absence of a test substance or in the presence of a positive control, and measuring the severity of cell damage,
[0446] (Step 3) A step of evaluating the toxicity of the test substance in Step 1 based on the difference between the results measured in (Step 1) and (Step 2).
[0447] As used herein, "in the absence of a test substance" includes adding only a culture medium or a solvent for dissolving the test substance without adding a test substance. In addition, a "positive control" means a compound known to be toxic. Examples of methods for measuring the severity of cell damage include methods for measuring the number of viable cells, for example, a method for measuring the amount of intracellular ATP, a method for measuring the number of viable cells by cell staining (e.g., nuclear staining) and morphological observation, and the like.
[0448] In step 3, regarding the method of evaluating the toxicity of the test substance, the measured value in step 1 and the measured value of the negative control in step 2 are compared, and when the severity of cell damage in step 1 is high, the test substance can be judged to be toxic. In addition, the measured value in step 1 and the measured value of the positive control in step 2 are compared, and when the severity of cell damage in step 1 is the same or higher, the test substance can be judged to be toxic.
[0449] 5. Pharmaceutical Composition
[0450] The present invention provides a pharmaceutical composition comprising an effective amount of neural tissue or neural cells (e.g., retinal tissue, retinal progenitor cells, neurons specific to retinal layers, brain tissue, brain neural progenitor cells, neurons specific to brain layers) produced by preparation method 1, 2 or 3 of the present invention.
[0451] The pharmaceutical composition comprises an effective amount of neural tissue or neural cells (e.g., retinal tissue, retinal progenitor cells, neurons specific to the retinal layer, brain tissue, brain neural progenitor cells, neurons specific to the brain layer) produced by preparation method 1, 2 or 3 of the present invention and a pharmaceutically acceptable carrier.
[0452] As for the pharmaceutical carrier, a physiological aqueous solvent (saline, buffer, serum-free medium, etc.) can be used. If necessary, in transplantation therapy, the drug containing the tissue or cell to be transplanted may contain a preservative, stabilizer, reducing agent, isotonic agent, etc. for convenient use.
[0453] The pharmaceutical composition of the present invention can be prepared into a suspension by suspending the nerve tissue or nerve cells produced by the preparation method 1, 2 or 3 of the present invention in an appropriate physiological aqueous solvent. If necessary, the composition can be added with an antifreeze agent, frozen for preservation, thawed when used, washed with a buffer, and used for transplantation therapy.
[0454] The neural tissue obtained by the preparation method of the present invention can also be cut into appropriate sizes using forceps or the like to produce a sheet preparation.
[0455] The cells obtained by the preparation method of the present invention can also be subjected to adherent culture in step (3) for differentiation induction, thereby forming sheet-like cells and producing sheet preparations.
[0456] The pharmaceutical composition of the present invention can be used as a drug for treating diseases caused by disorders of neural tissue or neural cells (e.g., retinal tissue, retinal progenitor cells, neurons specific to retinal layers, brain tissue, brain neural progenitor cells, neurons specific to brain layers).
[0457] 6. Therapeutic drugs
[0458] The neural tissue or neural cells (e.g., retinal tissue, retinal progenitor cells, neurons exclusively in the retinal layer, brain tissue, brain neural precursor cells, neurons exclusively in the brain layer) produced by the preparation method 1, 2 or 3 of the present invention can be used for transplantation treatment of diseases caused by disorders of neural tissue or neural cells. Therefore, the present invention provides a drug for treating diseases caused by disorders of neural tissue or neural cells, which comprises neural tissue or neural cells (e.g., retinal tissue, retinal progenitor cells, neurons exclusively in the retinal layer, brain tissue, brain neural precursor cells, neurons exclusively in the brain layer) produced by the preparation method 1, 2 or 3 of the present invention. The neural tissue or neural cells (e.g., retinal tissue, retinal progenitor cells, neurons exclusively in the retinal layer, brain tissue, brain neural precursor cells, neurons exclusively in the brain layer) produced by the preparation method 1, 2 or 3 of the present invention can be used as a drug for treating diseases caused by disorders of neural tissue or neural cells or for supplementing the corresponding injury site in the neural tissue of the damaged state. Diseased or damaged neural tissues due to disorders of neural tissues or neural cells can be treated by transplanting neural tissues or neural cells produced by preparation methods 1, 2 or 3 of the present invention into patients with diseased or damaged neural tissues due to disorders of neural tissues or neural cells (who need transplantation), thereby replenishing neural cells or disordered neural tissues themselves. Examples of diseases caused by disorders of nervous tissue or nerve-related cells include neurodegenerative diseases (e.g., cerebral ischemic disorder, cerebral infarction, Parkinson's disease, spinal cord injury, cerebrovascular disorders or brain / spinal cord traumatic disorders (e.g., cerebral infarction, head traumatic brain injury (TBI) or spinal cord injury multiple system atrophy), local neurodegenerative diseases (typical neurodegenerative diseases) (amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Parkinson syndrome,Dementia of Alzheimer type, progressive supranuclear paralysis (PSP), Huntington's disease, multiple system atrophy (MSA), spinal cord cerebellar degeneration (SCD), demyelinating disease or neuromuscular disease (multiple sclerosis (MS), acute disseminated encephalomyelitis (ADEM), inflammatory pervasive sclerosis (Schilder disease), subacute sclerosing panencephalitis, progressive multifocal leukoencephalopathy, cerebral hypoxia hypoxia, central pontine myelinolysis, Binswanger disease, Guillain-Barre syndrome, Fisher syndrome, chronic inflammatory demyelinating polyneuropathy, syringomyelia, spinocerebella degeneration, striatonigral denaturation (SND), olivopontoserebellaratrophy (OPCA), Shy-Drager syndrome), ophthalmologic diseases (macular degeneration, age-related macular degeneration),Retinal pigment denaturation, cataract, glaucoma, cornea disease, retinopathy, refractory epilepsy, progressive supranuclear paralysis, syringomyelia, spinal muscular atrophy (SMA), spinobulbarmuscular atrophy (SBMA), primary lateral sclerosis (PLS), progressive supranuclear paralysis (PSP), corticobasal degeneration (CBD), Huntington's disease (HD), choreoacanthocytosis, syringomyelia, frontotemporal lobar degeneration lobardegeneration), Xia-Ma-, Figure 3The diseases caused by the disorders of brain tissue or brain-related cells include neurodegenerative diseases (e.g., cerebral ischemic injury, cerebral infarction, motor neuron disease, ALS, Alzheimer's disease, polyglutamine disease, and cotricobasal degeneration). Examples of diseases caused by disorders of retinal tissue or retina-related cells include retinal deauration, pigmentary degeneration of the retina, age-related macular degeneration, organic mercury poisoning, chloroquine retinopathy, glaucoma, diabetic retinopathy, retinopathy of newborn babies, etc. Examples of damaged states of neural tissue include patients after separation of neural tissue, patients after irradiation of tumors in neural tissue, and trauma.
[0459] In transplantation therapy, rejection due to differences in histocompatibility antigens usually constitutes a problem. However, this problem can be solved by using pluripotent stem cells (e.g., induced pluripotent stem cells) established by the somatic cells of the transplant recipient. That is, in a preferred embodiment, the pluripotent stem cells (e.g., induced pluripotent stem cells) established by the somatic cells of the recipient are used as the pluripotent stem cells in the method of the present invention, and neural tissue or neural cells that are immune to the recipient are produced and transplanted into the recipient.
[0460] In addition, allogeneic neural tissue or neural cells can be generated from pluripotent stem cells (eg, induced pluripotent stem cells) established from somatic cells of other humans that are immunocompatible (eg, compatible in terms of HLA type and MHC type) with the recipient and transplanted into the recipient. [Example]
[0461] The present invention is explained in detail hereinafter by referring to Examples, which should not be construed as limitative.
[0462] Example 1: Pre-treatment of human iPS cells with a TGFβ family signal transduction pathway inhibitor in step 1 Example
[0463] Human iPS cells (1231A3 strain, obtained from Kyoto University) were cultured without feeder cells according to the method described in "Scientific Reports, 4, 3594 (2014)". For the feeder-free medium, StemFit medium (AK03, manufactured by Ajinomoto Co., Inc.) was used, and for the feeder-free framework, laminin 511-E8 (manufactured by Nippi, Inc.) was used.
[0464] Regarding the specific maintenance culture operation, sub-confluent human iPS cells (1231A3 strain) were first washed with PBS and dispersed into single cells using TrypLE Select (manufactured by Life Technologies). Then, the human iPS cells dispersed into single cells were inoculated in a plastic culture dish coated with laminin 511-E8 and cultured without feeder cells in StemFit medium in the presence of Y27632 (ROCK inhibitor, 10 μM). When using a 6-well plate (manufactured by Iwaki, for cell culture, the culture area is 9.4 cm 2 ) as the aforementioned plastic culture dish, the number of cells plated with respect to the human iPS cells dispersed into single cells was adjusted to 6×10 3 One day after seeding, the medium was changed to StemFit medium without Y27632. Then, once every 1-2 days, the medium was changed to StemFit medium without Y27632. Thereafter, 6 days after seeding, the cells were cultured to subconfluence (60% of the culture area was covered by cells).
[0465] As a specific example of the pretreatment in step 1 of the preparation method of the present invention, the following operation is performed. First, the above-mentioned sub-confluent human iPS cells (1231A3 strain) are washed with PBS and dispersed into single cells by using TrypLE Select (manufactured by Life Technologies). Then, the above-mentioned human iPS cells dispersed into single cells are inoculated in a plastic culture dish (manufactured by Iwaki) coated with laminin 511-E8, and cultured in StemFit medium without feeder cells in the presence of Y27632 (ROCK inhibitor, 10 μM). When using a 6-well plate (manufactured by Iwaki, with a culture area of 9.4 cm 2 ) as the above-mentioned plastic culture dish, the number of cells plated with respect to the above-mentioned human iPS cells dispersed into single cells was adjusted to 6×10 3 When using a 60 mm dish (manufactured by Iwaki, with a culture area of 21 cm 2 ) as the above-mentioned plastic culture dish, the number of cells plated with respect to the above-mentioned human iPS cells dispersed into single cells was adjusted to 13×10 3 . One day after seeding, the medium was replaced with StemFit medium without Y27632. Then, once every 1-2 days, the medium was replaced with StemFit medium without Y27632. Thereafter, the cells were cultured until 5 days after seeding, that is, one day before subconfluence (50% of the culture area was covered with cells). Similar results were shown even when cultured for 6 days after seeding. Human iPS cells that were subconfluent one day in the above-mentioned feeder-free culture were incubated in the presence of SB431542 (TGFβR inhibitor (TGFβRi), 5 μM) (Step 1: Pre-treatment, Figure 1 "TGFβRi 24 hr pretreatment") or in the absence of it (step 1: treatment without pretreatment, Figure 1 The cells were cultured without feeder cells for 1 day under an inverted microscope (KEYENCE). The results showed that the morphology of human iPS cells was not greatly affected by the treatment with TGFβR inhibitor (SB431542) during the culture without feeder cells. Figure 1 ).
[0466] Example 2: In step 1, a TGFβ family signal transduction pathway inhibitor or Shh activating substance is used to pre-treat Example 2 of Human iPS Cells
[0467] According to the method described in Example 1, human iPS cells (1231A3 strain) were cultured in a feeder-free culture medium until the day before subconfluence. Human iPS cells on the day before subconfluence were cultured in a feeder-free culture medium for 1 day in the presence of SB431542 (TGFβR inhibitor, 5 μM), LDN193189 (BMPR inhibitor, 100 nM), SAG (Shh activating substance, 300 nM), or TGFβR inhibitor and BMPR inhibitor (SB431542 5 μM, and LDN193189 100 nM) (Step 1: Treatment with pretreatment) or in the absence of them (Step 1: No pretreatment). The obtained cells were fixed with 4% paraformaldehyde, stained for Oct3 / 4 (which is one of the pluripotent stem cell markers), and the immunostained cells were observed under an inverted fluorescence microscope (BIOREVO, KEYENCE) for bright field observation and fluorescence image observation. When judging whether the above marker is positive in the immunostaining analysis, an intensity value not less than 2 times higher than the background is determined as positive. As a result, it was found that cells pre-treated with any compound were all Oct3 / 4-positive, which was similar to cells not pre-treated ( Figure 2 ). That is, cells pre-treated under these conditions were found to have a maintained pluripotent-like state.
[0468] Example 3: Formation of human iPS cells by using a TGFβ family signal transduction pathway inhibitory substance in step 1 Examples of cell aggregates
[0469] Human iPS cells (1231A3 strain) were cultured in a feeder-free culture medium in accordance with the method described in Example 1 until the day before subconfluence. Human iPS cells on the day before subconfluence were cultured in a feeder-free culture in the presence of SB431542 (TGFβR inhibitor, 5 μM) (Step 1: pretreatment: TGFβRi treatment) or in the absence of SB431542 (Step 1: no pretreatment) for 1 day.
[0470] The human iPS cells were treated with a cell dispersion solution using TrypLE Select (Life Technologies), further dispersed into single cells by pipetting, and the human iPS cells dispersed into single cells were cultured at 1.2×10 4Cells / well were suspended in 100 μl of serum-free medium in a non-cell-adhesive 96-well culture plate (PrimeSurface 96 V-bottom plate, manufactured by SUMITOMO BAKELITE), and suspension culture was performed at 37°C, 5% CO2. As for the serum-free medium (gfCDM+KSR) used therefor, a serum-free medium that was a 1:1 mixture of F-12 medium supplemented with 10% KSR, 450 μM 1-monothioglycerol and 1× chemically defined lipid concentrate and IMDM medium was used. At the start of suspension culture (at the 0th day after the start of suspension culture, step 2 was started), Y27632 (final concentration was 20 μM) was added to the above serum-free medium. By the second day after the start of suspension culture, cell aggregates were formed both under the pre-treatment condition and under the condition without pre-treatment (step 2 was ended and step 3 was started). On the third day after the start of suspension culture, a serum-free medium (50 μl) not containing Y27632 was added.
[0471] The cells prepared in this way on day 6 after the start of suspension culture were observed under a bright field microscope (KEYENCE) Figure 3 As a result, it was found that the cell aggregates of the treated cells pre-treated in the presence of the TGFβR inhibitor (SB431542) Figure 3 B) has a higher number of aggregates than those of cells not pre-treated ( Figure 3 A) Better shape.
[0472] Furthermore, bright field observation of the shape of the cell aggregates on day 6 after the start of the suspension culture was performed under an inverted microscope, and the shapes were classified as good shapes ( Figure 3 C, black bar, spherical, smooth surface and dense interior), medium-level shape ( Figure 3 , gray bars, spherical, cystic) and poor shape ( Figure 3 C, white bar, not spherical, collapsed) and quantified. As a result, it was found that under the condition without pre-treatment, about 90% of the cell aggregates had a poor shape, about 10% of the cell aggregates had a medium shape, and about 0% of the cell aggregates had a good shape ( Figure 3 C "Control", first bar from the left). In contrast, it was found that under the pre-treated treatment conditions, about 0% of the cell aggregates had poor shape, about 0% of the cell aggregates had moderate shape, and about 100% of the cell aggregates had good shape ( Figure 3 C "Pre-treatment (TGFβRi)", third bar from the left). That is, it was found that pre-treatment with a TGFβR inhibitor (SB431542, 5 μM) in step 1 resulted in well-shaped cell aggregates in steps 2 and 3.
[0473] Example 4: In step 1 or step 2, the TGFβ family signal transduction pathway inhibitory substance is used to generate a signal transduction pathway inhibitory substance from human iPS cells. Example of cells forming cell aggregates
[0474] Human iPS cells (1231A3 strain) were cultured in a feeder-free culture medium until the day before subconfluence according to the method described in Example 1. Human iPS cells on the day before subconfluence were cultured in a feeder-free culture for 1 day in the presence of SB431542 (TGFβR inhibitor, 5 μM) (step 1, pre-treatment: TGFβRi treatment) or in the absence of SB431542 (step 1: no pre-treatment).
[0475] The human iPS cells were treated with a cell dispersion solution using TrypLE Select (Life Technologies), further dispersed into single cells by pipetting, and the human iPS cells dispersed into single cells were cultured at 1.2×10 4 Each cell / well was suspended in 100 μl of serum-free medium in a non-cell-adhesive 96-well culture plate (PrimeSurface 96 V-bottom plate, manufactured by SUMITOMO BAKELITE), and suspension culture was performed at 37°C, 5% CO2. As for the serum-free medium (gfCDM+KSR) used therefor, a serum-free medium which was a 1:1 mixture of F-12 medium supplemented with 10% KSR, 450 μM 1-monothioglycerol, 1× chemically defined lipid concentrate and IMDM medium was used. At the start of suspension culture (at day 0 after the start of suspension culture, step 2 was started), Y27632 (final concentration of 20 μM) and a TGFβR inhibitor (SB431542, 5 μM) were added to the above serum-free medium. By day 2 after the start of suspension culture, cell aggregates were formed both under the pre-treatment condition and under the condition without pre-treatment (step 2 was ended, step 3 was started). On day 3 after the start of suspension culture, serum-free medium (50 μl) without Y27632 and supplemented with a TGFβR inhibitor (SB431542, 5 μM) was added.
[0476] The shapes of the cell aggregates thus prepared on the 6th day after the start of suspension culture were observed according to the method described in Example 3. As a result, under the conditions of treatment without pretreatment in step 1 and supplementation with the TGFβR inhibitor (SB431542) in step 2, it was found that about 30% of the cell aggregates had a poor shape, about 60% of the cell aggregates had a moderate shape, and about 10% of the cell aggregates had a good shape ( Figure 3C, 'Control + SB', second bar from the left). In contrast, it was found that under the conditions where the pre-treatment was performed in step 1 and the TGFβR inhibitor (SB431542) was added in step 2, about 0% of the cell aggregates had poor shape, about 0% of the cell aggregates had moderate shape, and about 100% of the cell aggregates had good shape ( Figure 3 C, 'Pretreatment (TGFβRi) + SB', fourth bar from the left). That is, it was found that the treatment with the TGFβR inhibitor (SB431542, 5 μM) pretreatment in step 1 resulted in well-shaped cell aggregates compared with the treatment without pretreatment in step 1 and even under the condition of adding the TGFβR inhibitor (SB431542) in steps 2 and 3.
[0477] In addition, comparison of Example 3 and Example 4 revealed that compared with the condition in which no pretreatment was performed in step 1 and a TGFβR inhibitor (SB431542) was added in steps 2 and 3 ( Figure 3 C "Control + SB", second bar from the left), compared to the condition where the treatment was pre-treated with a TGFβR inhibitor (SB431542) in step 1 and no TGFβR inhibitor (SB431542) was added in steps 2 and 3 ( Figure 3 °C "Pre-treatment (TGFβRi)", third bar from the left) produced a higher proportion of cell aggregates with a good shape. That is, it was found that the preferred timing for adding the TGFβR inhibitor (SB431542) was in step 1 (pre-treatment).
[0478] Example 5: Formation of human iPS cells by using a TGFβ family signal transduction pathway inhibitory substance in step 1 Examples of cell aggregates
[0479] Human iPS cells (1231A3 strain) were cultured in a feeder-free culture medium until the day before subconfluence according to the method described in Example 1. Human iPS cells on the day before subconfluence were cultured in a feeder-free culture in the presence (step 1: pre-treatment) or in the absence (step 1: no pre-treatment) of SB431542 (TGFβR inhibitor, 5 μM) or LDN193189 (BMPR inhibitor, 100 nM) for 1 day.
[0480] The human iPS cells were treated with a cell dispersion solution using TrypLE Select (Life Technologies), further dispersed into single cells by pipetting, and the human iPS cells dispersed into single cells were cultured at 1.2×10 4Each cell / well was suspended in 100 μl of serum-free medium in a non-cell-adhesive 96-well culture plate (PrimeSurface 96 V-bottom plate, manufactured by SUMITOMO BAKELITE), and suspension culture was performed at 37°C, 5% CO2. As for the serum-free medium (gfCDM+KSR) used therefor, a serum-free medium which was a 1:1 mixture of F-12 medium supplemented with 10% KSR, 450 μM 1-monothioglycerol and 1× chemically defined lipid concentrate and IMDM medium was used. At the start of suspension culture (at the 0th day after the start of suspension culture, step 2 was started), Y27632 (final concentration was 20 μM) was added to the above serum-free medium. By the second day after the start of suspension culture, cell aggregates were formed both under the pre-treatment condition and under the condition without pre-treatment (step 2 was ended, step 3 was started). On the third day after the start of suspension culture, a serum-free medium (50 μl) not containing Y27632 was added. On the 6th day or later after the start of suspension culture, 50-70% of the volume of the medium was replaced with the above-mentioned serum-free medium not containing Y27632, and the replacement was performed every 2-4 days.
[0481] The cell aggregates prepared in this way on day 9 after the start of suspension culture were observed under a bright field microscope (KEYENCE) Figure 4 ). As a result, it was found that, similar to Example 3, compared with the untreated group ( Figure 4 A) Compared to the cells pre-treated in step 1 in the presence of a TGFβR inhibitor (SB431542), cells showed well-shaped cell aggregates in step 3 ( Figure 4 B). In addition, it was found that compared with the untreated group ( Figure 4 Compared to A), even cells pre-treated in the presence of a BMPR inhibitor (SB431542) in step 1 showed well-shaped cell aggregates in step 3 ( Figure 4 C) That is, it was found that the treatment (step 1) using any one of a TGFβR inhibitor (SB431542) and a BMPR inhibitor (LDN193189), which are TGFβ family signal transduction pathway inhibitory substances, for pre-treatment provides an effect of obtaining a well-shaped cell aggregate.
[0482] Example 6: Human iPS cells pre-treated with a TGFβ family signal transduction pathway inhibitory substance in step 1 Example of cells forming neural tissue
[0483] Human iPS cells (1231A3 strain) were cultured in a feeder-free culture medium until the day before subconfluence according to the method described in Example 1. Human iPS cells on the day before subconfluence were cultured in a feeder-free culture for 1 day in the presence (step 1: pretreatment) or in the absence (step 1: no pretreatment) of LDN193189 (BMPR inhibitor, 100 nM).
[0484] The human iPS cells were treated with a cell dispersion solution using TrypLE Select (Life Technologies), further dispersed into single cells by pipetting, and the human iPS cells dispersed into single cells were cultured at 1.2×10 4 Each cell / well was suspended in 100 μl of serum-free medium in a non-cell-adhesive 96-well culture plate (PrimeSurface 96 V-bottom plate, manufactured by SUMITOMO BAKELITE), and suspension culture was performed at 37°C, 5% CO2. As for the serum-free medium (gfCDM+KSR) used therefor, a serum-free medium which was a 1:1 mixture of F-12 medium supplemented with 10% KSR, 450 μM 1-monothioglycerol, 1× chemically defined lipid concentrate and IMDM medium was used. At the start of suspension culture (at the 0th day after the start of suspension culture, step 2 was started), Y27632 (final concentration was 20 μM) was added to the above serum-free medium. By the second day after the start of suspension culture, cell aggregates were formed both under the pre-treatment condition and under the condition without pre-treatment (step 2 was ended, step 3 was started). On the third day after the start of suspension culture, a serum-free medium (50 μl) not containing Y27632 was added. On or after the 6th day after the start of suspension culture, half of the medium was replaced with the above-mentioned serum-free medium without Y27632, and the replacement was performed every 2-4 days. In the half-medium replacement operation, half of the volume of the medium in the culture container, i.e., 75 μl, was discarded, and the above-mentioned fresh serum-free medium (75 μl) was added to make the total medium volume 150 μl.
[0485] The cells prepared in this way were observed under a bright field microscope (KEYENCE) on the 23rd day after the start of the suspension culture. Figure 5 A, B). As a result, it was found that under the treatment condition without pretreatment in step 1, the cell aggregates collapsed in step 3 and no neural tissue was formed at all ( Figure 5 A). On the other hand, it was found that the cells treated in the presence of a BMPR inhibitor (LDN193189) in step 1 formed well-shaped cell aggregates in step 3 and formed neural tissues having a neuroepithelial structure ( Figure 5 B). In addition, the cells on the 23rd day after the start of suspension culture were subjected to bright field observation under an inverted microscope (KEYENCE), and the “collapsed cell aggregates in which the neural tissue portion exceeded 3% (cell aggregates with poor shape)”, “maintained cell aggregates in which the neural tissue did not exceed 10% (cell aggregates with a medium level of shape)” and “maintained cell aggregates in which the neural tissue was not less than 10% (cell aggregates containing neural tissue)” were quantified respectively. As a result, it was found that under the condition without pretreatment in step 1, about 100% were cell aggregates with poor shape, about 0% were cell aggregates with a medium level of shape, and about 0% were cell aggregates containing neural tissue. In contrast, it was found that under the condition of pretreatment in step 1, about 0% were cell aggregates with poor shape, about 0% were cell aggregates with a medium level of shape, and about 100% were cell aggregates containing neural tissue.
[0486] In addition, iPS cells treated with the above-mentioned pretreatment on day 23 after the start of suspension culture were used as starting materials ( Figure 5 B) were fixed with 4% paraformaldehyde to prepare frozen sections. These frozen sections were immunostained for nestin (anti-nestin antibody, Millipore KK, mouse) (which is a neural tissue marker (neural precursor cells)), TuJ1 (anti-βIII-tubulin antibody, Promega KK, mouse) (which is a neural tissue marker (neurons)) or PSA-NCAM (anti-PSA-NCAM antibody, Millipore KK, mouse IgM) (which is a neural tissue marker). These immunostained sections were observed under an inverted fluorescence microscope. As a result, it was found that in the cell aggregates prepared under the condition of pre-treatment with the BMPR inhibitor (LDN193189), the proportion of nestin-positive cells in the total cells was about 20%, the proportion of TuJ1-positive cells in the total cells was about 70%, and the proportion of PSA-NCAM-positive cells in the total cells was about 70% ( Figure 5 CE). In addition, it was confirmed from the analysis of serial sections that the areas that could be identified as neural tissue by morphological observation in the bright field under an inverted microscope were nestin-positive, TuJ1-positive, and PSA-NCAM-positive ( Figure 5 CE). From these results, it was found that neural tissues can be efficiently generated in step 3 by using human iPS cells subjected to feeder-free culture as a starting material in step 1 and pre-treating with a TGFβ family signal transduction pathway inhibitory substance.
[0487] Example 7: Example of forming retinal tissue from human iPS cells, comprising using TGFβ family signaling in step 1 Pretreatment with BMP signaling pathway inhibitors and use of BMP signaling pathway activators as differentiation inducing factors in step 3 son
[0488] Human iPS cells (1231A3 strain) were cultured in a feeder-free manner in StemFit medium until the day before subconfluence according to the method described in Example 1. Human iPS cells on the day before subconfluence were cultured in a feeder-free manner in the presence of LDN193189 (BMPR inhibitor, 100 nM) (step 1: pretreatment) for 1 day.
[0489] The human iPS cells were treated with a cell dispersion solution using TrypLE Select (Life Technologies), further dispersed into single cells by pipetting, and the human iPS cells dispersed into single cells were cultured at 1.2×10 4 Each cell / well was suspended in 100 μl of serum-free medium in a non-cell-adhesive 96-well culture plate (PrimeSurface 96 V-bottom plate, manufactured by SUMITOMO BAKELITE), and suspension culture was performed at 37°C, 5% CO2. As for the serum-free medium (gfCDM+KSR) used therefor, a serum-free medium that was a 1:1 mixture of F-12 medium supplemented with 10% KSR, 450 μM 1-monothioglycerol, 1× chemically defined lipid concentrate and IMDM medium was used. At the start of suspension culture (at the 0th day after the start of suspension culture, step 2 was started), Y27632 (final concentration was 20 μM) was added to the above serum-free medium. By the second day after the start of suspension culture, cell aggregates were formed under the pre-treatment conditions (step 2 was ended, step 3 was started). On the third day after the start of suspension culture, a serum-free medium (50 μl) not containing Y27632 was added.
[0490] Here, as step 3, culture was performed under the following conditions 1 and 2: Under condition 1 (+BMP), on day 6 after the start of suspension culture, the medium was replaced with a medium containing no Y27632 but human recombinant BMP4 (manufactured by R&D) so that the final concentration of exogenous human recombinant BMP4 was 1.5 nM (55 ng / ml) ( Figure 6 B, D). Under condition 2 (-BMP), on day 6 after the start of suspension culture, half of the medium was replaced with a medium without Y27632 and BMP signal transduction pathway activating substances, and no exogenous human recombinant BMP4 was added ( Figure 6 A, C).
[0491] On the 6th day or later after the start of suspension culture, half of the medium was replaced with the above-mentioned serum-free medium without Y27632 and human recombinant BMP4, and the replacement was performed every 2-4 days. On the 23rd day after the start of suspension culture, the morphology was observed by an inverted microscope. As a result, it was found that in this embodiment, using the pre-treated iPS cells as the starting material, the cell aggregates were maintained and neural tissue was formed.
[0492] The cell aggregates produced by using the iPS cells pre-treated in step 1 as the starting material on day 23 after the start of suspension culture were fixed with 4% paraformaldehyde to prepare frozen sections. These frozen sections were immunostained for Chx10 (anti-Chx10 antibody, Exalpha, sheep) (which is a retinal tissue marker) or Rx (anti-Rx antibody, Takara, guinea pig) (which is a retinal tissue marker). These immunostained sections were observed under an inverted fluorescence microscope. As a result, it was found that in the cell aggregates prepared under the conditions of pre-treatment with the BMPR inhibitor (LDN193189) in step 1 and without adding BMP4 in step 3, the proportion of Rx-positive cells in the total cells was less than 10% (Rx-strongly positive (corresponding to the retina) was less than 3%, and Rx-weakly positive (corresponding to neural tissues other than the retina) was less than 7%), and the proportion of Chx10-positive cells was also less than 3% ( Figure 6 On the other hand, it was found that in the cell aggregates prepared under the conditions of pre-treatment with the BMPR inhibitor (LDN193189) in step 1 and addition of BMP4 in step 3, the proportion of Rx-positive cells in the total cells was about 60%, and the proportion of Chx10-positive cells in the total cells was also about 60% ( Figure 6 B, D). In addition, analysis of serial sections showed that Rx was also strongly positive in neural tissues with a high proportion (about 95%) of Chx10-positive cells ( Figure 6 From these results, it was found that neural tissue was formed under the conditions involving the pretreatment in step 1, and further, by adding a BMP signal transduction pathway activating substance as a differentiation inducing factor during suspension culture in step 3, retinal tissue can be efficiently produced from feeder-free human iPS cells (hereinafter sometimes referred to as feeder-free human iPS cells).
[0493] Example 8: In step 1, a TGFβ family signal transduction pathway inhibitor or Shh signal transduction pathway activator is used. Living substances and substances activating the Shh signaling pathway in step 2 are used to form neurons from feeder-free human iPS cells Example of organization
[0494] Human iPS cells (1231A3 strain) were cultured in a feeder-free culture medium until the day before subconfluence according to the method described in Example 1. Human iPS cells on the day before subconfluence were cultured in a feeder-free culture for 1 day in the presence or absence of SB431542 (TGFβR inhibitor, 5 μM), LDN193189 (BMPR inhibitor, 100 nM) or SAG (Shh signaling pathway activator, 300 nM).
[0495] The human iPS cells were treated with a cell dispersion solution using TrypLE Select (Life Technologies), further dispersed into single cells by pipetting, and the human iPS cells dispersed into single cells were cultured at 1.2×10 4 Each cell / well was suspended in 100 μl of a serum-free medium in a non-cell-adhesive 96-well culture plate (PrimeSurface 96 V-bottom plate, manufactured by SUMITOMO BAKELITE), and suspension culture was performed at 37° C., 5% CO 2 . As the serum-free medium (gfCDM+KSR) used therefor, a serum-free medium which was a 1:1 mixture of F-12 medium supplemented with 10% KSR, 450 μM 1-monothioglycerol, 1× chemically defined lipid concentrate and IMDM medium was used.
[0496] At the start of suspension culture (at day 0 after the start of suspension culture, step 2 was started), the cells were cultured under the following conditions 1 and 2. Under condition 1 (+SAG), Y27632 (final concentration 20 μM) and SAG (Shh signaling pathway activator, 300 nM) were added to the above serum-free medium at the start of suspension culture ( Figure 7 BD, FH, '+SAG'). Under condition 2 (-SAG), Y27632 (final concentration 20 μM) but no SAG was added to the above serum-free medium at the beginning of suspension culture ( Figure 7 A, E, '-'). By day 2 after the start of suspension culture, cell aggregates were formed under both conditions (step 2 ended, step 3 started). On day 3 after the start of suspension culture, serum-free medium (50 μl) without Y27632 and SAG was added.
[0497] On day 6 after the start of suspension culture, the medium was replaced with a medium containing no Y27632 and SAG and containing or not containing human recombinant BMP4 (manufactured by R&D) to provide a medium containing exogenous human recombinant BMP4 at a final concentration of 1.5 nM ( Figure 7EH), or medium without BMP signaling pathway activating substances ( Figure 7 AD). On or after the 6th day after the start of suspension culture, half of the medium was replaced with the above-mentioned serum-free medium without Y27632, SAG and human recombinant BMP4, and the replacement was performed every 2-4 days.
[0498] On the 23rd day after the start of suspension culture, the cells prepared in this way were observed under an inverted microscope (KEYENCE) for bright field observation ( Figure 7 In addition, on the 23rd day after the start of suspension culture, the shape of the cell aggregates was quantified according to the method described in Example 6 ( Figure 7 I). As a result, it was found that, under the conditions of no pretreatment in step 1 and no addition of SAG in step 2, the cell aggregates collapsed and no neural tissue was formed ( Figure 7 A, E). On the other hand, it was found that under the conditions involving pre-treatment with a TGFβR inhibitor (SB431542), a BMPR inhibitor (LDN193189) or a Shh signaling pathway activating substance in step 1 and adding the Shh signaling pathway activating substance in step 2, cell aggregates were formed and neural tissues could be effectively formed ( Figure 7 BD, FI).
[0499] In addition, the above-mentioned cell aggregates produced by the iPS cells treated with the TGFβR inhibitor (SB431542) or BMPR inhibitor (LDN193189) as the starting material on the 23rd day after the start of suspension culture were conditioned with 4% paraformaldehyde to prepare frozen sections. These frozen sections were immunostained for nestin (anti-nestin antibody, NihonMillipore KK, mouse) (which is a neural tissue marker (neural precursor cells)), TuJ1 (anti-βIII-tubulin antibody, Promega KK, mouse) (which is a neural tissue marker (neurons)) or PSA-NCAM (anti-PSA-NCAM antibody, Millipore KK, mouse IgM) (which is a neural tissue marker). These immunostained sections were observed under an inverted fluorescence microscope. As a result, it was found that in the cell aggregates prepared under the condition of pre-treatment with the TGFβR inhibitor (SB431542) or the BMPR inhibitor (LDN193189), the proportion of nestin-positive cells in the total cells was about 20%, the proportion of TuJ1-positive cells in the total cells was about 70%, and the proportion of PSA-NCAM-positive cells was about 70% ( Figure 8AF). In addition, analysis of serial sections was able to confirm that areas that could be identified as neural tissue by morphological observation in bright field images were nestin-positive, TuJ1-positive, and PSA-NCAM-positive ( Figure 8 AF).
[0500] From these results, it was found that under conditions involving pre-treatment with a TGFβ family signaling pathway inhibitory substance or a Shh signaling pathway activating substance in step 1, and further involving addition of a Shh signaling pathway activating substance in step 2, even when a BMP signaling pathway activating substance was added or not added in step 3, neural tissue could be efficiently generated from feeder-free human iPS cells.
[0501] Example 9: In step 1, a TGFβ family signal transduction pathway inhibitor is used, and in step 2, a Shh signal transduction pathway inhibitor is used. In step 3, a BMP signal transduction pathway activating substance is used as a differentiation inducing factor. Example of formation of retinal tissue from human iPS cells using feeder cells
[0502] Cell aggregates were prepared according to the method described in Example 8 under the conditions that human iPS cells using StemFit medium as a feeder-free medium were used as starting materials, TGFβR inhibitory substances (SB431542) or BMPR inhibitory substances (LDN193189) were used in step 1, Shh signal transduction pathway activating substances were used in step 2, and BMP signal transduction pathway activating substances were added or not added in step 3. On the 23rd day after the start of suspension culture, neural tissues were formed in all the aggregates formed under all these conditions. The above cell aggregates were fixed with 4% paraformaldehyde to prepare frozen sections. These frozen sections were immunostained for Chx10 (anti-Chx10 antibody, Exalpha, sheep) (which is a retinal tissue marker) or Rx (anti-Rx antibody, Takara, guinea pig) (which is a retinal tissue marker). These immunostained sections were observed under a fluorescence microscope. As a result, it was found that in the cell aggregates produced under the conditions involving pre-treatment with a TGFβR inhibitor (SB431542) or a BMPR inhibitor (LDN193189) in step 1, addition of a Shh signaling pathway activating substance in step 2, and no addition of BMP4 in step 3, the proportion of Rx-positive cells in the total cells was less than 10% (Rx-strongly positive (corresponding to the retina) was less than 3%, and Rx-weakly positive (corresponding to neural tissues other than the retina) was less than 7%), and the proportion of Chx10-positive cells was also less than 3% ( Fig. 9On the other hand, it was found that in the cell aggregates produced under the conditions involving pre-treatment with a TGFβR inhibitor (SB431542) in step 1, addition of a Shh signaling pathway activating substance in step 2, and addition of BMP4 in step 3, the proportion of Rx-positive cells in the total cells was 80% or more, and the proportion of Chx10-positive cells in the total cells was also 70% or more ( Fig. 9 B, F). In addition, it was found that in the cell aggregates produced under the conditions involving pre-treatment with a BMPR inhibitor (LDN193189) in step 1, addition of a Shh signaling pathway activating substance in step 2, and addition of BMP4 in step 3, the proportion of Rx-positive cells in the total cells was 50% or more, and the proportion of Chx10-positive cells in the total cells was also 40% or more ( Fig. 9 D, H). In addition, analysis of serial sections revealed that Rx was also strongly positive in neural tissues with a high proportion (not less than 95%) of Chx10-positive cells ( Fig. 9 B, D, F, H).
[0503] From these results, it was found that retinal tissue can be efficiently generated from feeder-free human iPS cells by pre-treating with a TGFβ family signaling pathway inhibitory substance in step 1, adding a Shh signaling pathway activating substance in step 2, and adding a BMP signaling pathway activating substance as a differentiation-inducing substance in the suspension culture in step 3.
[0504] Example 10: Human WT cells in Essential 8 medium as feeder-free medium were used in step 1 iPS cells were used as starting material and TGFβ family signal transduction pathway inhibitors were used. shape Examples of cell aggregates
[0505] Human iPS cells (1231A3 strain, obtained from Kyoto University) were cultured without feeder cells according to the method described in "Scientific Reports, 4, 3594 (2014)". For the feeder-free medium, Essential 8 medium (manufactured by Life Technologies, Nature Methods, 8, 424-429 (2011)) was used, and for the feeder-free framework, laminin 511-E8 (manufactured by Nippi, Inc.) was used.
[0506] Regarding the specific maintenance culture operation, subconfluent (about 60% of the culture area is covered by cells) human iPS cells (1231A3 strain) were first washed with PBS and dispersed into single cells using TrypLE Select (manufactured by Life Technologies). Then, the human iPS cells dispersed into single cells were inoculated in a plastic culture dish (manufactured by Iwaki) coated with laminin 511-E8 and cultured without feeder cells in Essential 8 medium in the presence of Y27632 (10 μM, ROCK inhibitor). When using a 6-well plate (manufactured by Iwaki, culture area 9.4 cm 2 ) as the aforementioned plastic culture dish, the number of cells plated with respect to the human iPS cells dispersed into single cells was adjusted to 6×10 3 One day after seeding, the medium was changed to Essential 8 medium without Y27632. Then, the cells were cultured until 6 days after seeding, ie, subconfluent (60% of the culture area was covered by cells).
[0507] Regarding the pretreatment operation, subconfluent human iPS cells (1231A3 strain) were first washed with PBS and dispersed into single cells by using TrypLE Select (manufactured by Life Technologies). Then, the human iPS cells dispersed into single cells were seeded in a plastic culture dish (manufactured by Iwaki) coated with laminin 511-E8, and cultured without feeder cells in Essential 8 medium in the presence of Y27632 (10 μM, ROCK pathway inhibitor). When using a 6-well plate (manufactured by Iwaki, for cell culture, the culture area is 9.4 cm 2 ) as the above-mentioned plastic culture dish, the number of cells plated with the above-mentioned human iPS cells dispersed into single cells was set to 6×10 3. One day after inoculation, the culture medium was replaced with Essential 8 medium without Y27632. Then, the cells were cultured until 5 days after inoculation, that is, the day before subconfluence (50% of the culture area was covered by cells). The human iPS cells cultured without feeder cells the day before subconfluence were cultured without feeder cells for 1 day in the presence of SB431542 (TGFβR inhibitor, 5μM), LDN193189 (BMPR inhibitor, 100nM) or TGFβR and BMPR dual inhibitors (5μM SB431542, and 100nM LDN193189) (step 1: pre-treatment), or in the absence of them (step 1: no pre-treatment, control). Bright field observation of the cultured cells was performed under an inverted microscope (KEYENCE). As a result, it was found that treatment with TGFβ family signal transduction pathway inhibitors during feeder-free culture did not greatly affect the morphology of human iPS cells.
[0508] The human iPS cells were treated with a cell dispersion solution using TrypLE Select (Life Technologies), further dispersed into single cells by pipetting, and the human iPS cells dispersed into single cells were cultured at 1.2×10 4 Each cell / well was suspended in 100 μl of a serum-free medium in a non-cell-adhesive 96-well culture plate (PrimeSurface 96 V-bottom plate, manufactured by SUMITOMO BAKELITE), and suspension culture was performed at 37° C., 5% CO 2 . As the serum-free medium (gfCDM+KSR) used therefor, a serum-free medium which was a 1:1 mixture of F-12 medium supplemented with 10% KSR, 450 μM 1-monothioglycerol, 1× chemically defined lipid concentrate and IMDM medium was used.
[0509] At the start of suspension culture (at day 0 after the start of suspension culture, step 2 was started), the cells were cultured under the following two conditions including condition 1 and condition 2. Under condition 1 (+SAG), Y27632 (final concentration 20 μM) and SAG (Shh signal transduction pathway activator, 300 nM) were added to the above serum-free medium at the start of suspension culture ( Fig.10 C, F, H, J, L, N "+SAG"). Under condition 2 (-SAG), Y27632 (final concentration 20 μM) was added to the above serum-free medium at the beginning of suspension culture, and SAG was not added ( Fig.10A, B, D, E, G, I, K, M "-"). By day 2 after the start of suspension culture, cell aggregates were formed under both conditions (end of step 2, start of step 3). On day 3 after the start of suspension culture, serum-free medium (50 μl) without Y27632 and SAG was added.
[0510] On day 6 after the start of suspension culture, the medium was replaced with a medium containing no Y27632 and SAG but containing or not containing human recombinant BMP4 (manufactured by R&D) so that the medium contained exogenous human recombinant BMP4 ( Fig.10 DF), or the culture medium does not contain BMP signal transduction pathway activating substances ( Fig.10 KN). On or after the 6th day after the start of suspension culture, half of the medium was replaced with the above-mentioned serum-free medium without Y27632, SAG and human recombinant BMP4, and the replacement was performed every 2-4 days.
[0511] On the 7th day after the start of suspension culture, the cells prepared in this way were observed under an inverted microscope (KEYENCE) for bright field observation ( Fig.10 As a result, it was found that, under the conditions of no pretreatment in step 1 and no addition of SAG in step 2, the cell aggregates collapsed and no neural tissue was formed ( Fig.10 A). It was found that under the condition of pre-treatment in step 1, even when the Shh signal transduction pathway activating substance was not added in step 2 or when the Shh signal transduction pathway activating substance was added in step 2, cell aggregates could be formed ( Fig.10 ). That is, it was found that by pre-treating with a TGFβ family signal transduction pathway inhibitory substance in step 1, the shape of cell aggregates formed by human iPS cells became good even when Essential 8 medium was used as a feeder cell-free medium.
[0512] Example 11: Human iPS cells using Essential 8 medium as a feeder-free medium As starting materials, a TGFβ family signal transduction pathway inhibitory substance was used in step 1 and a Shh signal transduction pathway inhibitory substance was used in step 2. Example of transduction pathway activating substances forming neural tissue
[0513] By using Essential 8 medium as a feeder-free cultured human iPS cell as a starting material, using a TGFβR inhibitory substance (SB431542) in step 1 and using a Shh signal transduction pathway activating substance in step 2, cell aggregates were prepared according to the method described in Example 10. The cell aggregates on the 18th day after the start of suspension culture were fixed with 4% paraformaldehyde to prepare frozen sections. These frozen sections were immunostained for nestin (anti-nestin antibody, NihonMillipore KK, mouse) (which is a neural tissue marker (neuronal precursor cell)), TuJ1 (anti-βIII-tubulin antibody, Promega KK, mouse) (which is a neural tissue marker (neuron)) or PSA-NCAM (anti-PSA-NCAM antibody, Millipore KK, mouse IgM) (which is a neural tissue marker) and observed under a fluorescence microscope. As a result, it was found that in the above-mentioned cell aggregates, the proportion of nestin-positive cells in the total cells was about 30%, the proportion of TuJ1-positive cells in the total cells was about 70%, and the proportion of PSA-NCAM-positive cells was about 70% ( Fig.11 In addition, it was confirmed by serial section analysis that the area that could be identified as neural tissue by morphological observation in bright field images was nestin-positive, TuJ1-positive, and PSA-NCAM-positive ( Fig.11 ). That is, it was found that in the cell aggregate produced under the conditions involving pre-treatment with a TGFβR inhibitory substance in step 1 and addition of SAG in step 2, neural tissue can be efficiently formed.
[0514] Example 12: Human iPS cells cultured in Essential 8 medium as feeder-free culture medium Starting materials, TGFβ family signal transduction pathway inhibitory substances used in step 1, Shh signal transduction pathway inhibitory substances used in step 2 In one embodiment, a BMP signal transduction pathway activating substance is used to form a retinal tissue.
[0515] By using Essential 8 medium as a feeder-free cultured human iPS cell as a starting material, using a TGFβR inhibitory substance (SB431542) in step 1, using a Shh signal transduction pathway activating substance in step 2, and adding or not adding a BMP signal transduction pathway activating substance in step 3, according to the method described in Example 10, cell aggregates were prepared. The cell aggregates on the 18th day after the start of suspension culture were fixed with 4% paraformaldehyde to prepare frozen sections. These frozen sections were immunostained for Chx10 (anti-Chx10 antibody, Exalpha, sheep) (which is a retinal tissue marker) or Rx (anti-Rx antibody, Takara, guinea pig) (which is a retinal tissue marker) and observed under a fluorescence microscope. As a result, it was found that in the cell aggregates prepared under the conditions of pre-treatment with a TGFβR inhibitor (SB431542) in step 1, addition of a Shh signaling pathway activating substance in step 2, and no addition of BMP4 in step 3, the proportion of Rx-positive cells in the total cells was less than 10% (Rx-strongly positive (corresponding to the retina) was less than 3%, and Rx-weakly positive (corresponding to neural tissues other than the retina) was less than 7%), and the proportion of Chx10-positive cells was also less than 3% ( Fig.12 On the other hand, it was found that in the cell aggregates prepared under the conditions of pre-treatment with a TGFβR inhibitor (SB431542) in step 1, addition of a Shh signaling pathway activating substance in step 2, and addition of BMP4 in step 3, the proportion of Rx-strongly positive cells in the total cells was about 30% or more, and the proportion of Chx10-positive cells in the total cells was also about 20% or more ( Fig.12 ). In addition, from the analysis of serial sections, it was found that Rx was also strongly positive in the neural tissue with a high ratio (not less than 95%) of Chx10-positive cells. From these results, it was found that retinal tissue can be generated under the conditions of using human iPS cells cultured without feeder cells using Essential 8 medium as the starting material, using a TGFβR inhibitory substance in step 1, using a Shh signal transduction pathway activating substance in step 2, and using a BMP signal transduction pathway activating substance in step 3.
[0516] Example 13: Human iPS cells in StemFit as feeder-free medium as starting material In step 1, a TGFβ signal transduction pathway inhibitory substance and a Shh signal transduction pathway activating substance are used, and in step 3 Example of using BMP signal transduction pathway activating substances to form retinal tissue
[0517] Human iPS cells (1231A3 strain) were cultured in a feeder-free culture medium until the day before subconfluence according to the method described in Example 1. Human iPS cells on the day before subconfluence were cultured in a feeder-free culture for one day in the presence of SB431542 (TGFβR inhibitor, 5 μM) and SAG (Shh signaling pathway activator, 300 nM) (step 1, pre-treatment: TGFβRi+SAG treatment).
[0518] The human iPS cells were treated with a cell dispersion solution using TrypLE Select (Life Technologies), further dispersed into single cells by pipetting, and the human iPS cells dispersed into single cells were cultured at 1.2×10 4 Each cell / well was suspended in 100 μl of serum-free medium in a non-cell-adhesive 96-well culture plate (PrimeSurface 96 V-bottom plate, manufactured by SUMITOMO BAKELITE), and suspension culture was performed at 37°C, 5% CO2. As the serum-free medium used therefor, a serum-free medium that was a 1:1 mixture of F-12 medium supplemented with 10% KSR and 450 μM 1-monothioglycerol, 1× chemically defined lipid concentrate, and IMDM medium was used. At the start of suspension culture (at the 0th day after the start of suspension culture, step 2 was started), Y27632 (final concentration of 20 μM) and SAG (Shh signal transduction pathway activating substance, 300 nM) were added to the above serum-free medium. Cell aggregates were formed one day to two days after the start of suspension culture (step 2 was ended, step 3 was started), and then culture under the following conditions 1-3 was performed in step 3.
[0519] Condition 1: On the 3rd day after the start of suspension culture, a serum-free medium (50 μl) not containing Y27632, SAG, and BMP signal transduction pathway activating substances was added. On the 6th day or later after the start of suspension culture, half of the medium was replaced with the above-mentioned serum-free medium not containing Y27632, SAG, and BMP signal transduction pathway activating substances (half of the volume of the medium, i.e., 75 μl, was discarded, and 75 μl of the above-mentioned serum-free medium not containing Y27632, SAG, and BMP activating substances was added), and the medium was replaced every 3 days.
[0520] Condition 2: On the 3rd day after the start of suspension culture, a serum-free medium containing no Y27632 and SAG but containing human recombinant BMP4 at a final concentration of 1.5 nM was added. On the 6th day or later after the start of suspension culture, half of the medium was replaced with the above-mentioned serum-free medium containing no Y27632, SAG and BMP activating substances (half of the volume of the medium, i.e., 75 μl, was discarded, and 75 μl of the above-mentioned serum-free medium containing no Y27632, SAG and BMP activating substances was added), and the medium was replaced every 3 days.
[0521] Condition 3: On the 3rd day after the start of suspension culture, a serum-free medium (50 μl) without Y27632, SAG and BMP signal transduction pathway activating substances was added. On the 6th day after the start of suspension culture, a serum-free medium without Y27632 and SAG but containing human recombinant BMP4 at a final concentration of 1.5 nM was added. On the 6th day or later after the start of suspension culture, half of the medium was replaced with the above-mentioned serum-free medium without Y27632, SAG and BMP activating substances (half of the volume of the medium, i.e., 75 μl, was discarded, and 75 μl of the above-mentioned serum-free medium without Y27632, SAG and BMP activating substances was added).
[0522] When cultured under the above conditions 1-3, cell aggregates were formed on the 26th day after the start of suspension culture under each condition, and neural tissue was formed. The above cell aggregates on the 26th day after the start of suspension culture were fixed with 4% para-formaldehyde to prepare frozen sections. These frozen sections were immunostained for Chx10 (anti-Chx10 antibody, Exalpha, sheep), which is a retinal tissue marker. As a result, it was found that the ratio of Chx10-positive cells in the total cells in the cell aggregates of condition 1 was less than 3% ( Fig.13 , left panel). On the other hand, in the cell aggregates of conditions 2 and 3, the proportion of Chx10-positive cells in the total cells was not less than 60% ( Fig.13 , middle panel, right panel). From these results, it was found that retinal tissue can be produced under the conditions of using a TGFβR inhibitory substance (SB431542) and a Shh signaling pathway activating substance in step 1, using a Shh signaling pathway activating substance in step 2, and using a BMP signaling pathway activating substance in step 3.
[0523] Example 14: Considerations for the number of cells plated in step 2 (in culture medium without feeder cells) Human iPS cells in StemFit were used as starting material, and TGFβ signaling pathway inhibitors and Shh signaling pathway inhibitors were used in step 1. Signal transduction pathway activating substances
[0524] Human iPS cells (1231A3 strain) were cultured in a feeder-free culture medium until the day before subconfluence according to the method described in Example 1. Human iPS cells on the day before subconfluence were cultured in a feeder-free culture for one day in the presence of SB431542 (TGFβR inhibitor, 5 μM) and SAG (Shh signaling pathway activator, 300 nM) (step 1, pre-treatment: TGFβRi+SAG treatment).
[0525] The human iPS cells were treated with a cell dispersion solution using TrypLE Select (Life Technologies), further dispersed into single cells by pipetting, and the human iPS cells dispersed into single cells were cultured under the following four conditions: 0.4×10 4 , 0.8x10 4 , 1.2x10 4 , or 1.6x10 4 Each cell / well was suspended in 100 μl of serum-free medium in a non-cell-adhesive 96-well culture plate (PrimeSurface 96 V-bottom plate, manufactured by SUMITOMO BAKELITE), and suspension culture was performed at 37°C, 5% CO2. As for the serum-free medium (gfCDM+KSR) used therefor, a serum-free medium which was a 1:1 mixture of F-12 medium supplemented with 10% KSR, 450 μM 1-monothioglycerol, 1× chemically defined lipid concentrate and IMDM medium was used. At the start of suspension culture (at the 0th day after the start of suspension culture, step 2 was started), Y27632 (final concentration 20 μM) and SAG (Shh signal transduction pathway activating substance, 300 nM) were added to the above serum-free medium. Cell aggregates were formed from one day to the second day after the start of suspension culture (step 2 was ended, step 3 was started). Then, in step 3, on day 3 after the start of suspension culture, a serum-free medium containing no Y27632 and SAG but containing human recombinant BMP4 at a final concentration of 1.5 nM was added. On day 6 or later after the start of suspension culture, half of the medium was replaced with the above serum-free medium containing no Y27632, SAG and BMP activating substance every 2-4 days.
[0526] Under each condition, cell aggregates were formed on day 18 after the start of suspension culture, and neural tissue ( Fig.14, upper figure). The above cell aggregates formed on the 18th day after the start of suspension culture were fixed with 4% paraformaldehyde to prepare frozen sections. These frozen sections were immunostained for Chx10 (anti-Chx10 antibody, Exalpha, sheep) (which is a retinal tissue marker) or Rx (anti-Rx antibody, Takara, guinea pig) (which is a retinal tissue marker) and observed under a fluorescence microscope. As a result, it was found that at any number of plated cells (0.4x10 4 , 0.8x10 4 , 1.2x10 4 , or 1.6x10 4 cells), the proportion of Chx10-positive cells in the total cells is not less than 20% ( Fig.14 , middle, right). In particular, with 0.8x10 4 or 1.2x10 4 The condition with a plated cell number of 0.4x10 cells showed a particularly high ratio of Chx10-positive cells. The results of the ratio of Rx-positive cells were the same as those of Chx10. From these results, it was found that in step 2, at 0.4x10 4 -1.6x10 4 Retinal tissue can be generated under the conditions of plating cell number of cells.
[0527] Example 15: In step 1, the TGFβ family signal transduction pathway inhibitor Lefty is used and in step 2, the Example of Forming Neural Tissue from Feeder-Free Human iPS Cells Using Shh Signaling Pathway Activator SAG
[0528] Human iPS cells (1231A3 strain, obtained from Kyoto University) were cultured without feeder cells according to the method described in "Scientific Reports, 4, 3594 (2014)". As a feeder-free medium, StemFit medium (AK03, manufactured by Ajinomoto Co., Inc.) was used, and as a feeder-free framework, laminin 511-E8 (manufactured by Nippi, Inc.) was used.
[0529] Human iPS cells (1231A3 strain) were cultured in a StemFit medium without feeder cells until one day before subconfluence according to the method described in Example 1. Then, the cells were cultured without feeder cells for one day under the following three conditions.
[0530] Condition 1: Human recombinant Lefty-A (Nodal / activin signal transduction pathway inhibitory substance, manufactured by R&D, Lefty-A C-terminus, 20 μg / ml)
[0531] Condition 2: Human recombinant Lefty-A (Nodal / activin signal transduction pathway inhibitory substance, manufactured by R&D, Lefty-A C-terminus, 20 μg / ml) and SAG (Shh signal transduction pathway activating substance, 300 nM)
[0532] Condition 3: No exogenous TGFβ family signal transduction pathway inhibitors and Shh signal transduction pathway activators (without pre-treatment)
[0533] The human iPS cells thus prepared under the above conditions 1 to 3 were treated with a cell dispersion solution by using TrypLE Select (manufactured by Life Technologies), further dispersed into single cells by pipetting, and the human iPS cells dispersed into single cells were cultured at 1.2×10 4 Each cell / well was suspended in 100 μl of a serum-free medium in a non-cell-adhesive 96-well culture plate (PrimeSurface 96 V-bottom plate, manufactured by SUMITOMO BAKELITE), and suspension culture was performed at 37° C., 5% CO 2 . As the serum-free medium (gfCDM+KSR) used therefor, a serum-free medium which was a 1:1 mixture of F-12 medium supplemented with 10% KSR, 450 μM 1-monothioglycerol, 1× chemically defined lipid concentrate and IMDM medium was used.
[0534] At the start of suspension culture (at day 0 after the start of suspension culture, step 2 starts), the cells were cultured under the following two conditions including condition 1 and condition 2. As condition 1 (+SAG), at the start of suspension culture, Y27632 (final concentration 20 μM) and SAG (Shh signaling pathway activating substance, 300 nM) were added to the above serum-free medium. As condition 2 (-SAG), at the start of suspension culture, Y27632 (final concentration 20 μM) was added to the above serum-free medium without adding SAG. By the second day after the start of suspension culture, cell aggregates were formed under both conditions (step 2 ends, step 3 starts). On the third day after the start of suspension culture, a medium (50 μl) containing no Y27632, SAG but human recombinant BMP4 (manufactured by R&D) was added so that the final concentration of exogenous human recombinant BMP4 was 1.5 nM (55 ng / ml). On the 6th day after the start of suspension culture, half of the medium was replaced with a serum-free medium without Y27632, SAG, and human recombinant BMP4. Then, half of the medium was replaced with the above serum-free medium without Y27632, SAG, and human recombinant BMP4 every 2-4 days.
[0535] On the 18th day after the start of suspension culture, the cells prepared in this way were observed under an inverted microscope (KEYENCE) for bright field observation ( Fig.15 As a result, it was found that under the conditions of no pretreatment in step 1 and no addition of SAG in step 2, the cell aggregates collapsed and no neural tissue was formed ( Fig.15 On the other hand, it was found that under conditions involving pre-treatment with a Nodal / activin signal transduction pathway inhibitory substance or a Nodal / activin signal transduction pathway inhibitory substance and a Shh signal transduction pathway activating substance in step 1 and adding or not adding a Shh signal transduction pathway activating substance in step 2, cell aggregates were formed and neural tissue could be effectively formed ( Fig.15 , B, C, D).
[0536] From these results, it was found that even under conditions involving pretreatment with the Nodal / activin signaling pathway inhibitory substance Lefty, which is a TGFβ family signaling pathway inhibitory substance, high-quality aggregates were formed from feeder-free human iPS cells and the generation efficiency of neuroepithelium was improved.
[0537] Example 16: By using the TGFβ family signal transduction pathway inhibitor A83-01 in step 1 and In step 2, the Shh signaling pathway activator SAG is used to form neural tissue and retina from feeder-free human iPS cells. Examples of membrane tissues
[0538] Human iPS cells (1231A3 strain, obtained from Kyoto University) were cultured without feeder cells according to the method described in "Scientific Reports, 4, 3594 (2014)". As a feeder-free medium, StemFit medium (AK03, manufactured by Ajinomoto Co., Inc.) was used, and as a feeder-free framework, laminin 511-E8 (manufactured by Nippi, Inc.) was used.
[0539] Human iPS cells prepared according to the method described in Example 15 on the day before subconfluence were cultured without feeder cells for one day in the presence (pre-treatment treatment) or in the absence (step 1: no pre-treatment) of A83-01 (manufactured by Wako, TGFβR inhibitor, 0.5 μM).
[0540] The human iPS cells were treated with a cell dispersion solution using TrypLE Select (manufactured by Life Technologies), further dispersed into single cells by pipetting, and the human iPS cells dispersed into single cells were plated at 1.0×10 4Each cell / well was suspended in 100 μl of a serum-free medium in a non-cell-adhesive 96-well culture plate (PrimeSurface 96 V-bottom plate, manufactured by SUMITOMO BAKELITE), and suspension culture was performed at 37°C, 5% CO 2 . As for the serum-free medium (gfCDM+KSR) used therefor, a serum-free medium which was a 1:1 mixture of F-12 medium supplemented with 10% KSR, 450 μM 1-monothioglycerol, 1× chemically defined lipid concentrate and IMDM medium was used.
[0541] At the start of suspension culture (at day 0 after the start of suspension culture, step 2 starts), the cells were cultured under the following two conditions including condition 1 and condition 2. As condition 1 (+SAG), at the start of suspension culture, Y27632 (final concentration of 20 μM) and SAG (Shh signaling pathway activating substance, final concentration of 30 nM) were added to the above serum-free medium. As condition 2 (-SAG), at the start of suspension culture, Y27632 (final concentration of 20 μM) was added to the above serum-free medium and SAG was not added. By the second day after the start of suspension culture, cell aggregates were formed under both conditions (step 2 ends, step 3 starts). On the third day after the start of suspension culture, a medium (50 μl) containing no Y27632 and SAG but containing human recombinant BMP4 (manufactured by R&D) was added so that the final concentration of exogenous human recombinant BMP4 was 1.5 nM (55 ng / ml). On the 6th day after the start of suspension culture, half of the medium was replaced with a serum-free medium without Y27632, SAG, and human recombinant BMP4. Then, half of the medium was replaced with the above serum-free medium without Y27632, SAG, and human recombinant BMP4 every 2-4 days.
[0542] On the 20th day after the start of suspension culture, the cells prepared in this way were observed under an inverted microscope (KEYENCE) for bright field observation ( Fig.16 As a result, it was found that under the conditions of no pretreatment in step 1 and no addition of SAG in step 2, the cell aggregates collapsed and no neural tissue was formed ( Fig.16 On the other hand, it was found that under the conditions involving pretreatment with A83-01 in step 1 and addition of SAG in step 2, cell aggregates were formed and neural tissues could be efficiently formed ( Fig.16 , B).
[0543] The above cell aggregates on the 20th day after the start of suspension culture were fixed with 4% paraformaldehyde to prepare frozen sections. These frozen sections were immunostained for Chx10 (anti-Chx10 antibody, Exalpha, sheep), which is a retinal tissue marker, and observed under a fluorescence microscope. As a result, it was found that when step 1 involved pretreatment with A83-01 and step 2 involved addition of SAG, the ratio of Chx10-positive cells in the total cells was about 20% ( Fig.16 , C).
[0544] From these results, it was found that under conditions involving pretreatment with TGFβR inhibitor A83-01 as a TGFβ family signaling pathway inhibitory substance in step 1 and addition of a Shh signaling pathway activating substance in step 2, retinal tissue can be produced.
[0545] Example 17: In step 1, the TGFβ family signal transduction pathway inhibitor A83-01 or TGFβ family Shh signal transduction pathway inhibitors (A83-01) and Shh signal transduction pathway activators (SAG, Purmorphamine, or In step 2, a Shh signal transduction pathway activating substance is used to generate feeder-free human iPS cells. Example of cells forming neural tissue
[0546] Human iPS cells (1231A3 strain, obtained from Kyoto University) were cultured without feeder cells according to the method described in "Scientific Reports, 4, 3594 (2014)". As a feeder-free medium, StemFit medium (AK03, manufactured by Ajinomoto Co., Inc.) was used, and as a feeder-free framework, laminin 511-E8 (manufactured by Nippi, Inc.) was used.
[0547] The human iPS cells prepared according to the method described in Example 15 on the day before subconfluence were cultured without feeder cells under the following 6 conditions for one day.
[0548] Condition 1: A83-01 (manufactured by Wako, TGFβR inhibitor, 0.5 μM)
[0549] Condition 2: A83-01 (manufactured by Wako, TGFβR inhibitor, 0.5 μM) and fAG (manufactured by Enzo, Shh signal transduction pathway activating substance, 300 nM)
[0550] Condition 3: A83-01 (manufactured by Wako, TGFβR inhibitor, 0.5 μM) and Purmorphamine (manufactured by Wako, Shh signal transduction pathway activating substance, 0.2 μM)
[0551] Condition 4: A83-01 (manufactured by Wako, TGFβR inhibitor, 0.5 μM) and human recombinant Shh (manufactured by R&D, Shh signal transduction pathway activating substance, 50 ng / ml)
[0552] Condition 5: A83-01 (manufactured by Wako, TGFβR inhibitor 0.5 μM) and human recombinant Shh (manufactured by R&D, Shh signal transduction pathway activating substance, 300 ng / ml)
[0553] Condition 6: No exogenous TGFβ family signal transduction pathway inhibitors and Shh signal transduction pathway activators (without pre-treatment)
[0554] The human iPS cells were treated with a cell dispersion solution using TrypLE Select (manufactured by Life Technologies), further dispersed into single cells by pipetting, and the human iPS cells dispersed into single cells were plated at 1.0×10 4 Each cell / well was suspended in 100 μl of a serum-free medium in a non-cell-adhesive 96-well culture plate (PrimeSurface 96 V-bottom plate, manufactured by SUMITOMO BAKELITE), and suspension culture was performed at 37°C, 5% CO 2 . As for the serum-free medium (gfCDM+KSR) used therefor, a serum-free medium which was a 1:1 mixture of F-12 medium supplemented with 10% KSR, 450 μM 1-monothioglycerol, 1× chemically defined lipid concentrate and IMDM medium was used.
[0555] At the start of suspension culture (at day 0 after the start of suspension culture, step 2 starts), the cells were cultured under the following two conditions including condition (A) and condition (B). As condition (A) (+SAG), Y27632 (final concentration of 20 μM) and SAG (Shh signaling pathway activator, 30 nM) were added to the above serum-free medium at the start of suspension culture. As condition (B) (-SAG), Y27632 (final concentration of 20 μM) was added to the above serum-free medium at the start of suspension culture, and SAG was not added.
[0556] By the second day after the start of suspension culture, cell aggregates were formed under both conditions (step 2 ended, step 3 started). On the third day after the start of suspension culture, a medium (50 μl) containing no Y27632, SAG, Purmorphamine and human recombinant Shh but containing human recombinant BMP4 (manufactured by R&D) was added so that the final concentration of exogenous human recombinant BMP4 was 1.5 nM (55 ng / ml). On the sixth day after the start of suspension culture, half of the medium was replaced with a serum-free medium containing no Y27632, SAG, Purmorphamine, human recombinant Shh and human recombinant BMP4. Then, half of the medium was replaced with the above-mentioned serum-free medium containing no Y27632, SAG, Purmorphamine, human recombinant Shh and human recombinant BMP4, and the replacement was performed every 2-4 days.
[0557] On the 20th day after the start of suspension culture, the cells prepared in this way were observed under an inverted microscope (KEYENCE) for bright field observation ( Fig.17 As a result, it was found that under the above-mentioned condition 6, i.e., the condition without pretreatment in step 1 and without adding SAG in step 2, the cell aggregates collapsed and no neural tissue was formed ( Fig.17 On the other hand, it was found that under the above-mentioned conditions 1 to 5, i.e., the conditions involving adding A83-01 and a Shh signal transduction pathway activating substance (SAG, PMA, human recombinant Shh 50 ng / ml, human recombinant Shh 300 ng / ml) in step 1 and adding SAG in step 2 (condition (A) (+SAG)), cell aggregates were formed and neural tissues could be effectively formed ( Fig.17 , BF).
[0558] From these results, it was found that under conditions involving pre-treatment with a TGFβ family signaling pathway inhibitory substance (A83-01) or a TGFβ family signaling pathway inhibitory substance (A83-01) and a Shh signaling pathway activating substance (any one of SAG, PMA, and human recombinant Shh) in step 1, neural tissue can be efficiently generated from human iPS cells cultured without feeder cells.
[0559] Example 18: In step 1, a TGFβ family signal transduction pathway inhibitor and a Shh signal transduction pathway inhibitor are used to inhibit the In step 2, a Shh signal transduction pathway activating substance (SAG, Purmorphamine, or human recombinant Example of formation of retinal tissue from feeder-free human iPS cells (any of Shh)
[0560] Human iPS cells (1231A3 strain, obtained from Kyoto University) were cultured without feeder cells according to the method described in "Scientific Reports, 4, 3594 (2014)". As a feeder-free medium, StemFit medium (AK03, manufactured by Ajinomoto Co., Inc.) was used, and as a feeder-free framework, laminin 511-E8 (manufactured by Nippi, Inc.) was used.
[0561] Human iPS cells prepared according to the method described in Example 15 on the day before confluence were cultured without feeder cells in the presence of A83-01 (manufactured by Wako, TGFβR inhibitor 0.5 μM) and SAG (Shh signaling pathway activating substance, 300 nM) (pre-treatment treatment) or in the absence thereof (step 1: no pre-treatment) for one day.
[0562] The human iPS cells were treated with a cell dispersion solution using TrypLE Select (manufactured by Life Technologies), further dispersed into single cells by pipetting, and the human iPS cells dispersed into single cells were plated at 1.0×10 4 Each cell / well was suspended in 100 μl of a serum-free medium in a non-cell-adhesive 96-well culture plate (PrimeSurface 96 V-bottom plate, manufactured by SUMITOMO BAKELITE), and suspension culture was performed at 37° C., 5% CO 2 . As the serum-free medium (gfCDM+KSR) used therefor, a serum-free medium which was a 1:1 mixture of F-12 medium supplemented with 10% KSR, 450 μM 1-monothioglycerol, 1× chemically defined lipid concentrate and IMDM medium was used.
[0563] Using the cells obtained in step 1, suspension culture was initiated under the following conditions as in step 2. Under either condition, the above-mentioned serum-free medium supplemented with Y27632 (final concentration 20 μM) was used.
[0564] Condition 1: SAG (manufactured by Enzo, Shh signal transduction pathway activating substance, 30 nM) was added.
[0565] Condition 2: Purmorphamine (manufactured by Wako, Shh signal transduction pathway activating substance, 0.2 μM) was added.
[0566] Condition 3: Addition of human recombinant Shh (manufactured by R&D, Shh signal transduction pathway activating substance, 300 ng / ml).
[0567] Condition 4: No exogenous Shh signal transduction pathway activating substance was added at the beginning of suspension culture.
[0568] By the second day after the start of suspension culture, cell aggregates were formed under either condition (step 2 ends, step 3 begins). On the third day after the start of suspension culture, a medium (50 μl) containing no Y27632, SAG, Purmorphamine, and human recombinant Shh but containing human recombinant BMP4 (manufactured by R&D) was added so that the final concentration of exogenous human recombinant BMP4 was 1.5 nM (55 ng / ml). On the sixth day after the start of suspension culture, half of the medium was replaced with a serum-free medium containing no Y27632, SAG, Purmorphamine, human recombinant Shh, and human recombinant BMP4. Then, half of the medium was replaced with the above-mentioned serum-free medium containing no Y27632, SAG, and human recombinant BMP4, and the replacement was performed every 2-4 days.
[0569] On the 20th day after the start of suspension culture, the cells prepared in this way were observed under an inverted microscope (KEYENCE) for bright field observation ( Fig.18 As a result, it was found that under the conditions without pretreatment in step 1 and without adding the Shh signal transduction pathway activating substance in step 2 (the above condition 4), the cell aggregates collapsed and no neural tissue was formed ( Fig.18 On the other hand, it was found that under the conditions involving pre-treatment with A83-01 and SAG in step 1 and not adding an exogenous Shh signal transduction pathway activating substance or adding any one of SAG, Purmorphamine (PMA) or human recombinant Shh as a Shh signal transduction pathway activating substance in step 2, cell aggregates were formed and neural tissue was efficiently formed ( Fig.18 , BE).
[0570] From these results, it was found that neural tissue can be efficiently generated from feeder-free human iPS cells under conditions involving pre-treatment with a TGFβ family signaling pathway inhibitory substance and a Shh signaling pathway activating substance in step 1 and adding any one of SAG, Purmorphamine, or human recombinant Shh as a Shh signaling pathway activating substance at the start of suspension culture.
[0571] The cell aggregates on the 20th day after the start of suspension culture were fixed with 4% paraformaldehyde to prepare frozen sections. These frozen sections were immunostained for Chx10 (anti-Chx10 antibody, Exalpha, sheep), which is a retinal tis...
Claims
1. A method for preparing retinal tissue, the method comprising the following steps: (1) In the first step, pluripotent stem cells are cultured in a medium containing (a) and (b) in the absence of feeder cells, thereby obtaining cells that maintain a pluripotent-like state: wherein, (a) is a TGFβ family signal transduction pathway inhibitor and / or a Sonichedgehog signal transduction pathway activator, (b) is a factor for maintaining an undifferentiated state, (2) a second step of dispersing the cells obtained in the first step and suspending and culturing the dispersed cells to form cell aggregates, (3) In the third step, the aggregates obtained in the second step are suspended and cultured in the presence of a substance that activates the BMP signal transduction pathway until cells expressing the Rx gene, the Pax6 gene and / or the Chx10 gene appear, thereby obtaining aggregates including retinal progenitor cells. (4) In the fourth step, the aggregates obtained in the third step are suspended and cultured in a culture medium not supplemented with any BMP signal transduction pathway activating substance for 7 to 200 days, thereby obtaining aggregates including retinal tissue. wherein the pluripotent stem cells are artificial pluripotent stem cells, non-human embryonic stem cells, or commercially available human embryonic stem cells, The TGFβ family signal transduction pathway inhibitory substance is one or more selected from the group consisting of Lefty, SB431542, A-83-01, LDN193189 and Dorsomorphin, The Sonic hedgehog signal transduction pathway activating substance is one or more substances selected from the group consisting of Shh, SAG or Purmorphamine, The BMP signal transduction pathway activating substance is one or more proteins selected from the group consisting of BMP2, BMP4, BMP7 and GDF7, The factor for maintaining the undifferentiated state is one or more proteins selected from the group consisting of bFGF, FGF4, FGF8, Nodal, Activin A, Activin B, TGFβ1, and TGFβ2.
2. The preparation method according to claim 1, wherein the BMP signal transduction pathway activating substance is BMP4.
3. The preparation method according to claim 1 or 2, wherein In the third step, the BMP signal transduction pathway activating substance is added to the culture medium between the 1st day and the 9th day after the start of the second step.
4. The preparation method according to claim 1 or 2, wherein: In the third step, the concentration of the BMP signal transduction pathway activating substance in the culture medium is a concentration corresponding to the signal transduction activity of 1nM-10nM BMP4, wherein the corresponding concentration refers to a concentration that imparts BMP signal transduction promoting activity equivalent to the above-mentioned concentration of BMP4.
5. The preparation method according to claim 1 or 2, wherein: In the first step, the concentration of the TGFβ family signal transduction pathway inhibitory substance in the culture medium is a concentration corresponding to the TGFβ family signal transduction pathway inhibitory activity of 2μM-50μM SB431542, wherein the corresponding concentration refers to a concentration that confers TGFβ family signal transduction pathway inhibitory activity equivalent to the above-mentioned concentration of SB431542.
6. The preparation method according to claim 1 or 2, wherein the aggregates obtained in the fourth step contain one or more cells selected from the group consisting of: retinal progenitor cells, neural retinal progenitor cells, photoreceptor precursor cells, photoreceptor cells, rod photoreceptor cells, cone photoreceptor cells, horizontal cells, amacrine cells, interneurons, ganglion cells, retinal pigment epithelial cells, and ciliary marginal zone cells.
7. The preparation method according to claim 1 or 2, wherein: In the second step, the cells are cultured in suspension in a serum-free medium containing a substance that activates the Sonichedgehog signaling pathway.
8. The preparation method according to claim 7, wherein the Sonic hedgehog signal transduction pathway activating substance in the culture medium in the first step and the second step has a concentration corresponding to the Sonic hedgehog signal transduction activity of 10nM-700nM SAG, wherein The corresponding concentration refers to a concentration that imparts Shh signaling promoting activity equivalent to that of the above-mentioned concentration of SAG.
9. The preparation method according to claim 8, wherein: In the third step, the aggregates are cultured in a medium containing a Sonic hedgehog signaling pathway activating substance at a concentration not exceeding a concentration corresponding to the Sonic hedgehog signaling activity of 700 nM SAG, wherein the corresponding concentration refers to a concentration that confers Shh signaling promoting activity equivalent to the above-mentioned concentration of SAG.
10. The preparation method according to claim 1 or 2, wherein the first step is performed by an adherent culture method. The preparation method according to claim 1 or 2, wherein the pluripotent stem cells are human pluripotent stem cells.
12. The preparation method according to claim 1 or 2, wherein the suspension culture is performed in the absence of a basement membrane preparation.
13. The preparation method according to claim 1 or 2, wherein the culture medium is gradually replaced with a culture medium not supplemented with any BMP signal transduction pathway activating substance.
14. A method for preparing a neural retina, comprising: preparing a cell aggregate comprising retinal tissue by the preparation method according to claim 1 or 2, and The retinal tissue was excised from the cell aggregates.
